Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314)
Active immunization where vaccine is administered for therapeutic or preventive purposes. This can include administration of immunopotentiating agents such as BCG vaccine and Corynebacterium parvum as well as biological response modifiers such as interferons, interleukins, and colony-stimulating factors in order to directly stimulate the immune system.
Immunosuppression by the administration of increasing doses of antigen. Though the exact mechanism is not clear, the therapy results in an increase in serum levels of allergen-specific IMMUNOGLOBULIN G, suppression of specific IgE, and an increase in suppressor T-cell activity.
Vaccines or candidate vaccines designed to prevent or treat cancer. Vaccines are produced using the patient's own whole tumor cells as the source of antigens, or using tumor-specific antigens, often recombinantly produced.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Administration of a soluble dosage form by placement under the tongue.
A method of treating an ALLERGY by administering ALLERGENS, in liquid formulation or tablets, to the ORAL MUCOSA under the tongue.
Allergic rhinitis that occurs at the same time every year. It is characterized by acute CONJUNCTIVITIS with lacrimation and ITCHING, and regarded as an allergic condition triggered by specific ALLERGENS.
Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2.
Specialized cells of the hematopoietic system that have branch-like extensions. They are found throughout the lymphatic system, and in non-lymphoid tissues such as SKIN and the epithelia of the intestinal, respiratory, and reproductive tracts. They trap and process ANTIGENS, and present them to T-CELLS, thereby stimulating CELL-MEDIATED IMMUNITY. They are different from the non-hematopoietic FOLLICULAR DENDRITIC CELLS, which have a similar morphology and immune system function, but with respect to humoral immunity (ANTIBODY PRODUCTION).
Antigen-type substances that produce immediate hypersensitivity (HYPERSENSITIVITY, IMMEDIATE).
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes.
Antibodies produced by a single clone of cells.
Lymphocytes that show specificity for autologous tumor cells. Ex vivo isolation and culturing of TIL with interleukin-2, followed by reinfusion into the patient, is one form of adoptive immunotherapy of cancer.
A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes.
Experimentally induced tumor that produces MELANIN in animals to provide a model for studying human MELANOMA.
Transfer of immunity from immunized to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (ADOPTIVE TRANSFER).
The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement.
A specific HLA-A surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-A*02 allele family.
Venoms obtained from Apis mellifera (honey bee) and related species. They contain various enzymes, polypeptide toxins, and other substances, some of which are allergenic or immunogenic or both. These venoms were formerly used in rheumatism to stimulate the pituitary-adrenal system.
Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION.
Inbred C57BL mice are a strain of laboratory mice that have been produced by many generations of brother-sister matings, resulting in a high degree of genetic uniformity and homozygosity, making them widely used for biomedical research, including studies on genetics, immunology, cancer, and neuroscience.
The fertilizing element of plants that contains the male GAMETOPHYTES.
The ability of tumors to evade destruction by the IMMUNE SYSTEM. Theories concerning possible mechanisms by which this takes place involve both cellular immunity (IMMUNITY, CELLULAR) and humoral immunity (ANTIBODY FORMATION), and also costimulatory pathways related to CD28 antigens (ANTIGENS, CD28) and CD80 antigens (ANTIGENS, CD80).
An immunoglobulin associated with MAST CELLS. Overexpression has been associated with allergic hypersensitivity (HYPERSENSITIVITY, IMMEDIATE).
Substances found in PLANTS that have antigenic activity.
An active immunizing agent and a viable avirulent attenuated strain of Mycobacterium tuberculosis, var. bovis, which confers immunity to mycobacterial infections. It is used also in immunotherapy of neoplasms due to its stimulation of antibodies and non-specific immunity.
Vaccines or candidate vaccines used to prevent or treat ALZHEIMER DISEASE.
Inbred BALB/c mice are a strain of laboratory mice that have been selectively bred to be genetically identical to each other, making them useful for scientific research and experiments due to their consistent genetic background and predictable responses to various stimuli or treatments.
Mononuclear leukocytes that have been expanded in CELL CULTURE and activated with CYTOKINES such as INTERLEUKIN-2 to produce large numbers of highly cytotoxic cells.
Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.
A cell line derived from cultured tumor cells.
A specific HLA-A surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-A*24 allele family.
Antigenic determinants recognized and bound by the T-cell receptor. Epitopes recognized by the T-cell receptor are often located in the inner, unexposed side of the antigen, and become accessible to the T-cell receptors after proteolytic processing of the antigen.
Bites and stings inflicted by insects.
Inflammation of the mucous membrane of the nose similar to that found in hay fever except that symptoms persist throughout the year. The causes are usually air-borne allergens, particularly dusts, feathers, molds, animal fur, etc.
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES.
Immunoglobulins induced by antigens specific for tumors other than the normally occurring HISTOCOMPATIBILITY ANTIGENS.
Polymorphic class I human histocompatibility (HLA) surface antigens present on almost all nucleated cells. At least 20 antigens have been identified which are encoded by the A locus of multiple alleles on chromosome 6. They serve as targets for T-cell cytolytic responses and are involved with acceptance or rejection of tissue/organ grafts.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
Cellular antigens that are specific for MELANOMA cells.
A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes.
Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
A melanosome-associated protein that plays a role in the maturation of the MELANOSOME.
Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type.
A lyophilized preparation of a low-virulence strain (SU) of Streptococcus pyogenes (S. hemolyticus), inactivated by heating with penicillin G. It has been proposed as a noncytotoxic antineoplastic agent because of its immune system-stimulating activity.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
CD4-positive T cells that inhibit immunopathology or autoimmune disease in vivo. They inhibit the immune response by influencing the activity of other cell types. Regulatory T-cells include naturally occurring CD4+CD25+ cells, IL-10 secreting Tr1 cells, and Th3 cells.
The process by which antigen is presented to lymphocytes in a form they can recognize. This is performed by antigen presenting cells (APCs). Some antigens require processing before they can be recognized. Antigen processing consists of ingestion and partial digestion of the antigen by the APC, followed by presentation of fragments on the cell surface. (From Rosen et al., Dictionary of Immunology, 1989)
Venoms produced by the wasp (Vespid) family of stinging insects, including hornets; the venoms contain enzymes, biogenic amines, histamine releasing factors, kinins, toxic polypeptides, etc., and are similar to bee venoms.
Tumors or cancers of the KIDNEY.
Cytolytic lymphocytes with the unique capacity of killing natural killer (NK)-resistant fresh tumor cells. They are INTERLEUKIN-2-activated NK cells that have no MAJOR HISTOCOMPATIBILITY COMPLEX restriction or need for antigen stimulation. LAK cells are used for ADOPTIVE IMMUNOTHERAPY in cancer patients.
A melanosome-specific protein that plays a role in the expression, stability, trafficking, and processing of GP100 MELANOMA ANTIGEN, which is critical to the formation of Stage II MELANOSOMES. The protein is used as an antigen marker for MELANOMA cells.
A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.
Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner.
The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc.
Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN.
Family of house dust mites, in the superfamily Analgoidea, order Astigmata. They include the genera Dermatophagoides and Euroglyphus.
Experimental transplantation of neoplasms in laboratory animals for research purposes.
Form of passive immunization where previously sensitized immunologic agents (cells or serum) are transferred to non-immune recipients. When transfer of cells is used as a therapy for the treatment of neoplasms, it is called adoptive immunotherapy (IMMUNOTHERAPY, ADOPTIVE).
Sites on an antigen that interact with specific antibodies.
Epicutaneous or intradermal application of a sensitizer for demonstration of either delayed or immediate hypersensitivity. Used in diagnosis of hypersensitivity or as a test for cellular immunity.
A plant genus of the family TAXODIACEAE. Its POLLEN is one of the major ALLERGENS.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
Antibodies, often monoclonal, in which the two antigen-binding sites are specific for separate ANTIGENIC DETERMINANTS. They are artificial antibodies produced by chemical crosslinking, fusion of HYBRIDOMA cells, or by molecular genetic techniques. They function as the main mediators of targeted cellular cytotoxicity and have been shown to be efficient in the targeting of drugs, toxins, radiolabeled haptens, and effector cells to diseased tissue, primarily tumors.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
Biologically active substances whose activities affect or play a role in the functioning of the immune system.
Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin.
An acute hypersensitivity reaction due to exposure to a previously encountered ANTIGEN. The reaction may include rapidly progressing URTICARIA, respiratory distress, vascular collapse, systemic SHOCK, and death.
Vaccines consisting of one or more antigens that stimulate a strong immune response. They are purified from microorganisms or produced by recombinant DNA techniques, or they can be chemically synthesized peptides.
Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
An extensive order of highly specialized insects including bees, wasps, and ants.
Allergic reaction to peanuts that is triggered by the immune system.
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role.
Antigens from the house dust mites (DERMATOPHAGOIDES), mainly D. farinae and D. pteronyssinus. They are proteins, found in mite feces or mite extracts, that can cause ASTHMA and other allergic diseases such as perennial rhinitis (RHINITIS, ALLERGIC, PERENNIAL) and atopic dermatitis (DERMATITIS, ATOPIC). More than 11 groups of Dermatophagoides ALLERGENS have been defined. Group I allergens, such as Der f I and Der p I from the above two species, are among the strongest mite immunogens in humans.
Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.
DNA molecules capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. Many are derived from PLASMIDS; BACTERIOPHAGES; or VIRUSES. They are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain GENETIC MARKERS to facilitate their selective recognition.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
Techniques and strategies which include the use of coding sequences and other conventional or radical means to transform or modify cells for the purpose of treating or reversing disease conditions.
A heterogeneous group of immunocompetent cells that mediate the cellular immune response by processing and presenting antigens to the T-cells. Traditional antigen-presenting cells include MACROPHAGES; DENDRITIC CELLS; LANGERHANS CELLS; and B-LYMPHOCYTES. FOLLICULAR DENDRITIC CELLS are not traditional antigen-presenting cells, but because they hold antigen on their cell surface in the form of IMMUNE COMPLEXES for B-cell recognition they are considered so by some authors.
The demonstration of the cytotoxic effect on a target cell of a lymphocyte, a mediator released by a sensitized lymphocyte, an antibody, or complement.
Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).
Tumors or cancer of the SKIN.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
An inhibitory T CELL receptor that is closely related to CD28 ANTIGEN. It has specificity for CD80 ANTIGEN and CD86 ANTIGEN and acts as a negative regulator of peripheral T cell function. CTLA-4 antigen is believed to play role in inducing PERIPHERAL TOLERANCE.
Proteins prepared by recombinant DNA technology.
A classification of T-lymphocytes, especially into helper/inducer, suppressor/effector, and cytotoxic subsets, based on structurally or functionally different populations of cells.
Testing of immune status in the diagnosis and therapy of cancer, immunoproliferative and immunodeficiency disorders, and autoimmune abnormalities. Changes in immune parameters are of special significance before, during and following organ transplantation. Strategies include measurement of tumor antigen and other markers (often by RADIOIMMUNOASSAY), studies of cellular or humoral immunity in cancer etiology, IMMUNOTHERAPY trials, etc.
Molecules on the surface of T-lymphocytes that recognize and combine with antigens. The receptors are non-covalently associated with a complex of several polypeptides collectively called CD3 antigens (ANTIGENS, CD3). Recognition of foreign antigen and the major histocompatibility complex is accomplished by a single heterodimeric antigen-receptor structure, composed of either alpha-beta (RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA) or gamma-delta (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA) chains.
Experimentally induced neoplasms of CONNECTIVE TISSUE in animals to provide a model for studying human SARCOMA.
Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).
Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques.
Recombinant DNA vectors encoding antigens administered for the prevention or treatment of disease. The host cells take up the DNA, express the antigen, and present it to the immune system in a manner similar to that which would occur during natural infection. This induces humoral and cellular immune responses against the encoded antigens. The vector is called naked DNA because there is no need for complex formulations or delivery agents; the plasmid is injected in saline or other buffers.
An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.
A large family of narrow-leaved herbaceous grasses of the order Cyperales, subclass Commelinidae, class Liliopsida (monocotyledons). Food grains (EDIBLE GRAIN) come from members of this family. RHINITIS, ALLERGIC, SEASONAL can be induced by POLLEN of many of the grasses.
A costimulatory ligand expressed by ANTIGEN-PRESENTING CELLS that binds to CTLA-4 ANTIGEN with high specificity and to CD28 ANTIGEN with low specificity. The interaction of CD80 with CD28 ANTIGEN provides a costimulatory signal to T-LYMPHOCYTES, while its interaction with CTLA-4 ANTIGEN may play a role in inducing PERIPHERAL TOLERANCE.
Conjunctivitis due to hypersensitivity to various allergens.
Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis.
Injections introduced directly into localized lesions.
A heterodimeric cytokine that plays a role in innate and adaptive immune responses. Interleukin-12 is a 70 kDa protein that is composed of covalently linked 40 kDa and 35 kDa subunits. It is produced by DENDRITIC CELLS; MACROPHAGES and a variety of other immune cells and plays a role in the stimulation of INTERFERON-GAMMA production by T-LYMPHOCYTES and NATURAL KILLER CELLS.
An acidic glycoprotein of MW 23 kDa with internal disulfide bonds. The protein is produced in response to a number of inflammatory mediators by mesenchymal cells present in the hemopoietic environment and at peripheral sites of inflammation. GM-CSF is able to stimulate the production of neutrophilic granulocytes, macrophages, and mixed granulocyte-macrophage colonies from bone marrow cells and can stimulate the formation of eosinophil colonies from fetal liver progenitor cells. GM-CSF can also stimulate some functional activities in mature granulocytes and macrophages.
A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed)
Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.
Tumors or cancer of the LUNG.
The property of the T-CELL RECEPTOR which enables it to react with some antigens and not others. The specificity is derived from the structure of the receptor's variable region which has the ability to recognize certain antigens in conjunction with the MAJOR HISTOCOMPATIBILITY COMPLEX molecule.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Immunosuppression by reduction of circulating lymphocytes or by T-cell depletion of bone marrow. The former may be accomplished in vivo by thoracic duct drainage or administration of antilymphocyte serum. The latter is performed ex vivo on bone marrow before its transplantation.
Glycoproteins found on the membrane or surface of cells.
The transfer of bacterial DNA by phages from an infected bacterium to another bacterium. This also refers to the transfer of genes into eukaryotic cells by viruses. This naturally occurring process is routinely employed as a GENE TRANSFER TECHNIQUE.
Complex of at least five membrane-bound polypeptides in mature T-lymphocytes that are non-covalently associated with one another and with the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL). The CD3 complex includes the gamma, delta, epsilon, zeta, and eta chains (subunits). When antigen binds to the T-cell receptor, the CD3 complex transduces the activating signals to the cytoplasm of the T-cell. The CD3 gamma and delta chains (subunits) are separate from and not related to the gamma/delta chains of the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA).
The milieu surrounding neoplasms consisting of cells, vessels, soluble factors, and molecules, that can influence and be influenced by, the neoplasm's growth.
Unglycosylated phosphoproteins expressed only on B-cells. They are regulators of transmembrane Ca2+ conductance and thought to play a role in B-cell activation and proliferation.
A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell.
Mature LYMPHOCYTES and MONOCYTES transported by the blood to the body's extravascular space. They are morphologically distinguishable from mature granulocytic leukocytes by their large, non-lobed nuclei and lack of coarse, heavily stained cytoplasmic granules.
Carbohydrate antigen elevated in patients with tumors of the breast, ovary, lung, and prostate as well as other disorders. The mucin is expressed normally by most glandular epithelia but shows particularly increased expression in the breast at lactation and in malignancy. It is thus an established serum marker for breast cancer.
The phenomenon of antibody-mediated target cell destruction by non-sensitized effector cells. The identity of the target cell varies, but it must possess surface IMMUNOGLOBULIN G whose Fc portion is intact. The effector cell is a "killer" cell possessing Fc receptors. It may be a lymphocyte lacking conventional B- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent.
Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are linear polypeptides that are normally synthesized on RIBOSOMES.
The transfer of lymphocytes from a donor to a recipient or reinfusion to the donor.
Gastrointestinal disturbances, skin eruptions, or shock due to allergic reactions to allergens in food.
Preparations made from animal tissues or organs (ANIMAL STRUCTURES). They usually contain many components, any one of which may be pharmacologically or physiologically active. Tissue extracts may contain specific, but uncharacterized factors or proteins with specific actions.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
Any arthropod of the subclass ACARI except the TICKS. They are minute animals related to the spiders, usually having transparent or semitransparent bodies. They may be parasitic on humans and domestic animals, producing various irritations of the skin (MITE INFESTATIONS). Many mite species are important to human and veterinary medicine as both parasite and vector. Mites also infest plants.
Process of classifying cells of the immune system based on structural and functional differences. The process is commonly used to analyze and sort T-lymphocytes into subsets based on CD antigens by the technique of flow cytometry.
A member of the tumor necrosis factor receptor superfamily with specificity for CD40 LIGAND. It is found on mature B-LYMPHOCYTES and some EPITHELIAL CELLS, lymphoid DENDRITIC CELLS. Evidence suggests that CD40-dependent activation of B-cells is important for generation of memory B-cells within the germinal centers. Mutations of the gene for CD40 antigen result in HYPER-IGM IMMUNODEFICIENCY SYNDROME, TYPE 3. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
A plant genus of the family BETULACEAE. The tree has smooth, resinous, varicolored or white bark, marked by horizontal pores (lenticels), which usually peels horizontally in thin sheets.
Species of European house dust mite, in the family PYROGLYPHIDAE. It is the most commonly found house dust mite.
An inhibitory T-lymphocyte receptor that has specificity for CD274 ANTIGEN and PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN. Signaling by the receptor limits T cell proliferation and INTERFERON GAMMA synthesis. The receptor also may play an essential role in the regulatory pathway that induces PERIPHERAL TOLERANCE.
An encapsulated lymphatic organ through which venous blood filters.
A plant genus of the family POACEAE that contains the Phl p 4 allergen.
Granular leukocytes characterized by a relatively pale-staining, lobate nucleus and cytoplasm containing coarse dark-staining granules of variable size and stainable by basic dyes.
Molecules on the surface of B- and T-lymphocytes that recognize and combine with specific antigens.
A plant genus of the family URTICACEAE which is the most common cause of pollinosis in Mediterranean countries. It is the source of 'allergen Par o I' and of Pollinex used for DESENSITIZATION, IMMUNOLOGIC.
A bacteria isolated from normal skin, intestinal contents, wounds, blood, pus, and soft tissue abscesses. It is a common contaminant of clinical specimens, presumably from the skin of patients or attendants.
An ERYTHROLEUKEMIA cell line derived from a CHRONIC MYELOID LEUKEMIA patient in BLAST CRISIS.
Nonsusceptibility to the invasive or pathogenic effects of foreign microorganisms or to the toxic effect of antigenic substances.
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
Allergic reaction to tree nuts that is triggered by the immune system.
Subset of helper-inducer T-lymphocytes which synthesize and secrete interleukin-2, gamma-interferon, and interleukin-12. Due to their ability to kill antigen-presenting cells and their lymphokine-mediated effector activity, Th1 cells are associated with vigorous delayed-type hypersensitivity reactions.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
The theory that T-cells monitor cell surfaces and detect structural changes in the plasma membrane and/or surface antigens of virally or neoplastically transformed cells.
A plant species of the family FABACEAE that yields edible seeds, the familiar peanuts, which contain protein, oil and lectins.
The forcing into the skin of liquid medication, nutrient, or other fluid through a hollow needle, piercing the top skin layer.
Allergic reaction to eggs that is triggered by the immune system.
Elements of limited time intervals, contributing to particular results or situations.
The sudden, forceful, involuntary expulsion of air from the NOSE and MOUTH caused by irritation to the MUCOUS MEMBRANES of the upper RESPIRATORY TRACT.
An albumin obtained from the white of eggs. It is a member of the serpin superfamily.
One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells. In addition to antiviral activity, it activates NATURAL KILLER CELLS and B-LYMPHOCYTES, and down-regulates VASCULAR ENDOTHELIAL GROWTH FACTOR expression through PI-3 KINASE and MAPK KINASES signaling pathways.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.
Process whereby the immune system reacts against the body's own tissues. Autoimmunity may produce or be caused by AUTOIMMUNE DISEASES.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
An inhibitory B7 antigen that has specificity for the T-CELL receptor PROGRAMMED CELL DEATH 1 PROTEIN. CD274 antigen provides negative signals that control and inhibit T-cell responses and is found at higher than normal levels on tumor cells, suggesting its potential role in TUMOR IMMUNE EVASION.
Alteration of the immune system or of an immune response by agents that activate or suppress its function. This can include IMMUNIZATION or administration of immunomodulatory drugs. Immunomodulation can also encompass non-therapeutic alteration of the immune system effected by endogenous or exogenous substances.
A member of the tumor necrosis factor receptor superfamily that is specific for 4-1BB LIGAND. It is found in a variety of immune cell types including activated T-LYMPHOCYTES; NATURAL KILLER CELLS; and DENDRITIC CELLS. Activation of the receptor on T-LYMPHOCYTES plays a role in their expansion, production of cytokines and survival. Signaling by the activated receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
Membrane glycoproteins consisting of an alpha subunit and a BETA 2-MICROGLOBULIN beta subunit. In humans, highly polymorphic genes on CHROMOSOME 6 encode the alpha subunits of class I antigens and play an important role in determining the serological specificity of the surface antigen. Class I antigens are found on most nucleated cells and are generally detected by their reactivity with alloantisera. These antigens are recognized during GRAFT REJECTION and restrict cell-mediated lysis of virus-infected cells.
Theoretical representations that simulate the behavior or activity of immune system, processes, or phenomena. They include the use of mathematical equations, computers, and other electrical equipment.
A technique of culturing mixed cell types in vitro to allow their synergistic or antagonistic interactions, such as on CELL DIFFERENTIATION or APOPTOSIS. Coculture can be of different types of cells, tissues, or organs from normal or disease states.
The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site.
Antibodies which react with the individual structural determinants (idiotopes) on the variable region of other antibodies.
Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.
A spontaneous diminution or abatement of a disease over time, without formal treatment.
ONCOGENE PROTEINS from papillomavirus that deregulate the CELL CYCLE of infected cells and lead to NEOPLASTIC CELL TRANSFORMATION. Papillomavirus E7 proteins have been shown to interact with various regulators of the cell cycle including RETINOBLASTOMA PROTEIN and certain cyclin-dependent kinase inhibitors.
Substances that are recognized by the immune system and induce an immune reaction.
Treatments with drugs which interact with or block synthesis of specific cellular components characteristic of the individual's disease in order to stop or interrupt the specific biochemical dysfunction involved in progression of the disease.
A cytokine produced by a variety of cell types, including T-LYMPHOCYTES; MONOCYTES; DENDRITIC CELLS; and EPITHELIAL CELLS that exerts a variety of effects on immunoregulation and INFLAMMATION. Interleukin-10 combines with itself to form a homodimeric molecule that is the biologically active form of the protein.
The body's defense mechanism against foreign organisms or substances and deviant native cells. It includes the humoral immune response and the cell-mediated response and consists of a complex of interrelated cellular, molecular, and genetic components.
The altered state of immunologic responsiveness resulting from initial contact with antigen, which enables the individual to produce antibodies more rapidly and in greater quantity in response to secondary antigenic stimulus.
A general term for various neoplastic diseases of the lymphoid tissue.
Combinations of diagnostic or therapeutic substances linked with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; or ANTIGENS. Often the diagnostic or therapeutic substance is a radionuclide. These conjugates are useful tools for specific targeting of DRUGS and RADIOISOTOPES in the CHEMOTHERAPY and RADIOIMMUNOTHERAPY of certain cancers.
Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.
They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.
Tumors or cancer of the PROSTATE.
A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.
The classes of BONE MARROW-derived blood cells in the monocytic series (MONOCYTES and their precursors) and granulocytic series (GRANULOCYTES and their precursors).
Peptides generated from AMYLOID BETA-PEPTIDES PRECURSOR. An amyloid fibrillar form of these peptides is the major component of amyloid plaques found in individuals with Alzheimer's disease and in aged individuals with trisomy 21 (DOWN SYNDROME). The peptide is found predominantly in the nervous system, but there have been reports of its presence in non-neural tissue.
Carbohydrate antigens expressed by malignant tissue. They are useful as tumor markers and are measured in the serum by means of a radioimmunoassay employing monoclonal antibodies.
The instillation or other administration of drugs into the bladder, usually to treat local disease, including neoplasms.
Cytokine that stimulates the proliferation of T-LYMPHOCYTES and shares biological activities with IL-2. IL-15 also can induce proliferation and differentiation of B-LYMPHOCYTES.
Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475)
Immunological rejection of tumor tissue/cells following bone marrow transplantation.
A family of non-enveloped viruses infecting mammals (MASTADENOVIRUS) and birds (AVIADENOVIRUS) or both (ATADENOVIRUS). Infections may be asymptomatic or result in a variety of diseases.
A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.
Tumors or cancer of the COLON.
DNA sequences, in cells of the T-lymphocyte lineage, that code for T-cell receptors. The TcR genes are formed by somatic rearrangement (see GENE REARRANGEMENT, T-LYMPHOCYTE and its children) of germline gene segments, and resemble Ig genes in their mechanisms of diversity generation and expression.
Antibodies obtained from a single clone of cells grown in mice or rats.
Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.
Differentiation antigens expressed on B-lymphocytes and B-cell precursors. They are involved in regulation of B-cell proliferation.
White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS.
The introduction of functional (usually cloned) GENES into cells. A variety of techniques and naturally occurring processes are used for the gene transfer such as cell hybridization, LIPOSOMES or microcell-mediated gene transfer, ELECTROPORATION, chromosome-mediated gene transfer, TRANSFECTION, and GENETIC TRANSDUCTION. Gene transfer may result in genetically transformed cells and individual organisms.
An in vitro allergen radioimmunoassay in which allergens are coupled to an immunosorbent. The coupled allergens bind the IgE in the sera of patients which in turn binds radioisotope-labeled anti-IMMUNOGLOBULIN E antibodies.
Methods used for studying the interactions of antibodies with specific regions of protein antigens. Important applications of epitope mapping are found within the area of immunochemistry.
Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs.
A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).
Injections into the lymph nodes or the lymphatic system.

Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma. (1/372)

PURPOSE: The primary objective of this clinical study was to assess the feasibility of administering recombinant interleukin-2 and recombinant interferon alfa-2a before and after combination cytotoxic chemotherapy. After encouraging initial responses, the study was expanded to further evaluate the therapeutic potential, clarify the toxicities of this regimen, and explore any associated immunologic changes. PATIENTS AND METHODS: Eighty-four patients with metastatic melanoma, including patients with brain metastases, were treated on this 6-week protocol. Patients received combination cisplatin (25 mg/m2/d) and dacarbazine (220 mg/m2/d) on days 1 through 3 and 22 through 24 plus carmustine (150 mg/m2) on day 1. Interleukin 2 (13.5 million IU/m2/d) and interferon alfa (6 MU/m2/d) were administered on days 4 through 8 and 17 through 21. RESULTS: Among 83 patients assessable for response, 12 complete and 34 partial responses were documented (55% response rate). The median time to disease progression was 7 months, the median survival from study entry was 12.2 months, and the median survival from diagnosis of metastatic disease was 15.5 months. Although patients were hospitalized to receive treatment, intensive care unit support generally was not needed. Dose-limiting toxicities were related to elevations in serum bilirubin and serum creatinine levels. No patient developed a grade 4 clinical toxicity. Treatment produced a skin depigmentation, which was associated with prolonged survival. CONCLUSION: A plateau in both the survival and time to progression curves beyond 2 years (15% of the patients) and a greater than 10% disease-free survival beyond 4 years indicate that there may be a long-term benefit for some patients. The limited toxicity of this regimen should permit its use in most oncology settings. A randomized trial of chemoimmunotherapy versus chemotherapy should be performed to establish the value of chemoimmunotherapy for melanoma.  (+info)

Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study. (2/372)

The idiotype (Id) determinant on the multiple myeloma (MM) protein can be regarded as a tumor-specific marker. Immunotherapy directed at the MM Id may stem the progression of this disease. We report here on the first 12 MM patients treated at our institution with high-dose therapy and peripheral blood stem cell transplantation (PBSCT) followed by Id immunizations. MM patients received PBSCT to eradicate the majority of the disease. PBSCT produced a complete response in 2 patients, a partial response in 9 patients and stable disease in 1 patient. Three to 7 months after high-dose therapy, patients received a series of monthly immunizations that consisted of two intravenous infusions of Id-pulsed autologous dendritic cells (DC) followed by five subcutaneous boosts of Id/keyhole limpet hemocyanin (KLH) administered with adjuvant. Between 1 and 11 x 10(6) DC were obtained by leukapheresis in all patients even after PBSCT. The administration of Id-pulsed DC and Id/KLH vaccines were well tolerated with patients experiencing only minor and transient side effects. Two of 12 patients developed an Id-specific, cellular proliferative immune response and one of three patients studied developed a transient but Id-specific cytotoxic T-cell (CTL) response. Eleven of the 12 patients generated strong KLH-specific cellular proliferative immune responses showing the patients' immunocompetence at the time of vaccination. The two patients who developed a cellular Id-specific immune response remain in complete remission. Of the 12 treated patients, 9 are currently alive after autologous transplantation with a minimum follow-up of 16 months, 2 patients died because of recurrent MM and 1 patient succumbed to acute leukemia. These studies show that patients make strong anti-KLH responses despite recent high-dose therapy and that DC-based Id vaccination is feasible after PBSCT and can induce Id-specific T-cell responses. Further vaccine development is necessary to increase the proportion of patients that make Id-specific immune responses. The clinical benefits of Id vaccination in MM remain to be determined.  (+info)

Prognostic importance of antigen-presenting dendritic cells during vaccine therapy in a murine hepatitis B virus carrier. (3/372)

As, the outcome of vaccine therapy was extremely heterogeneous in both human and murine hepatitis B virus (HBV)-carriers, the experiments presented here were performed to find out a prognostic marker of vaccine therapy using an animal model of HBV-carrier state, HBV-transgenic mice (Tg). Neither the prevaccinated titres of viral markers, such as hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg) or HBV DNA, nor the function of lymphocytes prior to vaccination, had significant influence on the outcome of vaccine therapy. Two independent, placebo-controlled, trials of vaccine therapy for 12 months, one in 17 HBV-Tg and the other in 26 HBV-Tg (total, n=43) showed that the eight of 17 and 15 of 26 HBV-Tg that had potent dendritic cell (DC) function at the start of vaccine therapy became completely negative for HBsAg, HBeAg and reduced HBV DNA, whereas all 19 HBV-Tg that had poor DC function at the start of vaccine therapy became complete non-responders, although, the prevaccinated titres of HBsAg, and HBeAg were similar in all 43 HBV-Tg. Further study to find the mechanism underlying this revealed that there was up-regulation of major histocompatibility complex (MHC) class II, CD86 antigens on DC and increased production of interleukin-12 (IL-12) by DC and of IL-2, and tumour necrosis factor-alpha (TNF-alpha) in DC/T-cell cultures when vaccine containing HBsAg was injected in HBV-Tg with potent DC function but not in HBV-Tg with poor DC function. This is the first report on the prognostic importance of DC during an immune therapy. Degree of activation of DC following vaccination would possibly help to predict the outcome of vaccine therapy in human HBV-carriers. These data also provide the scientific and logical basis to up-regulate the function of the DC before an immune therapy.  (+info)

Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. (4/372)

Direct infection of tumor cells with viruses transferring protective or therapeutic genes, a frequently used procedure for production of tumor vaccines in human gene therapy, is an approach which is often limited by the number of tumor cells that can reliably be infected as well as by issues of selectivity and safety. We report an efficient, selective and safe way of infecting human tumor cells with a natural virus with interesting pleiotropic immune stimulatory properties, the avian paramyxovirus Newcastle disease virus (NDV). Two of the six viral genes (HN and F) modify the tumor cell surface by introduction of new adhesion molecules for lymphocyte interactions and other viral genes stimulate host cell genes and local production of cytokines and chemokines which can recruit a broad antitumor response in vivo. A large variety of human tumor cells is shown to be efficiently infected by NDV with viral replication being independent of tumor cell proliferation. Such properties make NDV a suitable agent for modification of noncultured freshly isolated and gamma-irradiated patient-derived tumor cells. For the apathogenic non-lytic strain NDV-Ulster which is used in our clinical vaccine trials, we demonstrate selective replication in tumor cells as compared with corresponding normal cells. Furthermore, we present evidence that new virions produced by infected tumor cells are non-infectious using three different quantitative test methods. Our results demonstrate feasibility and broad applicability of this strategy of human tumor vaccine modification. Post-operative vaccination with the autologous virus-modified vaccine ATV-NDV thus provides a reasonable potential for pleiotropic modifications of the immune response of cancer patients against their own tumor.  (+info)

Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin. (5/372)

Despite active therapies for small cell lung cancer (SCLC), most patients relapse and die of the disease. The present study evaluates immunization using the anti-idiotypic antibody BEC2, which mimics the ganglioside GD3 expressed on the surface of most SCLC tumors, combined with Bacillus Calmette-Guerin (BCG) as an immune adjuvant. We hypothesized that active immunization could alter the natural history of the disease. Fifteen patients who had completed standard therapy for SCLC received a series of five intradermal immunizations consisting of 2.5 mg of BEC2 plus BCG over a 10-week period. Blood was collected for serological analysis, and outcome was monitored. All patients developed anti-BEC2 antibodies, despite having received chemotherapy with or without thoracic radiation. We detected anti-GD3 antibodies in five patients, including those with the longest relapse-free survival. The median relapse-free survival for patients with extensive stage disease is 11 months and has not been reached for patients with limited stage disease (>47 months), with only one of seven patients having relapsed after a median follow-up of 47 months. Immunization of patients with SCLC after standard therapy using BEC2 plus BCG can induce anti-GD3 antibodies and is safe. The survival and relapse-free survival in this group of patients are substantially better than those observed in a prior group of similar patients. A Phase III trial is being conducted to evaluate BEC2 plus BCG as adjuvant therapy after chemotherapy and irradiation.  (+info)

A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. (6/372)

Dendritic cells (DCs), antigen-presenting cells capable of priming naive T cells to specific antigens in an HLA-restricted fashion, have been demonstrated to induce protective T cell-mediated immunity in tumor-bearing animals. We performed this study to test the safety, feasibility, and clinical response of immunizations with in vitro-generated DCs, loaded with an HLA-A2-restricted peptide fragment of the tumor antigen carcinoembryonic antigen (CEA), for the treatment of patients with advanced CEA-expressing malignancies. Cell preparations enriched for autologous DCs were generated from the patients' plastic adherent peripheral blood mononuclear cells in serum-free media supplemented with granulocyte macrophage colony-stimulating factor and interleukin-4. Within the cell preparation, 66% of the cells expressed the phenotype typical for DCs (CD86high, HLA-DRhigh, and CD14low). The DCs were loaded with the CEA peptide CAP-1 and cryopreserved. Groups of three to six patients received four weekly or biweekly i.v. infusions of the CAP-1-loaded DC in escalating dose levels of 1 x 10(7), 3 x 10(7), and 1 x 10(8) cells/dose. A subset of the patients in the last group also received intradermal injections of 1 x 10(6) DCs. There were no toxicities directly referable to the treatments. One patient had a minor response, and one had stable disease. Skin punch biopsy at DC injection sites demonstrated pleomorphic infiltrates in the three patients evaluated. We conclude that it is feasible and safe to generate and administer large numbers of previously cryopreserved DCs loaded with CAP-1 peptide to patients with advanced malignancies.  (+info)

Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. (7/372)

Dendritic cells (DCs) are professional Ag-presenting cells that are being considered as potential immunotherapeutic agents to promote host immune responses against tumor Ags. In this study, recombinant adenovirus (Ad) vectors encoding melanoma-associated Ags were used to transduce murine DCs, which were then tested for their ability to activate CTL and induce protective immunity against B16 melanoma tumor cells. Immunization of C57BL/6 mice with DCs transduced with Ad vector encoding the hugp100 melanoma Ag (Ad2/hugp100) elicited the development of gp100-specific CTLs capable of lysing syngeneic fibroblasts transduced with Ad2/hugp100, as well as B16 cells expressing endogenous murine gp100. The induction of gp100-specific CTLs was associated with long term protection against lethal s.c. challenge with B16 cells. It was also possible to induce effective immunity against a murine melanoma self Ag, tyrosinase-related protein-2, using DCs transduced with Ad vector encoding the Ag. The level of antitumor protection achieved was dependent on the dose of DCs and required CD4+ T cell activity. Importantly, immunization with Ad vector-transduced DCs was not impaired in mice that had been preimmunized against Ad to mimic the immune status of the general human population. Finally, DC-based immunization also afforded partial protection against established B16 tumor cells, and the inhibition of tumor growth was improved by simultaneous immunization against two melanoma-associated Ags as opposed to either one alone. Taken together, these results support the concept of cancer immunotherapy using DCs transduced with Ad vectors encoding tumor-associated Ags.  (+info)

Pretreatment serum markers and lymphocyte response to interleukin-2 therapy. (8/372)

Lymphocytosis is a marker of subcutaneous interleukin (IL)-2 therapy efficacy, whereas baseline elevated inflammatory indices were noticed in IL-2-resistant disease. The aim of this study was to analyse the relationship between pretreatment circulating values of IL-6, neopterin, sIL-2R, ESR and the changes in lymphocyte number in response to IL-2 administration. Twenty metastatic renal cell cancer patients were treated with subcutaneous IL-2 immunotherapy (6 000 000 IU day(-1) for 6 days per week for 4 weeks); tumour response consisted of partial response (PR) in four patients, stable disease (SD) in eight patients and progressive disease (PD) in eight patients. Abnormally high pretreatment values of each marker were found as follows: IL-6 in seven patients, neopterin in nine patients, sIL-2R in 13 patients. In response to IL-2 immunotherapy, a significantly higher mean increase in lymphocyte number and a higher percentage of patients with tumour response or stable disease were observed when pretreatment values of IL-6, neopterin and sIL-2R were within the normal range, in comparison to patients with high values for these markers. The pretreatment excess of these serum inflammatory markers seems to negatively influence both the host and tumour response to IL-2 administration, by preventing the IL-2-induced lymphocytosis and resulting in tumour progression. Further studies are requested to verify if overall survival and quality of life may depend on pretreatment host immune status and/or lymphocyte response after IL-2 administration.  (+info)

Immunotherapy is a type of medical treatment that uses the body's own immune system to fight against diseases, such as cancer. It involves the use of substances (like vaccines, medications, or immune cells) that stimulate or suppress the immune system to help it recognize and destroy harmful disease-causing cells or agents, like tumor cells.

Immunotherapy can work in several ways:

1. Activating the immune system: Certain immunotherapies boost the body's natural immune responses, helping them recognize and attack cancer cells more effectively.
2. Suppressing immune system inhibitors: Some immunotherapies target and block proteins or molecules that can suppress the immune response, allowing the immune system to work more efficiently against diseases.
3. Replacing or enhancing specific immune cells: Immunotherapy can also involve administering immune cells (like T-cells) that have been genetically engineered or modified to recognize and destroy cancer cells.

Immunotherapies have shown promising results in treating various types of cancer, autoimmune diseases, and allergies. However, they can also cause side effects, as an overactive immune system may attack healthy tissues and organs. Therefore, careful monitoring is necessary during immunotherapy treatment.

Adoptive immunotherapy is a type of cancer treatment that involves the removal of immune cells from a patient, followed by their modification and expansion in the laboratory, and then reinfusion back into the patient to help boost their immune system's ability to fight cancer. This approach can be used to enhance the natural ability of T-cells (a type of white blood cell) to recognize and destroy cancer cells.

There are different types of adoptive immunotherapy, including:

1. T-cell transfer therapy: In this approach, T-cells are removed from the patient's tumor or blood, activated and expanded in the laboratory, and then reinfused back into the patient. Some forms of T-cell transfer therapy involve genetically modifying the T-cells to express chimeric antigen receptors (CARs) that recognize specific proteins on the surface of cancer cells.
2. Tumor-infiltrating lymphocyte (TIL) therapy: This type of adoptive immunotherapy involves removing T-cells directly from a patient's tumor, expanding them in the laboratory, and then reinfusing them back into the patient. The expanded T-cells are specifically targeted to recognize and destroy cancer cells.
3. Dendritic cell (DC) vaccine: DCs are specialized immune cells that help activate T-cells. In this approach, DCs are removed from the patient, exposed to tumor antigens in the laboratory, and then reinfused back into the patient to stimulate a stronger immune response against cancer cells.

Adoptive immunotherapy has shown promise in treating certain types of cancer, such as melanoma and leukemia, but more research is needed to determine its safety and efficacy in other types of cancer.

Active immunotherapy, also known as active immunization or vaccination, is a type of medical treatment that stimulates the immune system to develop an adaptive response against specific antigens, thereby providing protection against future exposures to those antigens. This is typically achieved through the administration of vaccines, which contain either weakened or inactivated pathogens, or components of pathogens (such as proteins or sugars), along with adjuvants that enhance the immune response. The goal of active immunotherapy is to induce long-term immunity by generating memory T and B cells, which can quickly recognize and respond to subsequent infections or reinfections with the targeted pathogen.

In contrast to passive immunotherapy, where preformed antibodies or immune cells are directly administered to a patient for immediate but temporary protection, active immunotherapy relies on the recipient's own immune system to mount a specific and durable response against the antigen of interest. This approach has been instrumental in preventing and controlling various infectious diseases, such as measles, mumps, rubella, polio, hepatitis B, and influenza, among others. Additionally, active immunotherapy is being explored as a potential strategy for treating cancer and other chronic diseases by targeting disease-specific antigens or modulating the immune system to enhance its ability to recognize and eliminate abnormal cells.

Desensitization, Immunologic is a medical procedure that aims to decrease the immune system's response to an allergen. This is achieved through the controlled exposure of the patient to gradually increasing amounts of the allergen, ultimately leading to a reduction in the severity of allergic reactions upon subsequent exposures. The process typically involves administering carefully measured and incrementally larger doses of the allergen, either orally, sublingually (under the tongue), or by injection, under medical supervision. Over time, this repeated exposure can help the immune system become less sensitive to the allergen, thereby alleviating allergic symptoms.

The specific desensitization protocol and administration method may vary depending on the type of allergen and individual patient factors. Immunologic desensitization is most commonly used for environmental allergens like pollen, dust mites, or pet dander, as well as insect venoms such as bee or wasp stings. It is important to note that this procedure should only be performed under the close supervision of a qualified healthcare professional, as there are potential risks involved, including anaphylaxis (a severe and life-threatening allergic reaction).

Cancer vaccines are a type of immunotherapy that stimulate the body's own immune system to recognize and destroy cancer cells. They can be prophylactic (preventive) or therapeutic (treatment) in nature. Prophylactic cancer vaccines, such as the human papillomavirus (HPV) vaccine, are designed to prevent the initial infection that can lead to certain types of cancer. Therapeutic cancer vaccines, on the other hand, are used to treat existing cancer by boosting the immune system's ability to identify and eliminate cancer cells. These vaccines typically contain specific antigens (proteins or sugars) found on the surface of cancer cells, which help the immune system to recognize and target them.

It is important to note that cancer vaccines are different from vaccines used to prevent infectious diseases, such as measles or influenza. While traditional vaccines introduce a weakened or inactivated form of a virus or bacteria to stimulate an immune response, cancer vaccines focus on training the immune system to recognize and attack cancer cells specifically.

There are several types of cancer vaccines under investigation, including:

1. Autologous cancer vaccines: These vaccines use the patient's own tumor cells, which are processed and then reintroduced into the body to stimulate an immune response.
2. Peptide-based cancer vaccines: These vaccines contain specific pieces (peptides) of proteins found on the surface of cancer cells. They are designed to trigger an immune response against cells that express these proteins.
3. Dendritic cell-based cancer vaccines: Dendritic cells are a type of immune cell responsible for presenting antigens to other immune cells, activating them to recognize and destroy infected or cancerous cells. In this approach, dendritic cells are isolated from the patient's blood, exposed to cancer antigens in the lab, and then reintroduced into the body to stimulate an immune response.
4. DNA-based cancer vaccines: These vaccines use pieces of DNA that code for specific cancer antigens. Once inside the body, these DNA fragments are taken up by cells, leading to the production of the corresponding antigen and triggering an immune response.
5. Viral vector-based cancer vaccines: In this approach, a harmless virus is modified to carry genetic material encoding cancer antigens. When introduced into the body, the virus infects cells, causing them to produce the cancer antigen and stimulating an immune response.

While some cancer vaccines have shown promising results in clinical trials, none have yet been approved for widespread use by regulatory authorities such as the US Food and Drug Administration (FDA). Researchers continue to explore and refine various vaccine strategies to improve their efficacy and safety.

Neoplasm antigens, also known as tumor antigens, are substances that are produced by cancer cells (neoplasms) and can stimulate an immune response. These antigens can be proteins, carbohydrates, or other molecules that are either unique to the cancer cells or are overexpressed or mutated versions of normal cellular proteins.

Neoplasm antigens can be classified into two main categories: tumor-specific antigens (TSAs) and tumor-associated antigens (TAAs). TSAs are unique to cancer cells and are not expressed by normal cells, while TAAs are present at low levels in normal cells but are overexpressed or altered in cancer cells.

TSAs can be further divided into viral antigens and mutated antigens. Viral antigens are produced when cancer is caused by a virus, such as human papillomavirus (HPV) in cervical cancer. Mutated antigens are the result of genetic mutations that occur during cancer development and are unique to each patient's tumor.

Neoplasm antigens play an important role in the immune response against cancer. They can be recognized by the immune system, leading to the activation of immune cells such as T cells and natural killer (NK) cells, which can then attack and destroy cancer cells. However, cancer cells often develop mechanisms to evade the immune response, allowing them to continue growing and spreading.

Understanding neoplasm antigens is important for the development of cancer immunotherapies, which aim to enhance the body's natural immune response against cancer. These therapies include checkpoint inhibitors, which block proteins that inhibit T cell activation, and therapeutic vaccines, which stimulate an immune response against specific tumor antigens.

Sublingual administration refers to a route of delivering medication or other substances through placement under the tongue, allowing for rapid absorption into the bloodstream through the mucous membranes located there. This method can allow for quick onset of action and avoids first-pass metabolism in the liver that may occur with oral administration. Common examples of sublingual medications include nitroglycerin for angina pectoris and certain forms of hormone replacement therapy.

Sublingual immunotherapy (SLIT) is a form of allergen immunotherapy that involves the administration of allergens under the tongue, typically in the form of dissolvable tablets or liquid drops. This treatment modality is used to treat allergic rhinitis (hay fever), allergic asthma, and other allergic conditions by exposing the immune system to small amounts of an allergen over a period of time, with the goal of inducing tolerance and reducing the severity of symptoms upon subsequent exposure to the allergen. The sublingual route is preferred because it allows for direct absorption of the allergen into the bloodstream while minimizing the risk of severe allergic reactions associated with injection-based immunotherapy.

Allergic rhinitis, seasonal (also known as hay fever) is a type of inflammation in the nose which occurs when an individual breathes in allergens such as pollen or mold spores. The immune system identifies these substances as harmful and releases histamine and other chemicals, causing symptoms such as sneezing, runny or stuffy nose, red, watery, and itchy eyes, cough, and fatigue. Unlike perennial allergic rhinitis, seasonal allergic rhinitis is worse during specific times of the year when certain plants pollinate.

Cytotoxic T-lymphocytes, also known as CD8+ T cells, are a type of white blood cell that plays a central role in the cell-mediated immune system. They are responsible for identifying and destroying virus-infected cells and cancer cells. When a cytotoxic T-lymphocyte recognizes a specific antigen presented on the surface of an infected or malignant cell, it becomes activated and releases toxic substances such as perforins and granzymes, which can create pores in the target cell's membrane and induce apoptosis (programmed cell death). This process helps to eliminate the infected or malignant cells and prevent the spread of infection or cancer.

Dendritic cells (DCs) are a type of immune cell that play a critical role in the body's defense against infection and cancer. They are named for their dendrite-like projections, which they use to interact with and sample their environment. DCs are responsible for processing antigens (foreign substances that trigger an immune response) and presenting them to T cells, a type of white blood cell that plays a central role in the immune system's response to infection and cancer.

DCs can be found throughout the body, including in the skin, mucous membranes, and lymphoid organs. They are able to recognize and respond to a wide variety of antigens, including those from bacteria, viruses, fungi, and parasites. Once they have processed an antigen, DCs migrate to the lymph nodes, where they present the antigen to T cells. This interaction activates the T cells, which then go on to mount a targeted immune response against the invading pathogen or cancerous cells.

DCs are a diverse group of cells that can be divided into several subsets based on their surface markers and function. Some DCs, such as Langerhans cells and dermal DCs, are found in the skin and mucous membranes, where they serve as sentinels for invading pathogens. Other DCs, such as plasmacytoid DCs and conventional DCs, are found in the lymphoid organs, where they play a role in activating T cells and initiating an immune response.

Overall, dendritic cells are essential for the proper functioning of the immune system, and dysregulation of these cells has been implicated in a variety of diseases, including autoimmune disorders and cancer.

An allergen is a substance that can cause an allergic reaction in some people. These substances are typically harmless to most people, but for those with allergies, the immune system mistakenly identifies them as threats and overreacts, leading to the release of histamines and other chemicals that cause symptoms such as itching, sneezing, runny nose, rashes, hives, and difficulty breathing. Common allergens include pollen, dust mites, mold spores, pet dander, insect venom, and certain foods or medications. When a person comes into contact with an allergen, they may experience symptoms that range from mild to severe, depending on the individual's sensitivity to the substance and the amount of exposure.

Neoplasms are abnormal growths of cells or tissues in the body that serve no physiological function. They can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms are typically slow growing and do not spread to other parts of the body, while malignant neoplasms are aggressive, invasive, and can metastasize to distant sites.

Neoplasms occur when there is a dysregulation in the normal process of cell division and differentiation, leading to uncontrolled growth and accumulation of cells. This can result from genetic mutations or other factors such as viral infections, environmental exposures, or hormonal imbalances.

Neoplasms can develop in any organ or tissue of the body and can cause various symptoms depending on their size, location, and type. Treatment options for neoplasms include surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapy, among others.

T-lymphocytes, also known as T-cells, are a type of white blood cell that plays a key role in the adaptive immune system's response to infection. They are produced in the bone marrow and mature in the thymus gland. There are several different types of T-cells, including CD4+ helper T-cells, CD8+ cytotoxic T-cells, and regulatory T-cells (Tregs).

CD4+ helper T-cells assist in activating other immune cells, such as B-lymphocytes and macrophages. They also produce cytokines, which are signaling molecules that help coordinate the immune response. CD8+ cytotoxic T-cells directly kill infected cells by releasing toxic substances. Regulatory T-cells help maintain immune tolerance and prevent autoimmune diseases by suppressing the activity of other immune cells.

T-lymphocytes are important in the immune response to viral infections, cancer, and other diseases. Dysfunction or depletion of T-cells can lead to immunodeficiency and increased susceptibility to infections. On the other hand, an overactive T-cell response can contribute to autoimmune diseases and chronic inflammation.

Melanoma is defined as a type of cancer that develops from the pigment-containing cells known as melanocytes. It typically occurs in the skin but can rarely occur in other parts of the body, including the eyes and internal organs. Melanoma is characterized by the uncontrolled growth and multiplication of melanocytes, which can form malignant tumors that invade and destroy surrounding tissue.

Melanoma is often caused by exposure to ultraviolet (UV) radiation from the sun or tanning beds, but it can also occur in areas of the body not exposed to the sun. It is more likely to develop in people with fair skin, light hair, and blue or green eyes, but it can affect anyone, regardless of their skin type.

Melanoma can be treated effectively if detected early, but if left untreated, it can spread to other parts of the body and become life-threatening. Treatment options for melanoma include surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapy, depending on the stage and location of the cancer. Regular skin examinations and self-checks are recommended to detect any changes or abnormalities in moles or other pigmented lesions that may indicate melanoma.

Interleukin-2 (IL-2) is a type of cytokine, which are signaling molecules that mediate and regulate immunity, inflammation, and hematopoiesis. Specifically, IL-2 is a growth factor for T cells, a type of white blood cell that plays a central role in the immune response. It is primarily produced by CD4+ T cells (also known as T helper cells) and stimulates the proliferation and differentiation of activated T cells, including effector T cells and regulatory T cells. IL-2 also has roles in the activation and function of other immune cells, such as B cells, natural killer cells, and dendritic cells. Dysregulation of IL-2 production or signaling can contribute to various pathological conditions, including autoimmune diseases, chronic infections, and cancer.

Monoclonal antibodies are a type of antibody that are identical because they are produced by a single clone of cells. They are laboratory-produced molecules that act like human antibodies in the immune system. They can be designed to attach to specific proteins found on the surface of cancer cells, making them useful for targeting and treating cancer. Monoclonal antibodies can also be used as a therapy for other diseases, such as autoimmune disorders and inflammatory conditions.

Monoclonal antibodies are produced by fusing a single type of immune cell, called a B cell, with a tumor cell to create a hybrid cell, or hybridoma. This hybrid cell is then able to replicate indefinitely, producing a large number of identical copies of the original antibody. These antibodies can be further modified and engineered to enhance their ability to bind to specific targets, increase their stability, and improve their effectiveness as therapeutic agents.

Monoclonal antibodies have several mechanisms of action in cancer therapy. They can directly kill cancer cells by binding to them and triggering an immune response. They can also block the signals that promote cancer growth and survival. Additionally, monoclonal antibodies can be used to deliver drugs or radiation directly to cancer cells, increasing the effectiveness of these treatments while minimizing their side effects on healthy tissues.

Monoclonal antibodies have become an important tool in modern medicine, with several approved for use in cancer therapy and other diseases. They are continuing to be studied and developed as a promising approach to treating a wide range of medical conditions.

Tumor-infiltrating lymphocytes (TILs) are a type of immune cell that have migrated from the bloodstream into a tumor. They are primarily composed of T cells, B cells, and natural killer (NK) cells. TILs can be found in various types of solid tumors, and their presence and composition have been shown to correlate with patient prognosis and response to certain therapies.

TILs play a crucial role in the immune response against cancer, as they are able to recognize and kill cancer cells. They can also release cytokines and chemokines that attract other immune cells to the tumor site, enhancing the anti-tumor immune response. However, tumors can develop mechanisms to evade or suppress the immune response, including the suppression of TILs.

TILs have emerged as a promising target for cancer immunotherapy, with adoptive cell transfer (ACT) being one of the most widely studied approaches. In ACT, TILs are isolated from a patient's tumor, expanded in the laboratory, and then reinfused back into the patient to enhance their anti-tumor immune response. This approach has shown promising results in clinical trials for several types of cancer, including melanoma and cervical cancer.

CD8-positive T-lymphocytes, also known as CD8+ T cells or cytotoxic T cells, are a type of white blood cell that plays a crucial role in the adaptive immune system. They are named after the CD8 molecule found on their surface, which is a protein involved in cell signaling and recognition.

CD8+ T cells are primarily responsible for identifying and destroying virus-infected cells or cancerous cells. When activated, they release cytotoxic granules that contain enzymes capable of inducing apoptosis (programmed cell death) in the target cells. They also produce cytokines such as interferon-gamma, which can help coordinate the immune response and activate other immune cells.

CD8+ T cells are generated in the thymus gland and are a type of T cell, which is a lymphocyte that matures in the thymus and plays a central role in cell-mediated immunity. They recognize and respond to specific antigens presented on the surface of infected or cancerous cells in conjunction with major histocompatibility complex (MHC) class I molecules.

Overall, CD8+ T cells are an essential component of the immune system's defense against viral infections and cancer.

I cannot provide a specific medical definition for "Melanoma, Experimental," as it is not a standardized medical term. However, I can give you information about melanoma and experimental treatments related to this disease.

Melanoma is a type of cancer that develops from pigment-producing cells known as melanocytes. It usually occurs in the skin but can rarely occur in other parts of the body, such as the eyes or internal organs. Melanoma is characterized by the uncontrolled growth and multiplication of melanocytes, forming malignant tumors.

Experimental treatments for melanoma refer to novel therapeutic strategies that are currently being researched and tested in clinical trials. These experimental treatments may include:

1. Targeted therapies: Drugs that target specific genetic mutations or molecular pathways involved in melanoma growth and progression. Examples include BRAF and MEK inhibitors, such as vemurafenib, dabrafenib, and trametinib.
2. Immunotherapies: Treatments designed to enhance the immune system's ability to recognize and destroy cancer cells. These may include checkpoint inhibitors (e.g., ipilimumab, nivolumab, pembrolizumab), adoptive cell therapies (e.g., CAR T-cell therapy), and therapeutic vaccines.
3. Oncolytic viruses: Genetically modified viruses that can selectively infect and kill cancer cells while leaving healthy cells unharmed. Talimogene laherparepvec (T-VEC) is an example of an oncolytic virus approved for the treatment of advanced melanoma.
4. Combination therapies: The use of multiple experimental treatments in combination to improve efficacy and reduce the risk of resistance. For instance, combining targeted therapies with immunotherapies or different types of immunotherapies.
5. Personalized medicine approaches: Using genetic testing and biomarker analysis to identify the most effective treatment for an individual patient based on their specific tumor characteristics.

It is essential to consult with healthcare professionals and refer to clinical trial databases, such as ClinicalTrials.gov, for up-to-date information on experimental treatments for melanoma.

Passive immunization is a type of temporary immunity that is transferred to an individual through the injection of antibodies produced outside of the body, rather than through the active production of antibodies in the body in response to vaccination or infection. This can be done through the administration of preformed antibodies, such as immune globulins, which contain a mixture of antibodies that provide immediate protection against specific diseases.

Passive immunization is often used in situations where individuals have been exposed to a disease and do not have time to develop their own active immune response, or in cases where individuals are unable to produce an adequate immune response due to certain medical conditions. It can also be used as a short-term measure to provide protection until an individual can receive a vaccination that will confer long-term immunity.

Passive immunization provides immediate protection against disease, but the protection is typically short-lived, lasting only a few weeks or months. This is because the transferred antibodies are gradually broken down and eliminated by the body over time. In contrast, active immunization confers long-term immunity through the production of memory cells that can mount a rapid and effective immune response upon re-exposure to the same pathogen in the future.

Immunologic cytotoxicity refers to the damage or destruction of cells that occurs as a result of an immune response. This process involves the activation of immune cells, such as cytotoxic T cells and natural killer (NK) cells, which release toxic substances, such as perforins and granzymes, that can kill target cells.

In addition, antibodies produced by B cells can also contribute to immunologic cytotoxicity by binding to antigens on the surface of target cells and triggering complement-mediated lysis or antibody-dependent cellular cytotoxicity (ADCC) by activating immune effector cells.

Immunologic cytotoxicity plays an important role in the body's defense against viral infections, cancer cells, and other foreign substances. However, it can also contribute to tissue damage and autoimmune diseases if the immune system mistakenly targets healthy cells or tissues.

HLA-A2 antigen is a type of human leukocyte antigen (HLA) class I molecule, which is found on the surface of cells in our body. HLA molecules are responsible for presenting pieces of proteins (peptides) from inside the cell to the immune system's T-cells, helping them distinguish between "self" and "non-self" proteins.

HLA-A2 is one of the most common HLA class I antigens in the Caucasian population, with an estimated frequency of around 50%. It presents a variety of peptides to T-cells, including those derived from viruses and tumor cells. The presentation of these peptides can trigger an immune response, leading to the destruction of infected or malignant cells.

It is important to note that HLA typing is crucial in organ transplantation, as a mismatch between donor and recipient HLA antigens can lead to rejection of the transplanted organ. Additionally, HLA-A2 has been associated with certain autoimmune diseases and cancer types, making it an area of interest for researchers studying these conditions.

Bee venom is a poisonous substance that a honeybee (Apis mellifera) injects into the skin of a person or animal when it stings. It's produced in the venom gland and stored in the venom sac of the bee. Bee venom is a complex mixture of proteins, peptides, and other compounds. The main active components of bee venom include melittin, apamin, and phospholipase A2.

Melittin is a toxic peptide that causes pain, redness, and swelling at the site of the sting. It also has hemolytic (red blood cell-destroying) properties. Apamin is a neurotoxin that can affect the nervous system and cause neurological symptoms in severe cases. Phospholipase A2 is an enzyme that can damage cell membranes and contribute to the inflammatory response.

Bee venom has been used in traditional medicine for centuries, particularly in China and other parts of Asia. It's believed to have anti-inflammatory, analgesic (pain-relieving), and immunomodulatory effects. Some studies suggest that bee venom may have therapeutic potential for a variety of medical conditions, including rheumatoid arthritis, multiple sclerosis, and chronic pain. However, more research is needed to confirm these findings and to determine the safety and efficacy of bee venom therapy.

It's important to note that bee stings can cause severe allergic reactions (anaphylaxis) in some people, which can be life-threatening. If you experience symptoms such as difficulty breathing, rapid heartbeat, or hives after being stung by a bee, seek medical attention immediately.

Lymphocyte activation is the process by which B-cells and T-cells (types of lymphocytes) become activated to perform effector functions in an immune response. This process involves the recognition of specific antigens presented on the surface of antigen-presenting cells, such as dendritic cells or macrophages.

The activation of B-cells leads to their differentiation into plasma cells that produce antibodies, while the activation of T-cells results in the production of cytotoxic T-cells (CD8+ T-cells) that can directly kill infected cells or helper T-cells (CD4+ T-cells) that assist other immune cells.

Lymphocyte activation involves a series of intracellular signaling events, including the binding of co-stimulatory molecules and the release of cytokines, which ultimately result in the expression of genes involved in cell proliferation, differentiation, and effector functions. The activation process is tightly regulated to prevent excessive or inappropriate immune responses that can lead to autoimmunity or chronic inflammation.

C57BL/6 (C57 Black 6) is an inbred strain of laboratory mouse that is widely used in biomedical research. The term "inbred" refers to a strain of animals where matings have been carried out between siblings or other closely related individuals for many generations, resulting in a population that is highly homozygous at most genetic loci.

The C57BL/6 strain was established in 1920 by crossing a female mouse from the dilute brown (DBA) strain with a male mouse from the black strain. The resulting offspring were then interbred for many generations to create the inbred C57BL/6 strain.

C57BL/6 mice are known for their robust health, longevity, and ease of handling, making them a popular choice for researchers. They have been used in a wide range of biomedical research areas, including studies of cancer, immunology, neuroscience, cardiovascular disease, and metabolism.

One of the most notable features of the C57BL/6 strain is its sensitivity to certain genetic modifications, such as the introduction of mutations that lead to obesity or impaired glucose tolerance. This has made it a valuable tool for studying the genetic basis of complex diseases and traits.

Overall, the C57BL/6 inbred mouse strain is an important model organism in biomedical research, providing a valuable resource for understanding the genetic and molecular mechanisms underlying human health and disease.

Pollen, in a medical context, refers to the fine powder-like substance produced by the male reproductive organ of seed plants. It contains microscopic grains known as pollen grains, which are transported by various means such as wind, water, or insects to the female reproductive organ of the same or another plant species for fertilization.

Pollen can cause allergic reactions in some individuals, particularly during the spring and summer months when plants release large amounts of pollen into the air. These allergies, also known as hay fever or seasonal allergic rhinitis, can result in symptoms such as sneezing, runny nose, congestion, itchy eyes, and coughing.

It is important to note that while all pollen has the potential to cause allergic reactions, certain types of plants, such as ragweed, grasses, and trees, are more likely to trigger symptoms in sensitive individuals.

"Tumor escape" is not a widely recognized medical term with a specific definition. However, in the context of cancer biology and immunotherapy, "tumor escape" refers to the ability of cancer cells to evade or suppress the immune system's response, allowing the tumor to continue growing and spreading. This can occur through various mechanisms, such as downregulation of major histocompatibility complex (MHC) molecules, production of immunosuppressive cytokines, recruitment of regulatory T cells, or induction of apoptosis in immune effector cells. Understanding the mechanisms of tumor escape is crucial for developing more effective cancer treatments and improving patient outcomes.

Immunoglobulin E (IgE) is a type of antibody that plays a key role in the immune response to parasitic infections and allergies. It is produced by B cells in response to stimulation by antigens, such as pollen, pet dander, or certain foods. Once produced, IgE binds to receptors on the surface of mast cells and basophils, which are immune cells found in tissues and blood respectively. When an individual with IgE antibodies encounters the allergen again, the cross-linking of IgE molecules bound to the FcεRI receptor triggers the release of mediators such as histamine, leukotrienes, prostaglandins, and various cytokines from these cells. These mediators cause the symptoms of an allergic reaction, such as itching, swelling, and redness. IgE also plays a role in protecting against certain parasitic infections by activating eosinophils, which can kill the parasites.

In summary, Immunoglobulin E (IgE) is a type of antibody that plays a crucial role in the immune response to allergens and parasitic infections, it binds to receptors on the surface of mast cells and basophils, when an individual with IgE antibodies encounters the allergen again, it triggers the release of mediators from these cells causing the symptoms of an allergic reaction.

An antigen is any substance that can stimulate an immune response, leading to the production of antibodies or activation of immune cells. In plants, antigens are typically found on the surface of plant cells and may be derived from various sources such as:

1. Pathogens: Plant pathogens like bacteria, viruses, fungi, and oomycetes have unique molecules on their surfaces that can serve as antigens for the plant's immune system. These antigens are recognized by plant pattern recognition receptors (PRRs) and trigger an immune response.
2. Endogenous proteins: Some plant proteins, when expressed in abnormal locations or quantities, can be recognized as foreign by the plant's immune system and elicit an immune response. These proteins may serve as antigens and are involved in self/non-self recognition.
3. Glycoproteins: Plant cell surface glycoproteins, which contain carbohydrate moieties, can also act as antigens. They play a role in plant-microbe interactions and may be recognized by both the plant's immune system and pathogens.
4. Allergens: Certain plant proteins can cause allergic reactions in humans and animals when ingested or inhaled. These proteins, known as allergens, can also serve as antigens for the human immune system, leading to the production of IgE antibodies and triggering an allergic response.
5. Transgenic proteins: In genetically modified plants, new proteins introduced through genetic engineering may be recognized as foreign by the plant's immune system or even by the human immune system in some cases. These transgenic proteins can serve as antigens and have been a subject of concern in relation to food safety and potential allergies.

Understanding plant antigens is crucial for developing effective strategies for plant disease management, vaccine development, and improving food safety and allergy prevention.

BCG (Bacillus Calmette-Guérin) vaccine is a type of immunization used primarily to prevent tuberculosis (TB). It contains a live but weakened strain of Mycobacterium bovis, which is related to the bacterium that causes TB in humans (Mycobacterium tuberculosis).

The BCG vaccine works by stimulating an immune response in the body, enabling it to better resist infection with TB bacteria if exposed in the future. It is often given to infants and children in countries where TB is common, and its use varies depending on the national immunization policies. The protection offered by the BCG vaccine is moderate and may not last for a very long time.

In addition to its use against TB, the BCG vaccine has also been investigated for its potential therapeutic role in treating bladder cancer and some other types of cancer. The mechanism of action in these cases is thought to be related to the vaccine's ability to stimulate an immune response against abnormal cells.

There is currently no medical definition for "Alzheimer vaccines" as there are no vaccines that have been approved for use in preventing or curing Alzheimer's disease. However, there are several experimental immunotherapy treatments being investigated in clinical trials. These therapies aim to stimulate the immune system to target and clear beta-amyloid plaques, which are a hallmark pathological feature of Alzheimer's disease.

One type of experimental immunotherapy is known as an active immunization approach, where a vaccine is used to stimulate the patient's own immune system to produce antibodies against beta-amyloid. An example of this approach is the AN1792 vaccine, which was tested in clinical trials but unfortunately showed significant side effects and did not demonstrate clinical benefits.

Another type of experimental immunotherapy is known as a passive immunization approach, where pre-made antibodies are given to the patient through infusions. Several monoclonal antibodies targeting beta-amyloid have been tested in clinical trials, with some showing promise in reducing beta-amyloid levels and slowing cognitive decline. However, further research is needed to determine their safety and efficacy before they can be approved for use as a treatment or prevention for Alzheimer's disease.

BALB/c is an inbred strain of laboratory mouse that is widely used in biomedical research. The strain was developed at the Institute of Cancer Research in London by Henry Baldwin and his colleagues in the 1920s, and it has since become one of the most commonly used inbred strains in the world.

BALB/c mice are characterized by their black coat color, which is determined by a recessive allele at the tyrosinase locus. They are also known for their docile and friendly temperament, making them easy to handle and work with in the laboratory.

One of the key features of BALB/c mice that makes them useful for research is their susceptibility to certain types of tumors and immune responses. For example, they are highly susceptible to developing mammary tumors, which can be induced by chemical carcinogens or viral infection. They also have a strong Th2-biased immune response, which makes them useful models for studying allergic diseases and asthma.

BALB/c mice are also commonly used in studies of genetics, neuroscience, behavior, and infectious diseases. Because they are an inbred strain, they have a uniform genetic background, which makes it easier to control for genetic factors in experiments. Additionally, because they have been bred in the laboratory for many generations, they are highly standardized and reproducible, making them ideal subjects for scientific research.

Cytokine-Induced Killer (CIK) cells are a heterogeneous population of immune effector cells, primarily consisting of CD3+CD56+ T lymphocytes, generated through the ex vivo expansion of peripheral blood mononuclear cells in the presence of interferon-gamma, interleukin-2, and anti-CD3 antibody. These cells exhibit non-MHC-restricted cytotoxicity against various tumor cell types and have been investigated as a potential adoptive immunotherapy for cancer.

Hypersensitivity is an exaggerated or inappropriate immune response to a substance that is generally harmless to most people. It's also known as an allergic reaction. This abnormal response can be caused by various types of immunological mechanisms, including antibody-mediated reactions (types I, II, and III) and cell-mediated reactions (type IV). The severity of the hypersensitivity reaction can range from mild discomfort to life-threatening conditions. Common examples of hypersensitivity reactions include allergic rhinitis, asthma, atopic dermatitis, food allergies, and anaphylaxis.

A cell line that is derived from tumor cells and has been adapted to grow in culture. These cell lines are often used in research to study the characteristics of cancer cells, including their growth patterns, genetic changes, and responses to various treatments. They can be established from many different types of tumors, such as carcinomas, sarcomas, and leukemias. Once established, these cell lines can be grown and maintained indefinitely in the laboratory, allowing researchers to conduct experiments and studies that would not be feasible using primary tumor cells. It is important to note that tumor cell lines may not always accurately represent the behavior of the original tumor, as they can undergo genetic changes during their time in culture.

HLA-A24 antigen is a type of human leukocyte antigen (HLA) found on the surface of cells. The HLAs are a group of proteins that play an important role in the body's immune system. They help the immune system distinguish between the body's own cells and foreign substances, such as viruses and bacteria.

The HLA-A24 antigen is one of many different types of HLAs that can be present on the surface of a person's cells. It is located on chromosome 6 and is encoded by the HLA-A gene. The HLA-A24 antigen is found in approximately 15-20% of the Asian population, and is less common in other populations.

The HLA-A24 antigen is involved in presenting pieces of proteins (peptides) to T-cells, a type of white blood cell that plays a central role in the body's immune response. The presentation of these peptides helps the T-cells recognize and respond to foreign substances, such as viruses and cancer cells.

Certain diseases have been associated with the presence of the HLA-A24 antigen, including some types of autoimmune disorders and certain cancers. However, having the HLA-A24 antigen does not necessarily mean that a person will develop these conditions. It is important to note that many other factors, such as genetic and environmental factors, also contribute to the development of these diseases.

An epitope is a specific region on an antigen (a substance that triggers an immune response) that is recognized and bound by an antibody or a T-cell receptor. In the case of T-lymphocytes, which are a type of white blood cell that plays a central role in cell-mediated immunity, epitopes are typically presented on the surface of infected cells in association with major histocompatibility complex (MHC) molecules.

T-lymphocytes recognize and respond to epitopes through their T-cell receptors (TCRs), which are membrane-bound proteins that can bind to specific epitopes presented on the surface of infected cells. There are two main types of T-lymphocytes: CD4+ T-cells, also known as helper T-cells, and CD8+ T-cells, also known as cytotoxic T-cells.

CD4+ T-cells recognize epitopes presented in the context of MHC class II molecules, which are typically expressed on the surface of professional antigen-presenting cells such as dendritic cells, macrophages, and B-cells. CD4+ T-cells help to coordinate the immune response by producing cytokines that activate other immune cells.

CD8+ T-cells recognize epitopes presented in the context of MHC class I molecules, which are expressed on the surface of almost all nucleated cells. CD8+ T-cells are able to directly kill infected cells by releasing cytotoxic granules that contain enzymes that can induce apoptosis (programmed cell death) in the target cell.

In summary, epitopes are specific regions on antigens that are recognized and bound by T-lymphocytes through their T-cell receptors. CD4+ T-cells recognize epitopes presented in the context of MHC class II molecules, while CD8+ T-cells recognize epitopes presented in the context of MHC class I molecules.

Insect bites and stings refer to the penetration of the skin by insects, such as mosquitoes, fleas, ticks, or bees, often resulting in localized symptoms including redness, swelling, itching, and pain. The reaction can vary depending on the individual's sensitivity and the type of insect. In some cases, systemic reactions like anaphylaxis may occur, which requires immediate medical attention. Treatment typically involves relieving symptoms with topical creams, antihistamines, or in severe cases, epinephrine. Prevention measures include using insect repellent and protective clothing.

Allergic rhinitis, perennial type, is a medical condition characterized by inflammation of the nasal passages caused by an allergic response to environmental allergens that are present throughout the year. Unlike seasonal allergic rhinitis, which is triggered by specific pollens or molds during certain times of the year, perennial allergic rhinitis is a persistent condition that occurs year-round.

Common allergens responsible for perennial allergic rhinitis include dust mites, cockroaches, pet dander, and indoor mold spores. Symptoms may include sneezing, runny or stuffy nose, itchy eyes, ears, throat, or roof of the mouth. Treatment options typically involve avoiding exposure to the offending allergens, if possible, as well as medications such as antihistamines, nasal corticosteroids, and leukotriene receptor antagonists to manage symptoms. Immunotherapy (allergy shots) may also be recommended for long-term management in some cases.

Immunologic adjuvants are substances that are added to a vaccine to enhance the body's immune response to the antigens contained in the vaccine. They work by stimulating the immune system and promoting the production of antibodies and activating immune cells, such as T-cells and macrophages, which help to provide a stronger and more sustained immune response to the vaccine.

Immunologic adjuvants can be derived from various sources, including bacteria, viruses, and chemicals. Some common examples include aluminum salts (alum), oil-in-water emulsions (such as MF59), and bacterial components (such as lipopolysaccharide or LPS).

The use of immunologic adjuvants in vaccines can help to improve the efficacy of the vaccine, particularly for vaccines that contain weak or poorly immunogenic antigens. They can also help to reduce the amount of antigen needed in a vaccine, which can be beneficial for vaccines that are difficult or expensive to produce.

It's important to note that while adjuvants can enhance the immune response to a vaccine, they can also increase the risk of adverse reactions, such as inflammation and pain at the injection site. Therefore, the use of immunologic adjuvants must be carefully balanced against their potential benefits and risks.

Interferon-gamma (IFN-γ) is a soluble cytokine that is primarily produced by the activation of natural killer (NK) cells and T lymphocytes, especially CD4+ Th1 cells and CD8+ cytotoxic T cells. It plays a crucial role in the regulation of the immune response against viral and intracellular bacterial infections, as well as tumor cells. IFN-γ has several functions, including activating macrophages to enhance their microbicidal activity, increasing the presentation of major histocompatibility complex (MHC) class I and II molecules on antigen-presenting cells, stimulating the proliferation and differentiation of T cells and NK cells, and inducing the production of other cytokines and chemokines. Additionally, IFN-γ has direct antiproliferative effects on certain types of tumor cells and can enhance the cytotoxic activity of immune cells against infected or malignant cells.

'Antibodies, Neoplasm' is a medical term that refers to abnormal antibodies produced by neoplastic cells, which are cells that have undergone uncontrolled division and form a tumor or malignancy. These antibodies can be produced in large quantities and may have altered structures or functions compared to normal antibodies.

Neoplastic antibodies can arise from various types of malignancies, including leukemias, lymphomas, and multiple myeloma. In some cases, these abnormal antibodies can interfere with the normal functioning of the immune system and contribute to the progression of the disease.

In addition, neoplastic antibodies can also be used as tumor markers for diagnostic purposes. For example, certain types of monoclonal gammopathy, such as multiple myeloma, are characterized by the overproduction of a single type of immunoglobulin, which can be detected in the blood or urine and used to monitor the disease.

Overall, 'Antibodies, Neoplasm' is a term that encompasses a wide range of abnormal antibodies produced by neoplastic cells, which can have significant implications for both the diagnosis and treatment of malignancies.

HLA-A antigens are a type of human leukocyte antigen (HLA) found on the surface of cells in our body. They are proteins that play an important role in the immune system by helping the body recognize and distinguish its own cells from foreign substances such as viruses, bacteria, and transplanted organs.

The HLA-A antigens are part of the major histocompatibility complex (MHC) class I molecules, which present peptide fragments from inside the cell to CD8+ T cells, also known as cytotoxic T lymphocytes (CTLs). The CTLs then recognize and destroy any cells that display foreign or abnormal peptides on their HLA-A antigens.

Each person has a unique set of HLA-A antigens, which are inherited from their parents. These antigens can vary widely between individuals, making it important to match HLA types in organ transplantation to reduce the risk of rejection. Additionally, certain HLA-A antigens have been associated with increased susceptibility or resistance to various diseases, including autoimmune disorders and infectious diseases.

Combined modality therapy (CMT) is a medical treatment approach that utilizes more than one method or type of therapy simultaneously or in close succession, with the goal of enhancing the overall effectiveness of the treatment. In the context of cancer care, CMT often refers to the combination of two or more primary treatment modalities, such as surgery, radiation therapy, and systemic therapies (chemotherapy, immunotherapy, targeted therapy, etc.).

The rationale behind using combined modality therapy is that each treatment method can target cancer cells in different ways, potentially increasing the likelihood of eliminating all cancer cells and reducing the risk of recurrence. The specific combination and sequence of treatments will depend on various factors, including the type and stage of cancer, patient's overall health, and individual preferences.

For example, a common CMT approach for locally advanced rectal cancer may involve preoperative (neoadjuvant) chemoradiation therapy, followed by surgery to remove the tumor, and then postoperative (adjuvant) chemotherapy. This combined approach allows for the reduction of the tumor size before surgery, increases the likelihood of complete tumor removal, and targets any remaining microscopic cancer cells with systemic chemotherapy.

It is essential to consult with a multidisciplinary team of healthcare professionals to determine the most appropriate CMT plan for each individual patient, considering both the potential benefits and risks associated with each treatment method.

Melanoma-specific antigens are proteins or other molecules that are present on melanoma cells but not normally found on healthy cells in the body. These antigens can be recognized by the immune system as foreign and trigger an immune response, making them potential targets for immunotherapy treatments for melanoma.

There are two main types of melanoma-specific antigens: tumor-specific antigens (TSAs) and tumor-associated antigens (TAAs). TSAs are unique to cancer cells and are not found on normal cells, while TAAs are overexpressed or mutated versions of proteins that are also present in normal cells.

Examples of melanoma-specific antigens include Melan-A/MART-1, gp100, and tyrosinase. These antigens have been studied extensively as targets for cancer vaccines, adoptive cell therapy, and other immunotherapy approaches to treat melanoma.

CD4-positive T-lymphocytes, also known as CD4+ T cells or helper T cells, are a type of white blood cell that plays a crucial role in the immune response. They express the CD4 receptor on their surface and help coordinate the immune system's response to infectious agents such as viruses and bacteria.

CD4+ T cells recognize and bind to specific antigens presented by antigen-presenting cells, such as dendritic cells or macrophages. Once activated, they can differentiate into various subsets of effector cells, including Th1, Th2, Th17, and Treg cells, each with distinct functions in the immune response.

CD4+ T cells are particularly important in the immune response to HIV (human immunodeficiency virus), which targets and destroys these cells, leading to a weakened immune system and increased susceptibility to opportunistic infections. The number of CD4+ T cells is often used as a marker of disease progression in HIV infection, with lower counts indicating more advanced disease.

Experimental neoplasms refer to abnormal growths or tumors that are induced and studied in a controlled laboratory setting, typically in animals or cell cultures. These studies are conducted to understand the fundamental mechanisms of cancer development, progression, and potential treatment strategies. By manipulating various factors such as genetic mutations, environmental exposures, and pharmacological interventions, researchers can gain valuable insights into the complex processes underlying neoplasm formation and identify novel targets for cancer therapy. It is important to note that experimental neoplasms may not always accurately represent human cancers, and further research is needed to translate these findings into clinically relevant applications.

Clinical trials are research studies that involve human participants and are designed to evaluate the safety and efficacy of new medical treatments, drugs, devices, or behavioral interventions. The purpose of clinical trials is to determine whether a new intervention is safe, effective, and beneficial for patients, as well as to compare it with currently available treatments. Clinical trials follow a series of phases, each with specific goals and criteria, before a new intervention can be approved by regulatory authorities for widespread use.

Clinical trials are conducted according to a protocol, which is a detailed plan that outlines the study's objectives, design, methodology, statistical analysis, and ethical considerations. The protocol is developed and reviewed by a team of medical experts, statisticians, and ethicists, and it must be approved by an institutional review board (IRB) before the trial can begin.

Participation in clinical trials is voluntary, and participants must provide informed consent before enrolling in the study. Informed consent involves providing potential participants with detailed information about the study's purpose, procedures, risks, benefits, and alternatives, as well as their rights as research subjects. Participants can withdraw from the study at any time without penalty or loss of benefits to which they are entitled.

Clinical trials are essential for advancing medical knowledge and improving patient care. They help researchers identify new treatments, diagnostic tools, and prevention strategies that can benefit patients and improve public health. However, clinical trials also pose potential risks to participants, including adverse effects from experimental interventions, time commitment, and inconvenience. Therefore, it is important for researchers to carefully design and conduct clinical trials to minimize risks and ensure that the benefits outweigh the risks.

The gp100 melanoma antigen, also known as Pmel17 or gp100, is a protein found on the surface of melanocytes, which are the pigment-producing cells in the skin. It is overexpressed in melanoma cells and can be recognized by the immune system as a foreign target, making it an attractive candidate for cancer immunotherapy. The gp100 protein plays a role in the formation and transport of melanosomes, which are organelles involved in the production and distribution of melanin. In melanoma, mutations or abnormal regulation of gp100 can contribute to uncontrolled cell growth and survival, leading to the development of cancer. The gp100 protein is used as a target for various immunotherapeutic approaches, such as vaccines and monoclonal antibodies, to stimulate an immune response against melanoma cells.

Natural Killer (NK) cells are a type of lymphocyte, which are large granular innate immune cells that play a crucial role in the host's defense against viral infections and malignant transformations. They do not require prior sensitization to target and destroy abnormal cells, such as virus-infected cells or tumor cells. NK cells recognize their targets through an array of germline-encoded activating and inhibitory receptors that detect the alterations in the cell surface molecules of potential targets. Upon activation, NK cells release cytotoxic granules containing perforins and granzymes to induce target cell apoptosis, and they also produce a variety of cytokines and chemokines to modulate immune responses. Overall, natural killer cells serve as a critical component of the innate immune system, providing rapid and effective responses against infected or malignant cells.

Picibanil is not a commonly used medical term, and it may be more familiar as the brand name for a specific preparation of Group A Streptococcus OK-432. It is an immunotherapeutic agent that has been used in Japan for the treatment of certain types of cancer, such as nasopharyngeal carcinoma and soft tissue sarcoma.

Group A Streptococcus OK-432 is a weakened form of a bacterium that causes strep throat. When administered, it stimulates the immune system to produce cytokines, which are substances that help regulate the immune response. This can enhance the body's ability to fight off cancer cells and potentially slow or stop tumor growth.

It is important to note that Picibanil/OK-432 is not approved for use in the United States and its effectiveness as a cancer treatment has not been extensively studied outside of Japan.

Flow cytometry is a medical and research technique used to measure physical and chemical characteristics of cells or particles, one cell at a time, as they flow in a fluid stream through a beam of light. The properties measured include:

* Cell size (light scatter)
* Cell internal complexity (granularity, also light scatter)
* Presence or absence of specific proteins or other molecules on the cell surface or inside the cell (using fluorescent antibodies or other fluorescent probes)

The technique is widely used in cell counting, cell sorting, protein engineering, biomarker discovery and monitoring disease progression, particularly in hematology, immunology, and cancer research.

Regulatory T-lymphocytes (Tregs), also known as suppressor T cells, are a subpopulation of T-cells that play a critical role in maintaining immune tolerance and preventing autoimmune diseases. They function to suppress the activation and proliferation of other immune cells, thereby regulating the immune response and preventing it from attacking the body's own tissues.

Tregs constitutively express the surface markers CD4 and CD25, as well as the transcription factor Foxp3, which is essential for their development and function. They can be further divided into subsets based on their expression of other markers, such as CD127 and CD45RA.

Tregs are critical for maintaining self-tolerance by suppressing the activation of self-reactive T cells that have escaped negative selection in the thymus. They also play a role in regulating immune responses to foreign antigens, such as those encountered during infection or cancer, and can contribute to the immunosuppressive microenvironment found in tumors.

Dysregulation of Tregs has been implicated in various autoimmune diseases, including type 1 diabetes, rheumatoid arthritis, and multiple sclerosis, as well as in cancer and infectious diseases. Therefore, understanding the mechanisms that regulate Treg function is an important area of research with potential therapeutic implications.

Antigen presentation is the process by which certain cells in the immune system, known as antigen presenting cells (APCs), display foreign or abnormal proteins (antigens) on their surface to other immune cells, such as T-cells. This process allows the immune system to recognize and mount a response against harmful pathogens, infected or damaged cells.

There are two main types of antigen presentation: major histocompatibility complex (MHC) class I and MHC class II presentation.

1. MHC class I presentation: APCs, such as dendritic cells, macrophages, and B-cells, process and load antigens onto MHC class I molecules, which are expressed on the surface of almost all nucleated cells in the body. The MHC class I-antigen complex is then recognized by CD8+ T-cells (cytotoxic T-cells), leading to the destruction of infected or damaged cells.
2. MHC class II presentation: APCs, particularly dendritic cells and B-cells, process and load antigens onto MHC class II molecules, which are mainly expressed on the surface of professional APCs. The MHC class II-antigen complex is then recognized by CD4+ T-cells (helper T-cells), leading to the activation of other immune cells, such as B-cells and macrophages, to eliminate the pathogen or damaged cells.

In summary, antigen presentation is a crucial step in the adaptive immune response, allowing for the recognition and elimination of foreign or abnormal substances that could potentially harm the body.

Wasp venoms are complex mixtures of bioactive molecules produced by wasps (Hymenoptera: Vespidae) to defend themselves and paralyze prey. The main components include:

1. Phospholipases A2 (PLA2): Enzymes that can cause pain, inflammation, and damage to cell membranes.
2. Hyaluronidase: An enzyme that helps spread the venom by breaking down connective tissues.
3. Proteases: Enzymes that break down proteins and contribute to tissue damage and inflammation.
4. Antigen 5: A major allergen that can cause severe allergic reactions (anaphylaxis) in sensitive individuals.
5. Mastoparan: A peptide that induces histamine release, leading to localized inflammation and pain.
6. Neurotoxins: Some wasp venoms contain neurotoxins that can cause paralysis or neurological symptoms.

The composition of wasp venoms may vary among species, and individual sensitivity to the components can result in different reactions ranging from localized pain, swelling, and redness to systemic allergic responses.

Kidney neoplasms refer to abnormal growths or tumors in the kidney tissues that can be benign (non-cancerous) or malignant (cancerous). These growths can originate from various types of kidney cells, including the renal tubules, glomeruli, and the renal pelvis.

Malignant kidney neoplasms are also known as kidney cancers, with renal cell carcinoma being the most common type. Benign kidney neoplasms include renal adenomas, oncocytomas, and angiomyolipomas. While benign neoplasms are generally not life-threatening, they can still cause problems if they grow large enough to compromise kidney function or if they undergo malignant transformation.

Early detection and appropriate management of kidney neoplasms are crucial for improving patient outcomes and overall prognosis. Regular medical check-ups, imaging studies, and urinalysis can help in the early identification of these growths, allowing for timely intervention and treatment.

Lymphokine-activated killer (LAK) cells are a type of immune cell that has been activated to kill certain types of cells, including cancer cells and virus-infected cells. They are called "lymphokine-activated" because they are activated through the action of lymphokines, which are proteins secreted by other immune cells. LAK cells are a type of natural killer (NK) cell, which are a type of white blood cell that plays a role in the body's defense against viruses and cancer.

LAK cells are generated in the laboratory by incubating peripheral blood mononuclear cells (PBMCs), which include lymphocytes and monocytes, with high concentrations of interleukin-2 (IL-2) for several days. This process activates and expands the population of NK cells, resulting in the formation of LAK cells. These activated cells are then able to recognize and kill a wide range of tumor cells and virus-infected cells, regardless of whether they express specific antigens or not.

LAK cell therapy is an experimental form of cancer treatment that involves infusing patients with large numbers of LAK cells in order to enhance their immune response against cancer. While some studies have shown promising results, more research is needed to determine the safety and effectiveness of this approach.

MART-1, also known as Melanoma Antigen Recognized by T-Cells 1 or Melan-A, is a protein that is primarily found in melanocytes, which are the pigment-producing cells located in the skin, eyes, and hair follicles. It is a member of the family of antigens called melanoma differentiation antigens (MDAs) that are specifically expressed in melanocytes and melanomas. MART-1 is considered a tumor-specific antigen because it is overexpressed in melanoma cells compared to normal cells, making it an attractive target for immunotherapy.

MART-1 is presented on the surface of melanoma cells in complex with major histocompatibility complex (MHC) class I molecules, where it can be recognized by cytotoxic T lymphocytes (CTLs). This recognition triggers an immune response that can lead to the destruction of melanoma cells. MART-1 has been widely used as a target in various immunotherapy approaches, including cancer vaccines and adoptive cell transfer therapies, with the goal of enhancing the body's own immune system to recognize and eliminate melanoma cells.

Carcinoma, renal cell (also known as renal cell carcinoma or RCC) is a type of cancer that originates in the lining of the tubules of the kidney. These tubules are small structures within the kidney that help filter waste and fluids from the blood to form urine.

Renal cell carcinoma is the most common type of kidney cancer in adults, accounting for about 80-85% of all cases. It can affect people of any age, but it is more commonly diagnosed in those over the age of 50.

There are several subtypes of renal cell carcinoma, including clear cell, papillary, chromophobe, and collecting duct carcinomas, among others. Each subtype has a different appearance under the microscope and may have a different prognosis and response to treatment.

Symptoms of renal cell carcinoma can vary but may include blood in the urine, flank pain, a lump or mass in the abdomen, unexplained weight loss, fatigue, and fever. Treatment options for renal cell carcinoma depend on the stage and grade of the cancer, as well as the patient's overall health and preferences. Treatment may include surgery, radiation therapy, chemotherapy, immunotherapy, or targeted therapy.

Cytokines are a broad and diverse category of small signaling proteins that are secreted by various cells, including immune cells, in response to different stimuli. They play crucial roles in regulating the immune response, inflammation, hematopoiesis, and cellular communication.

Cytokines mediate their effects by binding to specific receptors on the surface of target cells, which triggers intracellular signaling pathways that ultimately result in changes in gene expression, cell behavior, and function. Some key functions of cytokines include:

1. Regulating the activation, differentiation, and proliferation of immune cells such as T cells, B cells, natural killer (NK) cells, and macrophages.
2. Coordinating the inflammatory response by recruiting immune cells to sites of infection or tissue damage and modulating their effector functions.
3. Regulating hematopoiesis, the process of blood cell formation in the bone marrow, by controlling the proliferation, differentiation, and survival of hematopoietic stem and progenitor cells.
4. Modulating the development and function of the nervous system, including neuroinflammation, neuroprotection, and neuroregeneration.

Cytokines can be classified into several categories based on their structure, function, or cellular origin. Some common types of cytokines include interleukins (ILs), interferons (IFNs), tumor necrosis factors (TNFs), chemokines, colony-stimulating factors (CSFs), and transforming growth factors (TGFs). Dysregulation of cytokine production and signaling has been implicated in various pathological conditions, such as autoimmune diseases, chronic inflammation, cancer, and neurodegenerative disorders.

Immune tolerance, also known as immunological tolerance or specific immune tolerance, is a state of unresponsiveness or non-reactivity of the immune system towards a particular substance (antigen) that has the potential to elicit an immune response. This occurs when the immune system learns to distinguish "self" from "non-self" and does not attack the body's own cells, tissues, and organs.

In the context of transplantation, immune tolerance refers to the absence of a destructive immune response towards the transplanted organ or tissue, allowing for long-term graft survival without the need for immunosuppressive therapy. Immune tolerance can be achieved through various strategies, including hematopoietic stem cell transplantation, costimulation blockade, and regulatory T cell induction.

In summary, immune tolerance is a critical mechanism that prevents the immune system from attacking the body's own structures while maintaining the ability to respond appropriately to foreign pathogens and antigens.

Transgenic mice are genetically modified rodents that have incorporated foreign DNA (exogenous DNA) into their own genome. This is typically done through the use of recombinant DNA technology, where a specific gene or genetic sequence of interest is isolated and then introduced into the mouse embryo. The resulting transgenic mice can then express the protein encoded by the foreign gene, allowing researchers to study its function in a living organism.

The process of creating transgenic mice usually involves microinjecting the exogenous DNA into the pronucleus of a fertilized egg, which is then implanted into a surrogate mother. The offspring that result from this procedure are screened for the presence of the foreign DNA, and those that carry the desired genetic modification are used to establish a transgenic mouse line.

Transgenic mice have been widely used in biomedical research to model human diseases, study gene function, and test new therapies. They provide a valuable tool for understanding complex biological processes and developing new treatments for a variety of medical conditions.

I apologize for any confusion, but "Pyroglyphidae" is not a medical term. It is actually a family of small arthropods, specifically mites, that are often found in houses and other buildings. These mites are commonly known as dust mites or storage mites, and some species are associated with allergies and asthma symptoms in humans. If you have any questions related to medical terminology, I'll be happy to help!

Neoplasm transplantation is not a recognized or established medical procedure in the field of oncology. The term "neoplasm" refers to an abnormal growth of cells, which can be benign or malignant (cancerous). "Transplantation" typically refers to the surgical transfer of living cells, tissues, or organs from one part of the body to another or between individuals.

The concept of neoplasm transplantation may imply the transfer of cancerous cells or tissues from a donor to a recipient, which is not a standard practice due to ethical considerations and the potential harm it could cause to the recipient. In some rare instances, researchers might use laboratory animals to study the transmission and growth of human cancer cells, but this is done for scientific research purposes only and under strict regulatory guidelines.

In summary, there is no medical definition for 'Neoplasm Transplantation' as it does not represent a standard or ethical medical practice.

Adoptive transfer is a medical procedure in which immune cells are transferred from a donor to a recipient with the aim of providing immunity or treating a disease, such as cancer. This technique is often used in the field of immunotherapy and involves isolating specific immune cells (like T-cells) from the donor, expanding their numbers in the laboratory, and then infusing them into the patient. The transferred cells are expected to recognize and attack the target cells, such as malignant or infected cells, leading to a therapeutic effect. This process requires careful matching of donor and recipient to minimize the risk of rejection and graft-versus-host disease.

An epitope is a specific region on the surface of an antigen (a molecule that can trigger an immune response) that is recognized by an antibody, B-cell receptor, or T-cell receptor. It is also commonly referred to as an antigenic determinant. Epitopes are typically composed of linear amino acid sequences or conformational structures made up of discontinuous amino acids in the antigen. They play a crucial role in the immune system's ability to differentiate between self and non-self molecules, leading to the targeted destruction of foreign substances like viruses and bacteria. Understanding epitopes is essential for developing vaccines, diagnostic tests, and immunotherapies.

Skin tests are medical diagnostic procedures that involve the application of a small amount of a substance to the skin, usually through a scratch, prick, or injection, to determine if the body has an allergic reaction to it. The most common type of skin test is the patch test, which involves applying a patch containing a small amount of the suspected allergen to the skin and observing the area for signs of a reaction, such as redness, swelling, or itching, over a period of several days. Another type of skin test is the intradermal test, in which a small amount of the substance is injected just beneath the surface of the skin. Skin tests are used to help diagnose allergies, including those to pollen, mold, pets, and foods, as well as to identify sensitivities to medications, chemicals, and other substances.

"Cryptomeria" is not a term commonly used in medical definitions. It is actually the scientific name for a type of evergreen tree, also known as Japanese cedar. In some cases, Cryptomeria pollen may cause allergic reactions in susceptible individuals, leading to symptoms such as sneezing, runny nose, and itchy eyes. However, it is not a medical condition itself.

'Tumor cells, cultured' refers to the process of removing cancerous cells from a tumor and growing them in controlled laboratory conditions. This is typically done by isolating the tumor cells from a patient's tissue sample, then placing them in a nutrient-rich environment that promotes their growth and multiplication.

The resulting cultured tumor cells can be used for various research purposes, including the study of cancer biology, drug development, and toxicity testing. They provide a valuable tool for researchers to better understand the behavior and characteristics of cancer cells outside of the human body, which can lead to the development of more effective cancer treatments.

It is important to note that cultured tumor cells may not always behave exactly the same way as they do in the human body, so findings from cell culture studies must be validated through further research, such as animal models or clinical trials.

Bispecific antibodies are a type of artificial protein that have been engineered to recognize and bind to two different antigens simultaneously. They are created by combining two separate antibody molecules, each with a unique binding site, into a single entity. This allows the bispecific antibody to link two cells or proteins together, bringing them into close proximity and facilitating various biological processes.

In the context of medicine and immunotherapy, bispecific antibodies are being investigated as a potential treatment for cancer and other diseases. For example, a bispecific antibody can be designed to recognize a specific tumor-associated antigen on the surface of cancer cells, while also binding to a component of the immune system, such as a T cell. This brings the T cell into close contact with the cancer cell, activating the immune system and triggering an immune response against the tumor.

Bispecific antibodies have several potential advantages over traditional monoclonal antibodies, which only recognize a single antigen. By targeting two different epitopes or antigens, bispecific antibodies can increase the specificity and affinity of the interaction, reducing off-target effects and improving therapeutic efficacy. Additionally, bispecific antibodies can bring together multiple components of the immune system, amplifying the immune response and enhancing the destruction of cancer cells.

Overall, bispecific antibodies represent a promising new class of therapeutics that have the potential to revolutionize the treatment of cancer and other diseases. However, further research is needed to fully understand their mechanisms of action and optimize their clinical use.

A neoplasm is a tumor or growth that is formed by an abnormal and excessive proliferation of cells, which can be benign or malignant. Neoplasm proteins are therefore any proteins that are expressed or produced in these neoplastic cells. These proteins can play various roles in the development, progression, and maintenance of neoplasms.

Some neoplasm proteins may contribute to the uncontrolled cell growth and division seen in cancer, such as oncogenic proteins that promote cell cycle progression or inhibit apoptosis (programmed cell death). Others may help the neoplastic cells evade the immune system, allowing them to proliferate undetected. Still others may be involved in angiogenesis, the formation of new blood vessels that supply the tumor with nutrients and oxygen.

Neoplasm proteins can also serve as biomarkers for cancer diagnosis, prognosis, or treatment response. For example, the presence or level of certain neoplasm proteins in biological samples such as blood or tissue may indicate the presence of a specific type of cancer, help predict the likelihood of cancer recurrence, or suggest whether a particular therapy will be effective.

Overall, understanding the roles and behaviors of neoplasm proteins can provide valuable insights into the biology of cancer and inform the development of new diagnostic and therapeutic strategies.

Immunologic factors refer to the elements of the immune system that contribute to the body's defense against foreign substances, infectious agents, and cancerous cells. These factors include various types of white blood cells (such as lymphocytes, neutrophils, monocytes, and eosinophils), antibodies, complement proteins, cytokines, and other molecules involved in the immune response.

Immunologic factors can be categorized into two main types: innate immunity and adaptive immunity. Innate immunity is the non-specific defense mechanism that provides immediate protection against pathogens through physical barriers (e.g., skin, mucous membranes), chemical barriers (e.g., stomach acid, enzymes), and inflammatory responses. Adaptive immunity, on the other hand, is a specific defense mechanism that develops over time as the immune system learns to recognize and respond to particular pathogens or antigens.

Abnormalities in immunologic factors can lead to various medical conditions, such as autoimmune disorders, immunodeficiency diseases, and allergies. Therefore, understanding immunologic factors is crucial for diagnosing and treating these conditions.

Subcutaneous injection is a route of administration where a medication or vaccine is delivered into the subcutaneous tissue, which lies between the skin and the muscle. This layer contains small blood vessels, nerves, and connective tissues that help to absorb the medication slowly and steadily over a period of time. Subcutaneous injections are typically administered using a short needle, at an angle of 45-90 degrees, and the dose is injected slowly to minimize discomfort and ensure proper absorption. Common sites for subcutaneous injections include the abdomen, thigh, or upper arm. Examples of medications that may be given via subcutaneous injection include insulin, heparin, and some vaccines.

Anaphylaxis is a severe, life-threatening systemic allergic reaction that occurs suddenly after exposure to an allergen (a substance that triggers an allergic reaction) to which the person has previously been sensitized. The symptoms of anaphylaxis include rapid onset of symptoms such as itching, hives, swelling of the throat and tongue, difficulty breathing, wheezing, cough, chest tightness, rapid heartbeat, hypotension (low blood pressure), shock, and in severe cases, loss of consciousness and death. Anaphylaxis is a medical emergency that requires immediate treatment with epinephrine (adrenaline) and other supportive measures to stabilize the patient's condition.

A subunit vaccine is a type of vaccine that contains a specific piece or component of the microorganism (such as a protein, sugar, or part of the bacterial outer membrane), instead of containing the entire organism. This piece of the microorganism is known as an antigen, and it stimulates an immune response in the body, allowing the development of immunity against the targeted infection without introducing the risk of disease associated with live vaccines.

Subunit vaccines offer several advantages over other types of vaccines. They are generally safer because they do not contain live or weakened microorganisms, making them suitable for individuals with weakened immune systems or specific medical conditions that prevent them from receiving live vaccines. Additionally, subunit vaccines can be designed to focus on the most immunogenic components of a pathogen, potentially leading to stronger and more targeted immune responses.

Examples of subunit vaccines include the Hepatitis B vaccine, which contains a viral protein, and the Haemophilus influenzae type b (Hib) vaccine, which uses pieces of the bacterial polysaccharide capsule. These vaccines have been crucial in preventing serious infectious diseases and reducing associated complications worldwide.

A vaccine is a biological preparation that provides active acquired immunity to a particular infectious disease. It typically contains an agent that resembles the disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and "remember" it, so that the immune system can more easily recognize and destroy any of these microorganisms that it encounters in the future.

Vaccines can be prophylactic (to prevent or ameliorate the effects of a future infection by a natural or "wild" pathogen), or therapeutic (to fight disease that is already present). The administration of vaccines is called vaccination. Vaccinations are generally administered through needle injections, but can also be administered by mouth or sprayed into the nose.

The term "vaccine" comes from Edward Jenner's 1796 use of cowpox to create immunity to smallpox. The first successful vaccine was developed in 1796 by Edward Jenner, who showed that milkmaids who had contracted cowpox did not get smallpox. He reasoned that exposure to cowpox protected against smallpox and tested his theory by injecting a boy with pus from a cowpox sore and then exposing him to smallpox, which the boy did not contract. The word "vaccine" is derived from Variolae vaccinae (smallpox of the cow), the term devised by Jenner to denote cowpox. He used it in 1798 during a conversation with a fellow physician and later in the title of his 1801 Inquiry.

Treatment outcome is a term used to describe the result or effect of medical treatment on a patient's health status. It can be measured in various ways, such as through symptoms improvement, disease remission, reduced disability, improved quality of life, or survival rates. The treatment outcome helps healthcare providers evaluate the effectiveness of a particular treatment plan and make informed decisions about future care. It is also used in clinical research to compare the efficacy of different treatments and improve patient care.

I'm sorry for any confusion, but "Hymenoptera" is not a medical term. It is a scientific classification in biology, specifically referring to an order of insects that includes sawflies, bees, ants, and wasps. These insects are characterized by having two pairs of membranous wings (except for some species that have only one pair or are wingless) and a slender waist. Some people may have allergic reactions to the venom of stinging Hymenoptera, such as bees and wasps, which can cause medical issues. However, "Hymenoptera" itself is not a medical term.

Peanut hypersensitivity, also known as peanut allergy, is an abnormal immune response to proteins found in peanuts. It is a type of IgE-mediated food hypersensitivity disorder. The body's immune system recognizes the peanut proteins as harmful and produces antibodies (IgE) against them. When the person comes into contact with peanuts again, these antibodies trigger the release of histamine and other chemicals, leading to a range of symptoms that can be mild or severe, including skin reactions, digestive problems, respiratory difficulties, and in some cases, anaphylaxis, which is a life-threatening emergency. It's important to note that peanut hypersensitivity should be diagnosed and managed by a medical professional.

Immunoglobulin G (IgG) is a type of antibody, which is a protective protein produced by the immune system in response to foreign substances like bacteria or viruses. IgG is the most abundant type of antibody in human blood, making up about 75-80% of all antibodies. It is found in all body fluids and plays a crucial role in fighting infections caused by bacteria, viruses, and toxins.

IgG has several important functions:

1. Neutralization: IgG can bind to the surface of bacteria or viruses, preventing them from attaching to and infecting human cells.
2. Opsonization: IgG coats the surface of pathogens, making them more recognizable and easier for immune cells like neutrophils and macrophages to phagocytose (engulf and destroy) them.
3. Complement activation: IgG can activate the complement system, a group of proteins that work together to help eliminate pathogens from the body. Activation of the complement system leads to the formation of the membrane attack complex, which creates holes in the cell membranes of bacteria, leading to their lysis (destruction).
4. Antibody-dependent cellular cytotoxicity (ADCC): IgG can bind to immune cells like natural killer (NK) cells and trigger them to release substances that cause target cells (such as virus-infected or cancerous cells) to undergo apoptosis (programmed cell death).
5. Immune complex formation: IgG can form immune complexes with antigens, which can then be removed from the body through various mechanisms, such as phagocytosis by immune cells or excretion in urine.

IgG is a critical component of adaptive immunity and provides long-lasting protection against reinfection with many pathogens. It has four subclasses (IgG1, IgG2, IgG3, and IgG4) that differ in their structure, function, and distribution in the body.

Cellular immunity, also known as cell-mediated immunity, is a type of immune response that involves the activation of immune cells, such as T lymphocytes (T cells), to protect the body against infected or damaged cells. This form of immunity is important for fighting off infections caused by viruses and intracellular bacteria, as well as for recognizing and destroying cancer cells.

Cellular immunity involves a complex series of interactions between various immune cells and molecules. When a pathogen infects a cell, the infected cell displays pieces of the pathogen on its surface in a process called antigen presentation. This attracts T cells, which recognize the antigens and become activated. Activated T cells then release cytokines, chemicals that help coordinate the immune response, and can directly attack and kill infected cells or help activate other immune cells to do so.

Cellular immunity is an important component of the adaptive immune system, which is able to learn and remember specific pathogens in order to mount a faster and more effective response upon subsequent exposure. This form of immunity is also critical for the rejection of transplanted organs, as the immune system recognizes the transplanted tissue as foreign and attacks it.

Dermatophagoides are a group of mites that are commonly found in house dust. They are a common cause of allergies and can be found in bedding, carpets, and upholstered furniture. Dermatophagoides mites feed on human skin cells and dander, and their feces and bodies contain proteins that can act as antigens. These antigens can trigger an immune response in some people, leading to the production of antibodies and the release of chemicals such as histamine, which can cause allergic symptoms such as sneezing, runny nose, and itchy eyes.

There are several species of Dermatophagoides mites that are known to cause allergies, including D. pteronyssinus and D. farinae. These mites are very small, measuring only about 0.3 millimeters in length, and are not visible to the naked eye. They thrive in warm, humid environments and are most active at night.

Exposure to Dermatophagoides antigens can occur through inhalation or skin contact. In people with allergies to these mites, symptoms can be triggered by activities such as making the bed, vacuuming, or sleeping on a mattress that is infested with mites. Allergy testing, such as a skin prick test or a blood test, can be used to diagnose an allergy to Dermatophagoides mites. Treatment options for allergies to these mites may include avoidance measures, medications, and immunotherapy (allergy shots).

CD (cluster of differentiation) antigens are cell-surface proteins that are expressed on leukocytes (white blood cells) and can be used to identify and distinguish different subsets of these cells. They are important markers in the field of immunology and hematology, and are commonly used to diagnose and monitor various diseases, including cancer, autoimmune disorders, and infectious diseases.

CD antigens are designated by numbers, such as CD4, CD8, CD19, etc., which refer to specific proteins found on the surface of different types of leukocytes. For example, CD4 is a protein found on the surface of helper T cells, while CD8 is found on cytotoxic T cells.

CD antigens can be used as targets for immunotherapy, such as monoclonal antibody therapy, in which antibodies are designed to bind to specific CD antigens and trigger an immune response against cancer cells or infected cells. They can also be used as markers to monitor the effectiveness of treatments and to detect minimal residual disease (MRD) after treatment.

It's important to note that not all CD antigens are exclusive to leukocytes, some can be found on other cell types as well, and their expression can vary depending on the activation state or differentiation stage of the cells.

A genetic vector is a vehicle, often a plasmid or a virus, that is used to introduce foreign DNA into a host cell as part of genetic engineering or gene therapy techniques. The vector contains the desired gene or genes, along with regulatory elements such as promoters and enhancers, which are needed for the expression of the gene in the target cells.

The choice of vector depends on several factors, including the size of the DNA to be inserted, the type of cell to be targeted, and the efficiency of uptake and expression required. Commonly used vectors include plasmids, adenoviruses, retroviruses, and lentiviruses.

Plasmids are small circular DNA molecules that can replicate independently in bacteria. They are often used as cloning vectors to amplify and manipulate DNA fragments. Adenoviruses are double-stranded DNA viruses that infect a wide range of host cells, including human cells. They are commonly used as gene therapy vectors because they can efficiently transfer genes into both dividing and non-dividing cells.

Retroviruses and lentiviruses are RNA viruses that integrate their genetic material into the host cell's genome. This allows for stable expression of the transgene over time. Lentiviruses, a subclass of retroviruses, have the advantage of being able to infect non-dividing cells, making them useful for gene therapy applications in post-mitotic tissues such as neurons and muscle cells.

Overall, genetic vectors play a crucial role in modern molecular biology and medicine, enabling researchers to study gene function, develop new therapies, and modify organisms for various purposes.

Animal disease models are specialized animals, typically rodents such as mice or rats, that have been genetically engineered or exposed to certain conditions to develop symptoms and physiological changes similar to those seen in human diseases. These models are used in medical research to study the pathophysiology of diseases, identify potential therapeutic targets, test drug efficacy and safety, and understand disease mechanisms.

The genetic modifications can include knockout or knock-in mutations, transgenic expression of specific genes, or RNA interference techniques. The animals may also be exposed to environmental factors such as chemicals, radiation, or infectious agents to induce the disease state.

Examples of animal disease models include:

1. Mouse models of cancer: Genetically engineered mice that develop various types of tumors, allowing researchers to study cancer initiation, progression, and metastasis.
2. Alzheimer's disease models: Transgenic mice expressing mutant human genes associated with Alzheimer's disease, which exhibit amyloid plaque formation and cognitive decline.
3. Diabetes models: Obese and diabetic mouse strains like the NOD (non-obese diabetic) or db/db mice, used to study the development of type 1 and type 2 diabetes, respectively.
4. Cardiovascular disease models: Atherosclerosis-prone mice, such as ApoE-deficient or LDLR-deficient mice, that develop plaque buildup in their arteries when fed a high-fat diet.
5. Inflammatory bowel disease models: Mice with genetic mutations affecting intestinal barrier function and immune response, such as IL-10 knockout or SAMP1/YitFc mice, which develop colitis.

Animal disease models are essential tools in preclinical research, but it is important to recognize their limitations. Differences between species can affect the translatability of results from animal studies to human patients. Therefore, researchers must carefully consider the choice of model and interpret findings cautiously when applying them to human diseases.

Genetic therapy, also known as gene therapy, is a medical intervention that involves the use of genetic material, such as DNA or RNA, to treat or prevent diseases. It works by introducing functional genes into cells to replace missing or faulty ones caused by genetic disorders or mutations. The introduced gene is incorporated into the recipient's genome, allowing for the production of a therapeutic protein that can help manage the disease symptoms or even cure the condition.

There are several approaches to genetic therapy, including:

1. Replacing a faulty gene with a healthy one
2. Inactivating or "silencing" a dysfunctional gene causing a disease
3. Introducing a new gene into the body to help fight off a disease, such as cancer

Genetic therapy holds great promise for treating various genetic disorders, including cystic fibrosis, muscular dystrophy, hemophilia, and certain types of cancer. However, it is still an evolving field with many challenges, such as efficient gene delivery, potential immune responses, and ensuring the safety and long-term effectiveness of the therapy.

Antigen-presenting cells (APCs) are a group of specialized cells in the immune system that play a critical role in initiating and regulating immune responses. They have the ability to engulf, process, and present antigens (molecules derived from pathogens or other foreign substances) on their surface in conjunction with major histocompatibility complex (MHC) molecules. This presentation of antigens allows APCs to activate T cells, which are crucial for adaptive immunity.

There are several types of APCs, including:

1. Dendritic cells (DCs): These are the most potent and professional APCs, found in various tissues throughout the body. DCs can capture antigens from their environment, process them, and migrate to lymphoid organs where they present antigens to T cells.
2. Macrophages: These large phagocytic cells are found in many tissues and play a role in both innate and adaptive immunity. They can engulf and digest pathogens, then present processed antigens on their MHC class II molecules to activate CD4+ T helper cells.
3. B cells: These are primarily responsible for humoral immune responses by producing antibodies against antigens. When activated, B cells can also function as APCs and present antigens on their MHC class II molecules to CD4+ T cells.

The interaction between APCs and T cells is critical for the development of an effective immune response against pathogens or other foreign substances. This process helps ensure that the immune system can recognize and eliminate threats while minimizing damage to healthy tissues.

Cytotoxicity tests, immunologic are a group of laboratory assays used to measure the immune-mediated damage or destruction (cytotoxicity) of cells. These tests are often used in medical research and clinical settings to evaluate the potential toxicity of drugs, biological agents, or environmental factors on specific types of cells.

Immunologic cytotoxicity tests typically involve the use of immune effector cells, such as cytotoxic T lymphocytes (CTLs) or natural killer (NK) cells, which can recognize and kill target cells that express specific antigens on their surface. The tests may also involve the use of antibodies or other immune molecules that can bind to target cells and trigger complement-mediated cytotoxicity.

There are several types of immunologic cytotoxicity tests, including:

1. Cytotoxic T lymphocyte (CTL) assays: These tests measure the ability of CTLs to recognize and kill target cells that express specific antigens. The test involves incubating target cells with CTLs and then measuring the amount of cell death or damage.
2. Natural killer (NK) cell assays: These tests measure the ability of NK cells to recognize and kill target cells that lack self-antigens or express stress-induced antigens. The test involves incubating target cells with NK cells and then measuring the amount of cell death or damage.
3. Antibody-dependent cellular cytotoxicity (ADCC) assays: These tests measure the ability of antibodies to bind to target cells and recruit immune effector cells, such as NK cells or macrophages, to mediate cell lysis. The test involves incubating target cells with antibodies and then measuring the amount of cell death or damage.
4. Complement-dependent cytotoxicity (CDC) assays: These tests measure the ability of complement proteins to bind to target cells and form a membrane attack complex that leads to cell lysis. The test involves incubating target cells with complement proteins and then measuring the amount of cell death or damage.

Immunologic cytotoxicity tests are important tools in immunology, cancer research, and drug development. They can help researchers understand how immune cells recognize and kill infected or damaged cells, as well as how to develop new therapies that enhance or inhibit these processes.

Antibodies are proteins produced by the immune system in response to the presence of a foreign substance, such as a bacterium or virus. They are capable of identifying and binding to specific antigens (foreign substances) on the surface of these invaders, marking them for destruction by other immune cells. Antibodies are also known as immunoglobulins and come in several different types, including IgA, IgD, IgE, IgG, and IgM, each with a unique function in the immune response. They are composed of four polypeptide chains, two heavy chains and two light chains, that are held together by disulfide bonds. The variable regions of the heavy and light chains form the antigen-binding site, which is specific to a particular antigen.

Skin neoplasms refer to abnormal growths or tumors in the skin that can be benign (non-cancerous) or malignant (cancerous). They result from uncontrolled multiplication of skin cells, which can form various types of lesions. These growths may appear as lumps, bumps, sores, patches, or discolored areas on the skin.

Benign skin neoplasms include conditions such as moles, warts, and seborrheic keratoses, while malignant skin neoplasms are primarily classified into melanoma, squamous cell carcinoma, and basal cell carcinoma. These three types of cancerous skin growths are collectively known as non-melanoma skin cancers (NMSCs). Melanoma is the most aggressive and dangerous form of skin cancer, while NMSCs tend to be less invasive but more common.

It's essential to monitor any changes in existing skin lesions or the appearance of new growths and consult a healthcare professional for proper evaluation and treatment if needed.

Antineoplastic agents are a class of drugs used to treat malignant neoplasms or cancer. These agents work by inhibiting the growth and proliferation of cancer cells, either by killing them or preventing their division and replication. Antineoplastic agents can be classified based on their mechanism of action, such as alkylating agents, antimetabolites, topoisomerase inhibitors, mitotic inhibitors, and targeted therapy agents.

Alkylating agents work by adding alkyl groups to DNA, which can cause cross-linking of DNA strands and ultimately lead to cell death. Antimetabolites interfere with the metabolic processes necessary for DNA synthesis and replication, while topoisomerase inhibitors prevent the relaxation of supercoiled DNA during replication. Mitotic inhibitors disrupt the normal functioning of the mitotic spindle, which is essential for cell division. Targeted therapy agents are designed to target specific molecular abnormalities in cancer cells, such as mutated oncogenes or dysregulated signaling pathways.

It's important to note that antineoplastic agents can also affect normal cells and tissues, leading to various side effects such as nausea, vomiting, hair loss, and myelosuppression (suppression of bone marrow function). Therefore, the use of these drugs requires careful monitoring and management of their potential adverse effects.

CTLA-4 (Cytotoxic T-Lymphocyte Associated Protein 4) antigen is a type of protein found on the surface of activated T cells, which are a type of white blood cell in the immune system. CTLA-4 plays an important role in regulating the immune response by functioning as a negative regulator of T cell activation.

CTLA-4 binds to CD80 and CD86 molecules on the surface of antigen-presenting cells, which are cells that display foreign antigens to T cells and activate them. By binding to these molecules, CTLA-4 inhibits T cell activation and helps prevent an overactive immune response.

CTLA-4 is a target for cancer immunotherapy because blocking its function can enhance the anti-tumor immune response. Certain drugs called checkpoint inhibitors work by blocking CTLA-4, allowing T cells to remain active and attack tumor cells more effectively.

Recombinant proteins are artificially created proteins produced through the use of recombinant DNA technology. This process involves combining DNA molecules from different sources to create a new set of genes that encode for a specific protein. The resulting recombinant protein can then be expressed, purified, and used for various applications in research, medicine, and industry.

Recombinant proteins are widely used in biomedical research to study protein function, structure, and interactions. They are also used in the development of diagnostic tests, vaccines, and therapeutic drugs. For example, recombinant insulin is a common treatment for diabetes, while recombinant human growth hormone is used to treat growth disorders.

The production of recombinant proteins typically involves the use of host cells, such as bacteria, yeast, or mammalian cells, which are engineered to express the desired protein. The host cells are transformed with a plasmid vector containing the gene of interest, along with regulatory elements that control its expression. Once the host cells are cultured and the protein is expressed, it can be purified using various chromatography techniques.

Overall, recombinant proteins have revolutionized many areas of biology and medicine, enabling researchers to study and manipulate proteins in ways that were previously impossible.

T-lymphocyte subsets refer to distinct populations of T-cells, which are a type of white blood cell that plays a central role in cell-mediated immunity. The two main types of T-lymphocytes are CD4+ and CD8+ cells, which are defined by the presence or absence of specific proteins called cluster differentiation (CD) molecules on their surface.

CD4+ T-cells, also known as helper T-cells, play a crucial role in activating other immune cells, such as B-lymphocytes and macrophages, to mount an immune response against pathogens. They also produce cytokines that help regulate the immune response.

CD8+ T-cells, also known as cytotoxic T-cells, directly kill infected cells or tumor cells by releasing toxic substances such as perforins and granzymes.

The balance between these two subsets of T-cells is critical for maintaining immune homeostasis and mounting effective immune responses against pathogens while avoiding excessive inflammation and autoimmunity. Therefore, the measurement of T-lymphocyte subsets is essential in diagnosing and monitoring various immunological disorders, including HIV infection, cancer, and autoimmune diseases.

Immunologic monitoring refers to the regular and systematic surveillance and evaluation of a patient's immune system response, particularly in the context of medical treatment or disease progression. This may involve measuring various immunological parameters such as levels of immune cells, antibodies, cytokines, and other markers of immune function.

The goal of immunologic monitoring is to assess the effectiveness of treatments that modulate the immune system, such as immunotherapy for cancer or immunosuppressive therapy for autoimmune diseases. It can also help detect any adverse effects or complications related to the treatment, such as immune-related toxicities or infections. Additionally, immunologic monitoring may provide insights into the underlying mechanisms of disease and inform personalized treatment strategies.

1. Receptors: In the context of physiology and medicine, receptors are specialized proteins found on the surface of cells or inside cells that detect and respond to specific molecules, known as ligands. These interactions can trigger a range of responses within the cell, such as starting a signaling pathway or changing the cell's behavior. There are various types of receptors, including ion channels, G protein-coupled receptors, and enzyme-linked receptors.

2. Antigen: An antigen is any substance (usually a protein) that can be recognized by the immune system, specifically by antibodies or T-cells, as foreign and potentially harmful. Antigens can be derived from various sources, such as bacteria, viruses, fungi, parasites, or even non-living substances like pollen, chemicals, or toxins. An antigen typically contains epitopes, which are the specific regions that antibodies or T-cell receptors recognize and bind to.

3. T-Cell: Also known as T lymphocytes, T-cells are a type of white blood cell that plays a crucial role in cell-mediated immunity, a part of the adaptive immune system. They are produced in the bone marrow and mature in the thymus gland. There are several types of T-cells, including CD4+ helper T-cells, CD8+ cytotoxic T-cells, and regulatory T-cells (Tregs). T-cells recognize antigens presented to them by antigen-presenting cells (APCs) via their surface receptors called the T-cell receptor (TCR). Once activated, T-cells can proliferate and differentiate into various effector cells that help eliminate infected or damaged cells.

I'm sorry for any confusion, but "Sarcoma, Experimental" is not a recognized medical term or definition. Sarcomas are a type of cancer that develop in the body's connective tissues, such as bones, muscles, tendons, cartilage, and fat. There are many different types of sarcomas, classified based on the specific type of tissue they originate from.

Experimental, on the other hand, refers to something that is being tested or tried out for the first time, typically as part of a scientific experiment or clinical trial. In the context of cancer treatment, an experimental therapy might refer to a new drug, procedure, or device that is still being studied in clinical trials to determine its safety and effectiveness.

Therefore, "Sarcoma, Experimental" could potentially refer to a clinical trial or research study involving a new treatment for sarcoma, but it would not be a medical definition in and of itself. If you have any specific questions about sarcomas or experimental treatments, I would recommend consulting with a healthcare professional or medical researcher for more accurate information.

Immunization is defined medically as the process where an individual is made immune or resistant to an infectious disease, typically through the administration of a vaccine. The vaccine stimulates the body's own immune system to recognize and fight off the specific disease-causing organism, thereby preventing or reducing the severity of future infections with that organism.

Immunization can be achieved actively, where the person is given a vaccine to trigger an immune response, or passively, where antibodies are transferred to the person through immunoglobulin therapy. Immunizations are an important part of preventive healthcare and have been successful in controlling and eliminating many infectious diseases worldwide.

A peptide fragment is a short chain of amino acids that is derived from a larger peptide or protein through various biological or chemical processes. These fragments can result from the natural breakdown of proteins in the body during regular physiological processes, such as digestion, or they can be produced experimentally in a laboratory setting for research or therapeutic purposes.

Peptide fragments are often used in research to map the structure and function of larger peptides and proteins, as well as to study their interactions with other molecules. In some cases, peptide fragments may also have biological activity of their own and can be developed into drugs or diagnostic tools. For example, certain peptide fragments derived from hormones or neurotransmitters may bind to receptors in the body and mimic or block the effects of the full-length molecule.

I could not find a specific medical definition for "Vaccines, DNA." However, I can provide you with some information about DNA vaccines.

DNA vaccines are a type of vaccine that uses genetically engineered DNA to stimulate an immune response in the body. They work by introducing a small piece of DNA into the body that contains the genetic code for a specific antigen (a substance that triggers an immune response). The cells of the body then use this DNA to produce the antigen, which prompts the immune system to recognize and attack it.

DNA vaccines have several advantages over traditional vaccines. They are relatively easy to produce, can be stored at room temperature, and can be designed to protect against a wide range of diseases. Additionally, because they use DNA to stimulate an immune response, DNA vaccines do not require the growth and culture of viruses or bacteria, which can make them safer than traditional vaccines.

DNA vaccines are still in the experimental stages, and more research is needed to determine their safety and effectiveness. However, they have shown promise in animal studies and are being investigated as a potential tool for preventing a variety of infectious diseases, including influenza, HIV, and cancer.

An Enzyme-Linked Immunosorbent Assay (ELISA) is a type of analytical biochemistry assay used to detect and quantify the presence of a substance, typically a protein or peptide, in a liquid sample. It takes its name from the enzyme-linked antibodies used in the assay.

In an ELISA, the sample is added to a well containing a surface that has been treated to capture the target substance. If the target substance is present in the sample, it will bind to the surface. Next, an enzyme-linked antibody specific to the target substance is added. This antibody will bind to the captured target substance if it is present. After washing away any unbound material, a substrate for the enzyme is added. If the enzyme is present due to its linkage to the antibody, it will catalyze a reaction that produces a detectable signal, such as a color change or fluorescence. The intensity of this signal is proportional to the amount of target substance present in the sample, allowing for quantification.

ELISAs are widely used in research and clinical settings to detect and measure various substances, including hormones, viruses, and bacteria. They offer high sensitivity, specificity, and reproducibility, making them a reliable choice for many applications.

Poaceae is not a medical term but a taxonomic category, specifically the family name for grasses. In a broader sense, you might be asking for a medical context where knowledge of this plant family could be relevant. For instance, certain members of the Poaceae family can cause allergies or negative reactions in some people.

In a medical definition, Poaceae would be defined as:

The family of monocotyledonous plants that includes grasses, bamboo, and sedges. These plants are characterized by narrow leaves with parallel veins, jointed stems (called "nodes" and "internodes"), and flowers arranged in spikelets. Some members of this family are important food sources for humans and animals, such as rice, wheat, corn, barley, oats, and sorghum. Other members can cause negative reactions, like skin irritation or allergies, due to their silica-based defense structures called phytoliths.

CD80 (also known as B7-1) is a cell surface protein that functions as a costimulatory molecule in the immune system. It is primarily expressed on antigen presenting cells such as dendritic cells, macrophages, and B cells. CD80 binds to the CD28 receptor on T cells, providing a critical second signal necessary for T cell activation and proliferation. This interaction plays a crucial role in the initiation of an effective immune response against pathogens and tumors.

CD80 can also interact with another receptor called CTLA-4 (cytotoxic T lymphocyte antigen 4), which is expressed on activated T cells. The binding of CD80 to CTLA-4 delivers a negative signal that helps regulate the immune response and prevent overactivation, contributing to the maintenance of self-tolerance and preventing autoimmunity.

In summary, CD80 is an important antigen involved in the regulation of the adaptive immune response by modulating T cell activation and proliferation through its interactions with CD28 and CTLA-4 receptors.

Allergic conjunctivitis is a type of conjunctivitis (inflammation of the conjunctiva, the membrane that covers the white part of the eye and the inner surface of the eyelids) caused by an allergic reaction to substances such as pollen, dust mites, or pet dander. It is often characterized by redness, itching, watering, and swelling of the eyes. In some cases, the eyes may also become sensitive to light. Allergic conjunctivitis is not contagious and can be treated with medications such as antihistamines, decongestants, or mast cell stabilizers.

Vaccination is a simple, safe, and effective way to protect people against harmful diseases, before they come into contact with them. It uses your body's natural defenses to build protection to specific infections and makes your immune system stronger.

A vaccination usually contains a small, harmless piece of a virus or bacteria (or toxins produced by these germs) that has been made inactive or weakened so it won't cause the disease itself. This piece of the germ is known as an antigen. When the vaccine is introduced into the body, the immune system recognizes the antigen as foreign and produces antibodies to fight it.

If a person then comes into contact with the actual disease-causing germ, their immune system will recognize it and immediately produce antibodies to destroy it. The person is therefore protected against that disease. This is known as active immunity.

Vaccinations are important for both individual and public health. They prevent the spread of contagious diseases and protect vulnerable members of the population, such as young children, the elderly, and people with weakened immune systems who cannot be vaccinated or for whom vaccination is not effective.

"Intralesional injection" is a medical term that refers to the administration of a medication directly into a lesion or skin abnormality, such as a tumor, cyst, or blister. This technique is used to deliver the medication directly to the site of action, allowing for higher local concentrations and potentially reducing systemic side effects. Common examples include the injection of corticosteroids into inflamed tissues to reduce swelling and pain, or the injection of chemotherapeutic agents directly into tumors to shrink them.

Interleukin-12 (IL-12) is a naturally occurring protein that is primarily produced by activated macrophages and dendritic cells, which are types of immune cells. It plays a crucial role in the regulation of the immune response, particularly in the development of cell-mediated immunity.

IL-12 is composed of two subunits, p35 and p40, which combine to form a heterodimer. This cytokine stimulates the differentiation and activation of naive T cells into Th1 cells, which are important for fighting intracellular pathogens such as viruses and bacteria. IL-12 also enhances the cytotoxic activity of natural killer (NK) cells and CD8+ T cells, which can directly kill infected or malignant cells.

In addition to its role in the immune response, IL-12 has been implicated in the pathogenesis of several autoimmune diseases, including multiple sclerosis, rheumatoid arthritis, and psoriasis. As a result, therapeutic strategies targeting IL-12 or its signaling pathways have been explored as potential treatments for these conditions.

Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) is a type of cytokine, which is a small signaling protein involved in immune response and hematopoiesis (the formation of blood cells). GM-CSF's specific role is to stimulate the production, proliferation, and activation of granulocytes (a type of white blood cell that fights against infection) and macrophages (large white blood cells that eat foreign substances, bacteria, and dead or dying cells).

In medical terms, GM-CSF is often used in therapeutic settings to boost the production of white blood cells in patients undergoing chemotherapy or radiation treatment for cancer. This can help to reduce the risk of infection during these treatments. It can also be used to promote the growth and differentiation of stem cells in bone marrow transplant procedures.

Fibrosarcoma is a type of soft tissue cancer that develops in the fibrous (or connective) tissue found throughout the body, including tendons, ligaments, and muscles. It is characterized by the malignant proliferation of fibroblasts, which are the cells responsible for producing collagen, a structural protein found in connective tissue.

The tumor typically presents as a painless, firm mass that grows slowly over time. Fibrosarcomas can occur at any age but are more common in adults between 30 and 60 years old. The exact cause of fibrosarcoma is not well understood, but it has been linked to radiation exposure, certain chemicals, and genetic factors.

There are several subtypes of fibrosarcoma, including adult-type fibrosarcoma, infantile fibrosarcoma, and dedifferentiated fibrosarcoma. Treatment usually involves surgical removal of the tumor, often followed by radiation therapy and/or chemotherapy to reduce the risk of recurrence. The prognosis for patients with fibrosarcoma depends on several factors, including the size and location of the tumor, the patient's age and overall health, and the presence or absence of metastasis (spread of cancer to other parts of the body).

SCID mice is an acronym for Severe Combined Immunodeficiency mice. These are genetically modified mice that lack a functional immune system due to the mutation or knockout of several key genes required for immunity. This makes them ideal for studying the human immune system, infectious diseases, and cancer, as well as testing new therapies and treatments in a controlled environment without the risk of interference from the mouse's own immune system. SCID mice are often used in xenotransplantation studies, where human cells or tissues are transplanted into the mouse to study their behavior and interactions with the human immune system.

Lung neoplasms refer to abnormal growths or tumors in the lung tissue. These tumors can be benign (non-cancerous) or malignant (cancerous). Malignant lung neoplasms are further classified into two main types: small cell lung carcinoma and non-small cell lung carcinoma. Lung neoplasms can cause symptoms such as cough, chest pain, shortness of breath, and weight loss. They are often caused by smoking or exposure to secondhand smoke, but can also occur due to genetic factors, radiation exposure, and other environmental carcinogens. Early detection and treatment of lung neoplasms is crucial for improving outcomes and survival rates.

T-cell antigen receptor (TCR) specificity refers to the ability of a T-cell's antigen receptor to recognize and bind to a specific antigenic peptide presented in the context of a major histocompatibility complex (MHC) molecule on the surface of an antigen-presenting cell. The TCR is a protein complex found on the surface of T-cells, which plays a critical role in adaptive immunity by identifying and responding to infected or cancerous cells.

The specificity of the TCR is determined by the complementarity-determining regions (CDRs) within its variable domains. These CDRs form a binding site that recognizes and interacts with a specific epitope, typically an 8-12 amino acid long peptide, presented in the groove of an MHC molecule. The TCR-antigen interaction is highly specific, allowing T-cells to distinguish between self and non-self antigens and initiate an appropriate immune response.

In summary, T-cell antigen receptor specificity refers to the unique ability of a T-cell's antigen receptor to recognize and bind to a specific antigenic peptide presented in the context of an MHC molecule, which is critical for the initiation and regulation of adaptive immune responses.

Neoplasm metastasis is the spread of cancer cells from the primary site (where the original or primary tumor formed) to other places in the body. This happens when cancer cells break away from the original (primary) tumor and enter the bloodstream or lymphatic system. The cancer cells can then travel to other parts of the body and form new tumors, called secondary tumors or metastases.

Metastasis is a key feature of malignant neoplasms (cancers), and it is one of the main ways that cancer can cause harm in the body. The metastatic tumors may continue to grow and may cause damage to the organs and tissues where they are located. They can also release additional cancer cells into the bloodstream or lymphatic system, leading to further spread of the cancer.

The metastatic tumors are named based on the location where they are found, as well as the type of primary cancer. For example, if a patient has a primary lung cancer that has metastasized to the liver, the metastatic tumor would be called a liver metastasis from lung cancer.

It is important to note that the presence of metastases can significantly affect a person's prognosis and treatment options. In general, metastatic cancer is more difficult to treat than cancer that has not spread beyond its original site. However, there are many factors that can influence a person's prognosis and response to treatment, so it is important for each individual to discuss their specific situation with their healthcare team.

Lymphocyte depletion is a medical term that refers to the reduction in the number of lymphocytes (a type of white blood cell) in the body. Lymphocytes play a crucial role in the immune system, as they help to fight off infections and diseases.

Lymphocyte depletion can occur due to various reasons, including certain medical treatments such as chemotherapy or radiation therapy, immune disorders, viral infections, or bone marrow transplantation. This reduction in lymphocytes can make a person more susceptible to infections and diseases, as their immune system is weakened.

There are different types of lymphocytes, including T cells, B cells, and natural killer (NK) cells, and lymphocyte depletion can affect one or all of these types. In some cases, lymphocyte depletion may be temporary and resolve on its own or with treatment. However, in other cases, it may be more prolonged and require medical intervention to manage the associated risks and complications.

Membrane glycoproteins are proteins that contain oligosaccharide chains (glycans) covalently attached to their polypeptide backbone. They are integral components of biological membranes, spanning the lipid bilayer and playing crucial roles in various cellular processes.

The glycosylation of these proteins occurs in the endoplasmic reticulum (ER) and Golgi apparatus during protein folding and trafficking. The attached glycans can vary in structure, length, and composition, which contributes to the diversity of membrane glycoproteins.

Membrane glycoproteins can be classified into two main types based on their orientation within the lipid bilayer:

1. Type I (N-linked): These glycoproteins have a single transmembrane domain and an extracellular N-terminus, where the oligosaccharides are predominantly attached via asparagine residues (Asn-X-Ser/Thr sequon).
2. Type II (C-linked): These glycoproteins possess two transmembrane domains and an intracellular C-terminus, with the oligosaccharides linked to tryptophan residues via a mannose moiety.

Membrane glycoproteins are involved in various cellular functions, such as:

* Cell adhesion and recognition
* Receptor-mediated signal transduction
* Enzymatic catalysis
* Transport of molecules across membranes
* Cell-cell communication
* Immunological responses

Some examples of membrane glycoproteins include cell surface receptors (e.g., growth factor receptors, cytokine receptors), adhesion molecules (e.g., integrins, cadherins), and transporters (e.g., ion channels, ABC transporters).

Genetic transduction is a process in molecular biology that describes the transfer of genetic material from one bacterium to another by a viral vector called a bacteriophage (or phage). In this process, the phage infects one bacterium and incorporates a portion of the bacterial DNA into its own genetic material. When the phage then infects a second bacterium, it can transfer the incorporated bacterial DNA to the new host. This can result in the horizontal gene transfer (HGT) of traits such as antibiotic resistance or virulence factors between bacteria.

There are two main types of transduction: generalized and specialized. In generalized transduction, any portion of the bacterial genome can be packaged into the phage particle, leading to a random assortment of genetic material being transferred. In specialized transduction, only specific genes near the site where the phage integrates into the bacterial chromosome are consistently transferred.

It's important to note that genetic transduction is not to be confused with transformation or conjugation, which are other mechanisms of HGT in bacteria.

CD3 antigens are a group of proteins found on the surface of T-cells, which are a type of white blood cell that plays a central role in the immune response. The CD3 antigens are composed of several different subunits (ε, δ, γ, and α) that associate to form the CD3 complex, which is involved in T-cell activation and signal transduction.

The CD3 complex is associated with the T-cell receptor (TCR), which recognizes and binds to specific antigens presented by antigen-presenting cells. When the TCR binds to an antigen, it triggers a series of intracellular signaling events that lead to T-cell activation and the initiation of an immune response.

CD3 antigens are important targets for immunotherapy in some diseases, such as certain types of cancer. For example, monoclonal antibodies that target CD3 have been developed to activate T-cells and enhance their ability to recognize and destroy tumor cells. However, CD3-targeted therapies can also cause side effects, such as cytokine release syndrome, which can be serious or life-threatening in some cases.

The tumor microenvironment (TME) is a complex and dynamic setting that consists of various cellular and non-cellular components, which interact with each other and contribute to the growth, progression, and dissemination of cancer. The TME includes:

1. Cancer cells: These are the malignant cells that grow uncontrollably, invade surrounding tissues, and can spread to distant organs.
2. Stromal cells: These are non-cancerous cells present within the tumor, including fibroblasts, immune cells, adipocytes, and endothelial cells. They play a crucial role in supporting the growth of cancer cells by providing structural and nutritional support, modulating the immune response, and promoting angiogenesis (the formation of new blood vessels).
3. Extracellular matrix (ECM): This is the non-cellular component of the TME, consisting of a network of proteins, glycoproteins, and polysaccharides that provide structural support and regulate cell behavior. The ECM can be remodeled by both cancer and stromal cells, leading to changes in tissue stiffness, architecture, and signaling pathways.
4. Soluble factors: These include various cytokines, chemokines, growth factors, and metabolites that are secreted by both cancer and stromal cells. They can act as signaling molecules, influencing cell behavior, survival, proliferation, and migration.
5. Blood vessels: The formation of new blood vessels (angiogenesis) within the TME is essential for providing nutrients and oxygen to support the growth of cancer cells. The vasculature in the TME is often disorganized, leading to hypoxic (low oxygen) regions and altered drug delivery.
6. Immune cells: The TME contains various immune cell populations, such as tumor-associated macrophages (TAMs), dendritic cells, natural killer (NK) cells, and different subsets of T lymphocytes. These cells can either promote or inhibit the growth and progression of cancer, depending on their phenotype and activation status.
7. Niche: A specific microenvironment within the TME that supports the survival and function of cancer stem cells (CSCs) or tumor-initiating cells. The niche is often characterized by unique cellular components, signaling molecules, and physical properties that contribute to the maintenance and propagation of CSCs.

Understanding the complex interactions between these various components in the TME can provide valuable insights into cancer biology and help inform the development of novel therapeutic strategies.

CD20 is not a medical definition of an antigen, but rather it is a cell surface marker that helps identify a specific type of white blood cell called B-lymphocytes or B-cells. These cells are part of the adaptive immune system and play a crucial role in producing antibodies to fight off infections.

CD20 is a protein found on the surface of mature B-cells, and it is used as a target for monoclonal antibody therapies in the treatment of certain types of cancer and autoimmune diseases. Rituximab is an example of a monoclonal antibody that targets CD20 and is used to treat conditions such as non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.

While CD20 itself is not an antigen, it can be recognized by the immune system as a foreign substance when a monoclonal antibody such as rituximab binds to it. This binding can trigger an immune response, leading to the destruction of the B-cells that express CD20 on their surface.

A dose-response relationship in immunology refers to the quantitative relationship between the dose or amount of an antigen (a substance that triggers an immune response) and the magnitude or strength of the resulting immune response. Generally, as the dose of an antigen increases, the intensity and/or duration of the immune response also increase, up to a certain point. This relationship helps in determining the optimal dosage for vaccines and immunotherapies, ensuring sufficient immune activation while minimizing potential adverse effects.

Mononuclear leukocytes are a type of white blood cells (leukocytes) that have a single, large nucleus. They include lymphocytes (B-cells, T-cells, and natural killer cells), monocytes, and dendritic cells. These cells play important roles in the body's immune system, including defending against infection and disease, and participating in immune responses and surveillance. Mononuclear leukocytes can be found in the bloodstream as well as in tissues throughout the body. They are involved in both innate and adaptive immunity, providing specific and nonspecific defense mechanisms to protect the body from harmful pathogens and other threats.

Mucin-1, also known as MUC1, is a type of protein called a transmembrane mucin. It is heavily glycosylated and found on the surface of many types of epithelial cells, including those that line the respiratory, gastrointestinal, and urogenital tracts.

Mucin-1 has several functions, including:

* Protecting the underlying epithelial cells from damage caused by friction, chemicals, and microorganisms
* Helping to maintain the integrity of the mucosal barrier
* Acting as a receptor for various signaling molecules
* Participating in immune responses

In cancer, MUC1 can be overexpressed or aberrantly glycosylated, which can contribute to tumor growth and metastasis. As a result, MUC1 has been studied as a potential target for cancer immunotherapy.

Antibody-Dependent Cell Cytotoxicity (ADCC) is a type of immune response in which the effector cells of the immune system, such as natural killer (NK) cells, cytotoxic T-cells or macrophages, recognize and destroy virus-infected or cancer cells that are coated with antibodies.

In this process, an antibody produced by B-cells binds specifically to an antigen on the surface of a target cell. The other end of the antibody then interacts with Fc receptors found on the surface of effector cells. This interaction triggers the effector cells to release cytotoxic substances, such as perforins and granzymes, which create pores in the target cell membrane and induce apoptosis (programmed cell death).

ADCC plays an important role in the immune defense against viral infections and cancer. It is also a mechanism of action for some monoclonal antibody therapies used in cancer treatment.

Peptides are short chains of amino acid residues linked by covalent bonds, known as peptide bonds. They are formed when two or more amino acids are joined together through a condensation reaction, which results in the elimination of a water molecule and the formation of an amide bond between the carboxyl group of one amino acid and the amino group of another.

Peptides can vary in length from two to about fifty amino acids, and they are often classified based on their size. For example, dipeptides contain two amino acids, tripeptides contain three, and so on. Oligopeptides typically contain up to ten amino acids, while polypeptides can contain dozens or even hundreds of amino acids.

Peptides play many important roles in the body, including serving as hormones, neurotransmitters, enzymes, and antibiotics. They are also used in medical research and therapeutic applications, such as drug delivery and tissue engineering.

A lymphocyte transfusion is not a standard medical practice. However, the term "lymphocyte transfusion" generally refers to the infusion of lymphocytes, a type of white blood cell, from a donor to a recipient. This procedure is rarely performed and primarily used in research or experimental settings, such as in the context of adoptive immunotherapy for cancer treatment.

In adoptive immunotherapy, T lymphocytes (a subtype of lymphocytes) are collected from the patient or a donor, activated, expanded in the laboratory, and then reinfused into the patient to enhance their immune response against cancer cells. This is not a common procedure and should only be performed under the guidance of experienced medical professionals in specialized centers.

It's important to note that lymphocyte transfusions are different from stem cell or bone marrow transplants, which involve the infusion of hematopoietic stem cells to reconstitute the recipient's entire blood and immune system.

Food hypersensitivity is an umbrella term that encompasses both immunologic and non-immunologic adverse reactions to food. It is also known as "food allergy" or "food intolerance." Food hypersensitivity occurs when the body's immune system or digestive system reacts negatively to a particular food or food component.

Immunologic food hypersensitivity, commonly referred to as a food allergy, involves an immune response mediated by immunoglobulin E (IgE) antibodies. Upon ingestion of the offending food, IgE antibodies bind to the food antigens and trigger the release of histamine and other chemical mediators from mast cells and basophils, leading to symptoms such as hives, swelling, itching, difficulty breathing, or anaphylaxis.

Non-immunologic food hypersensitivity, on the other hand, does not involve the immune system. Instead, it is caused by various mechanisms, including enzyme deficiencies, pharmacological reactions, and metabolic disorders. Examples of non-immunologic food hypersensitivities include lactose intolerance, gluten sensitivity, and histamine intolerance.

It's important to note that the term "food hypersensitivity" is often used interchangeably with "food allergy," but it has a broader definition that includes both immunologic and non-immunologic reactions.

Tissue extracts refer to the substances or compounds that are extracted from various types of biological tissues, such as plants, animals, or microorganisms. These extracts contain bioactive molecules, including proteins, peptides, lipids, carbohydrates, nucleic acids, and other small molecules, which can have therapeutic or diagnostic potential. The process of tissue extraction involves homogenizing the tissue, followed by separation and purification of the desired components using various techniques such as centrifugation, filtration, chromatography, or precipitation.

In medical research and clinical settings, tissue extracts are often used to study the biochemical and molecular properties of cells and tissues, investigate disease mechanisms, develop diagnostic tests, and identify potential drug targets. Examples of tissue extracts include cell lysates, subcellular fractions, organelle preparations, plasma membrane extracts, nuclear extracts, and various types of protein or nucleic acid extracts. It is important to note that the quality and purity of tissue extracts can significantly impact the accuracy and reproducibility of experimental results, and appropriate controls and validation methods should be employed to ensure their proper use.

"Cells, cultured" is a medical term that refers to cells that have been removed from an organism and grown in controlled laboratory conditions outside of the body. This process is called cell culture and it allows scientists to study cells in a more controlled and accessible environment than they would have inside the body. Cultured cells can be derived from a variety of sources, including tissues, organs, or fluids from humans, animals, or cell lines that have been previously established in the laboratory.

Cell culture involves several steps, including isolation of the cells from the tissue, purification and characterization of the cells, and maintenance of the cells in appropriate growth conditions. The cells are typically grown in specialized media that contain nutrients, growth factors, and other components necessary for their survival and proliferation. Cultured cells can be used for a variety of purposes, including basic research, drug development and testing, and production of biological products such as vaccines and gene therapies.

It is important to note that cultured cells may behave differently than they do in the body, and results obtained from cell culture studies may not always translate directly to human physiology or disease. Therefore, it is essential to validate findings from cell culture experiments using additional models and ultimately in clinical trials involving human subjects.

Mites are tiny arthropods belonging to the class Arachnida, which also includes spiders and ticks. They are characterized by their small size, usually measuring less than 1 mm in length, and their lack of obvious segmentation on their bodies. Many mites are parasitic, feeding on the skin cells, blood, or fluids of plants and animals, including humans. Some common mite infestations in humans include scabies, caused by the itch mite (Sarcoptes scabiei), and dust mites (e.g., Dermatophagoides pteronyssinus and D. farinae), which are commonly found in household dust and can cause allergic reactions in some people. It's worth noting that the majority of mites are not harmful to humans and play important roles in ecosystems as decomposers and predators.

Immunophenotyping is a medical laboratory technique used to identify and classify cells, usually in the context of hematologic (blood) disorders and malignancies (cancers), based on their surface or intracellular expression of various proteins and antigens. This technique utilizes specific antibodies tagged with fluorochromes, which bind to the target antigens on the cell surface or within the cells. The labeled cells are then analyzed using flow cytometry, allowing for the detection and quantification of multiple antigenic markers simultaneously.

Immunophenotyping helps in understanding the distribution of different cell types, their subsets, and activation status, which can be crucial in diagnosing various hematological disorders, immunodeficiencies, and distinguishing between different types of leukemias, lymphomas, and other malignancies. Additionally, it can also be used to monitor the progression of diseases, evaluate the effectiveness of treatments, and detect minimal residual disease (MRD) during follow-up care.

CD40 is a type of protein known as a tumor necrosis factor receptor that is found on the surface of various cells in the body, including B cells, dendritic cells, and activated T cells. It plays an important role in the immune system by interacting with another protein called CD154 (also known as CD40 ligand) to activate immune responses.

CD40 antigens are molecules that can stimulate an immune response when introduced into the body because they are recognized as foreign substances by the immune system. They may be used in vaccines or other immunotherapies to induce an immune response against specific targets, such as cancer cells or infectious agents.

CD40 antigens can also be found on some types of tumor cells, and activating CD40 with CD154 has been shown to enhance the anti-tumor immune response in preclinical models. Therefore, CD40 agonists are being investigated as potential cancer therapies.

In summary, CD40 antigens are proteins that can stimulate an immune response and are involved in activating immune cells. They have potential applications in vaccines, immunotherapies, and cancer treatments.

'Betula' is the genus name for a group of trees commonly known as birches. These trees belong to the family Betulaceae and are native to the cooler regions of the Northern Hemisphere. There are around 30-60 species in this genus, depending on the classification system used.

Birch trees are known for their distinctive bark, which is often white and peels away in thin layers. They also have simple, ovate leaves that are usually toothed or serrated along the edges. Many birches produce catkins, which are long, slender flowering structures that contain either male or female flowers.

Birch trees have a number of uses, both practical and cultural. The wood is lightweight and easy to work with, making it popular for uses such as furniture-making, paper production, and fuel. Birch bark has also been used historically for a variety of purposes, including canoe construction, writing surfaces, and medicinal remedies.

In addition to their practical uses, birch trees have cultural significance in many regions where they grow. For example, they are often associated with renewal and rebirth due to their ability to regrow from stumps or roots after being cut down. In some cultures, birch trees are also believed to have spiritual or mystical properties.

'Dermatophagoides pteronyssinus' is a species of mite that belongs to the family Pyroglyphidae. These mites are commonly known as house dust mites, and they are found in various environments, particularly in households. They thrive in warm and humid conditions, and their primary food source consists of human skin scales.

House dust mites like 'Dermatophagoides pteronyssinus' are associated with allergic reactions in humans, such as asthma, rhinitis, and dermatitis. Their feces and body parts contain protease enzymes that can trigger an immune response in sensitive individuals, leading to the release of histamine and other inflammatory mediators. These allergens can become airborne and inhaled or come into contact with the skin, causing symptoms such as sneezing, runny nose, itchy eyes, and difficulty breathing.

It is essential to maintain a clean living environment, particularly in bedding and upholstered furniture, to reduce the population of house dust mites and minimize allergen exposure. Measures such as using allergen-impermeable covers for mattresses and pillows, washing bedding in hot water, and reducing humidity levels can help control dust mite populations and alleviate allergic symptoms.

Programmed cell death 1 receptor (PD-1R), also known as CD279, is a type I transmembrane protein that belongs to the immunoglobulin superfamily. It is primarily expressed on the surface of activated T cells, B cells, and myeloid cells. PD-1R plays a crucial role in regulating immune responses by interacting with its ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC), which are mainly expressed on antigen-presenting cells and various tumor cells.

The interaction between PD-1R and its ligands leads to the inhibition of T cell activation, proliferation, and effector functions, thereby promoting immune tolerance and preventing autoimmunity. In the context of cancer, tumor cells upregulate PD-L1/PD-L2 expression as a mechanism to evade anti-tumor immunity by suppressing T cell activation through PD-1R engagement.

Immunotherapies targeting the PD-1/PD-L1 pathway have shown significant clinical benefits in various cancer types, including melanoma, non-small cell lung cancer, and renal cell carcinoma, among others, by restoring T cell-mediated anti-tumor immunity.

The spleen is an organ in the upper left side of the abdomen, next to the stomach and behind the ribs. It plays multiple supporting roles in the body:

1. It fights infection by acting as a filter for the blood. Old red blood cells are recycled in the spleen, and platelets and white blood cells are stored there.
2. The spleen also helps to control the amount of blood in the body by removing excess red blood cells and storing platelets.
3. It has an important role in immune function, producing antibodies and removing microorganisms and damaged red blood cells from the bloodstream.

The spleen can be removed without causing any significant problems, as other organs take over its functions. This is known as a splenectomy and may be necessary if the spleen is damaged or diseased.

"Phleum" is the genus name for a group of plants commonly known as Timothy-grass or Cat's-tail. It is a type of grass that is widely used in agriculture and gardening. I believe you might be looking for a medical term related to "phleum," so let me clarify:

In medical terminology, the term "phleum" is not commonly used. However, if you are referring to "phlebothrombosis," it is a term that could be relevant. Phlebothrombosis refers to the formation of a blood clot (thrombus) within a vein, which can occur due to various medical conditions or situations, such as immobility, surgery, or certain diseases. The term "phlebo-" means vein, and "-thrombosis" refers to the formation of a thrombus or blood clot.

If this is not the term you were looking for, please provide more context or clarify your question so I can give you a more accurate answer.

Basophils are a type of white blood cell that are part of the immune system. They are granulocytes, which means they contain granules filled with chemicals that can be released in response to an infection or inflammation. Basophils are relatively rare, making up less than 1% of all white blood cells.

When basophils become activated, they release histamine and other chemical mediators that can contribute to allergic reactions, such as itching, swelling, and redness. They also play a role in inflammation, helping to recruit other immune cells to the site of an infection or injury.

Basophils can be identified under a microscope based on their characteristic staining properties. They are typically smaller than other granulocytes, such as neutrophils and eosinophils, and have a multi-lobed nucleus with dark purple-staining granules in the cytoplasm.

While basophils play an important role in the immune response, abnormal levels of basophils can be associated with various medical conditions, such as allergies, infections, and certain types of leukemia.

Antigen receptors are specialized proteins found on the surface of immune cells, particularly B cells and T cells. These receptors are responsible for recognizing and binding to specific antigens, which are foreign substances such as proteins, carbohydrates, or lipids that stimulate an immune response.

B cell receptors (BCRs) are membrane-bound antibodies that recognize and bind to native antigens. When a BCR binds to its specific antigen, it triggers a series of intracellular signals that lead to the activation and differentiation of the B cell into an antibody-secreting plasma cell.

T cell receptors (TCRs) are membrane-bound proteins found on T cells that recognize and bind to antigens presented in the context of major histocompatibility complex (MHC) molecules on the surface of antigen-presenting cells. TCRs can distinguish between self and non-self antigens, allowing T cells to mount an immune response against infected or cancerous cells while sparing healthy cells.

Overall, antigen receptors play a critical role in the adaptive immune system's ability to recognize and respond to a wide variety of foreign substances.

"Parietaria" is a genus of flowering plants in the nettle family, Urticaceae. Commonly known as pellitory-of-the-wall or wall pennywort, these plants are found in many parts of the world and are often considered to be weeds. They can grow in a variety of environments, including walls, rocks, and soil.

In a medical context, Parietaria species are not well known for their medicinal properties, but some studies suggest that they may have anti-inflammatory and antioxidant effects. Contact with the plants can cause skin irritation or allergic reactions in some people, due to the presence of tiny hairs on the leaves and stems that can release histamine and other chemicals.

It's worth noting that "Parietaria" is not a commonly used medical term, and it is more frequently encountered in botany and horticulture than in clinical medicine. If you have any specific concerns about allergic reactions or skin irritation related to Parietaria or any other plant, it's always best to consult with a healthcare professional for personalized advice and treatment.

Propionibacterium acnes is a gram-positive, rod-shaped bacterium that naturally colonizes the skin, predominantly in areas with a high density of sebaceous glands such as the face, back, and chest. It is part of the normal skin flora but can contribute to the development of acne vulgaris when it proliferates excessively and clogs the pilosebaceous units (hair follicles).

The bacterium metabolizes sebum, producing propionic acid and other short-chain fatty acids as byproducts. In acne, these byproducts can cause an inflammatory response in the skin, leading to the formation of papules, pustules, and nodules. Propionibacterium acnes has also been implicated in various other skin conditions and occasionally in opportunistic infections in other parts of the body, particularly in immunocompromised individuals or following surgical procedures.

K562 cells are a type of human cancer cell that are commonly used in scientific research. They are derived from a patient with chronic myelogenous leukemia (CML), a type of cancer that affects the blood and bone marrow.

K562 cells are often used as a model system to study various biological processes, including cell signaling, gene expression, differentiation, and apoptosis (programmed cell death). They are also commonly used in drug discovery and development, as they can be used to test the effectiveness of potential new therapies against cancer.

K562 cells have several characteristics that make them useful for research purposes. They are easy to grow and maintain in culture, and they can be manipulated genetically to express or knock down specific genes. Additionally, K562 cells are capable of differentiating into various cell types, such as red blood cells and megakaryocytes, which allows researchers to study the mechanisms of cell differentiation.

It's important to note that while K562 cells are a valuable tool for research, they do not fully recapitulate the complexity of human CML or other cancers. Therefore, findings from studies using K562 cells should be validated in more complex model systems or in clinical trials before they can be translated into treatments for patients.

Immunity, in medical terms, refers to the body's ability to resist or fight against harmful foreign substances or organisms such as bacteria, viruses, parasites, and fungi. This resistance is achieved through various mechanisms, including the production of antibodies, the activation of immune cells like T-cells and B-cells, and the release of cytokines and other chemical messengers that help coordinate the immune response.

There are two main types of immunity: innate immunity and adaptive immunity. Innate immunity is the body's first line of defense against infection and involves nonspecific mechanisms such as physical barriers (e.g., skin and mucous membranes), chemical barriers (e.g., stomach acid and enzymes), and inflammatory responses. Adaptive immunity, on the other hand, is specific to particular pathogens and involves the activation of T-cells and B-cells, which recognize and remember specific antigens (foreign substances that trigger an immune response). This allows the body to mount a more rapid and effective response to subsequent exposures to the same pathogen.

Immunity can be acquired through natural means, such as when a person recovers from an infection and develops immunity to that particular pathogen, or artificially, through vaccination. Vaccines contain weakened or inactivated forms of a pathogen or its components, which stimulate the immune system to produce a response without causing the disease. This response provides protection against future infections with that same pathogen.

Brain neoplasms, also known as brain tumors, are abnormal growths of cells within the brain. These growths can be benign (non-cancerous) or malignant (cancerous). Benign brain tumors typically grow slowly and do not spread to other parts of the body. However, they can still cause serious problems if they press on sensitive areas of the brain. Malignant brain tumors, on the other hand, are cancerous and can grow quickly, invading surrounding brain tissue and spreading to other parts of the brain or spinal cord.

Brain neoplasms can arise from various types of cells within the brain, including glial cells (which provide support and insulation for nerve cells), neurons (nerve cells that transmit signals in the brain), and meninges (the membranes that cover the brain and spinal cord). They can also result from the spread of cancer cells from other parts of the body, known as metastatic brain tumors.

Symptoms of brain neoplasms may vary depending on their size, location, and growth rate. Common symptoms include headaches, seizures, weakness or paralysis in the limbs, difficulty with balance and coordination, changes in speech or vision, confusion, memory loss, and changes in behavior or personality.

Treatment for brain neoplasms depends on several factors, including the type, size, location, and grade of the tumor, as well as the patient's age and overall health. Treatment options may include surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of these approaches. Regular follow-up care is essential to monitor for recurrence and manage any long-term effects of treatment.

Nut hypersensitivity, also known as nut allergy, is an abnormal immune response to proteins found in certain nuts (such as peanuts, tree nuts like walnuts, almonds, cashews, pistachios, etc.). This reaction can range from mild symptoms (like itching of the mouth or skin) to severe and potentially life-threatening reactions (known as anaphylaxis), which may include difficulty breathing, rapid heartbeat, and a sudden drop in blood pressure. It's important to note that nut hypersensitivity is not typically outgrown and requires strict avoidance of the offending nuts and often carries the risk of cross-reactivity with other related nuts.

Th1 cells, or Type 1 T helper cells, are a subset of CD4+ T cells that play a crucial role in the cell-mediated immune response. They are characterized by the production of specific cytokines, such as interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), and interleukin-2 (IL-2). Th1 cells are essential for protecting against intracellular pathogens, including viruses, bacteria, and parasites. They activate macrophages to destroy ingested microorganisms, stimulate the differentiation of B cells into plasma cells that produce antibodies, and recruit other immune cells to the site of infection. Dysregulation of Th1 cell responses has been implicated in various autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis, and type 1 diabetes.

Cell proliferation is the process by which cells increase in number, typically through the process of cell division. In the context of biology and medicine, it refers to the reproduction of cells that makes up living tissue, allowing growth, maintenance, and repair. It involves several stages including the transition from a phase of quiescence (G0 phase) to an active phase (G1 phase), DNA replication in the S phase, and mitosis or M phase, where the cell divides into two daughter cells.

Abnormal or uncontrolled cell proliferation is a characteristic feature of many diseases, including cancer, where deregulated cell cycle control leads to excessive and unregulated growth of cells, forming tumors that can invade surrounding tissues and metastasize to distant sites in the body.

Immunologic surveillance is the concept that the immune system plays a critical role in monitoring and defending the body against the development of malignancies or cancers. The immune cells, particularly T-cells and natural killer (NK) cells, are constantly scanning the body for any abnormal changes in cells, such as mutations or viral infections, that could lead to cancer.

Once these abnormal cells are detected, the immune system mounts an immune response to eliminate them, preventing their proliferation and progression into full-blown cancers. This process of immunologic surveillance is a critical component of the body's defense mechanisms against cancer and helps to maintain tissue homeostasis and prevent tumorigenesis.

However, in some cases, cancer cells may evade or suppress the immune system's surveillance mechanisms, leading to the development and progression of malignancies. Therefore, understanding the mechanisms of immunologic surveillance is crucial for developing novel cancer therapies that harness the power of the immune system to fight against cancer.

'Arachis hypogaea' is the scientific name for the peanut plant. It is a legume crop that grows underground, which is why it is also known as a groundnut. The peanut plant produces flowers above ground, and when the flowers are pollinated, the ovary of the flower elongates and grows downwards into the soil where the peanut eventually forms and matures.

The peanut is not only an important food crop worldwide but also has various industrial uses, including the production of biodiesel, plastics, and animal feed. The plant is native to South America and was domesticated by indigenous peoples in what is now Brazil and Peru thousands of years ago. Today, peanuts are grown in many countries around the world, with China, India, and the United States being the largest producers.

An "injection, intradermal" refers to a type of injection where a small quantity of a substance is introduced into the layer of skin between the epidermis and dermis, using a thin gauge needle. This technique is often used for diagnostic or research purposes, such as conducting allergy tests or administering immunizations in a way that stimulates a strong immune response. The injection site typically produces a small, raised bump (wheal) that disappears within a few hours. It's important to note that intradermal injections should be performed by trained medical professionals to minimize the risk of complications.

Egg hypersensitivity, also known as egg allergy, is an abnormal immune response to proteins found in eggs. This reaction can occur when someone with a heightened sensitivity to these proteins comes into contact with them, either by ingesting eggs or being exposed to them through inhalation or skin contact.

The symptoms of egg hypersensitivity can vary widely, ranging from mild reactions such as hives, itching, and stomach discomfort to more severe reactions like anaphylaxis, which can be life-threatening. Anaphylaxis is a sudden and severe allergic reaction that can cause difficulty breathing, rapid heartbeat, and a drop in blood pressure.

If you suspect that you or someone else may have an egg allergy, it's important to speak with a healthcare professional for proper diagnosis and treatment. This may include avoiding eggs altogether, carrying an epinephrine auto-injector in case of a severe reaction, and wearing a medical alert bracelet to notify others of the allergy in case of an emergency.

In the field of medicine, "time factors" refer to the duration of symptoms or time elapsed since the onset of a medical condition, which can have significant implications for diagnosis and treatment. Understanding time factors is crucial in determining the progression of a disease, evaluating the effectiveness of treatments, and making critical decisions regarding patient care.

For example, in stroke management, "time is brain," meaning that rapid intervention within a specific time frame (usually within 4.5 hours) is essential to administering tissue plasminogen activator (tPA), a clot-busting drug that can minimize brain damage and improve patient outcomes. Similarly, in trauma care, the "golden hour" concept emphasizes the importance of providing definitive care within the first 60 minutes after injury to increase survival rates and reduce morbidity.

Time factors also play a role in monitoring the progression of chronic conditions like diabetes or heart disease, where regular follow-ups and assessments help determine appropriate treatment adjustments and prevent complications. In infectious diseases, time factors are crucial for initiating antibiotic therapy and identifying potential outbreaks to control their spread.

Overall, "time factors" encompass the significance of recognizing and acting promptly in various medical scenarios to optimize patient outcomes and provide effective care.

Sneezing is an involuntary, forceful expulsion of air through the nose and mouth, often triggered by irritation or inflammation in the nasal passages. It is a protective reflex that helps to clear the upper respiratory tract of irritants such as dust, pollen, or foreign particles. The sneeze begins with a deep inspiration of air, followed by closure of the glottis (the opening between the vocal cords) and contraction of the chest and abdominal muscles. This builds up pressure in the lungs, which is then suddenly released through the nose and mouth as the glottis opens and the velum (the soft tissue at the back of the roof of the mouth) rises to block the nasal passage. The result is a powerful burst of air that can travel at speeds of up to 100 miles per hour, expelling mucus and any trapped irritants along with it.

Ovalbumin is the major protein found in egg white, making up about 54-60% of its total protein content. It is a glycoprotein with a molecular weight of around 45 kDa and has both hydrophilic and hydrophobic regions. Ovalbumin is a single polypeptide chain consisting of 385 amino acids, including four disulfide bridges that contribute to its structure.

Ovalbumin is often used in research as a model antigen for studying immune responses and allergies. In its native form, ovalbumin is not allergenic; however, when it is denatured or degraded into smaller peptides through cooking or digestion, it can become an allergen for some individuals.

In addition to being a food allergen, ovalbumin has been used in various medical and research applications, such as vaccine development, immunological studies, and protein structure-function analysis.

Interferon-alpha (IFN-α) is a type I interferon, which is a group of signaling proteins made and released by host cells in response to the presence of viruses, parasites, and tumor cells. It plays a crucial role in the immune response against viral infections. IFN-α has antiviral, immunomodulatory, and anti-proliferative effects.

IFN-α is produced naturally by various cell types, including leukocytes (white blood cells), fibroblasts, and epithelial cells, in response to viral or bacterial stimulation. It binds to specific receptors on the surface of nearby cells, triggering a signaling cascade that leads to the activation of genes involved in the antiviral response. This results in the production of proteins that inhibit viral replication and promote the presentation of viral antigens to the immune system, enhancing its ability to recognize and eliminate infected cells.

In addition to its role in the immune response, IFN-α has been used as a therapeutic agent for various medical conditions, including certain types of cancer, chronic hepatitis B and C, and multiple sclerosis. However, its use is often limited by side effects such as flu-like symptoms, depression, and neuropsychiatric disorders.

An amino acid sequence is the specific order of amino acids in a protein or peptide molecule, formed by the linking of the amino group (-NH2) of one amino acid to the carboxyl group (-COOH) of another amino acid through a peptide bond. The sequence is determined by the genetic code and is unique to each type of protein or peptide. It plays a crucial role in determining the three-dimensional structure and function of proteins.

Recombinant fusion proteins are artificially created biomolecules that combine the functional domains or properties of two or more different proteins into a single protein entity. They are generated through recombinant DNA technology, where the genes encoding the desired protein domains are linked together and expressed as a single, chimeric gene in a host organism, such as bacteria, yeast, or mammalian cells.

The resulting fusion protein retains the functional properties of its individual constituent proteins, allowing for novel applications in research, diagnostics, and therapeutics. For instance, recombinant fusion proteins can be designed to enhance protein stability, solubility, or immunogenicity, making them valuable tools for studying protein-protein interactions, developing targeted therapies, or generating vaccines against infectious diseases or cancer.

Examples of recombinant fusion proteins include:

1. Etaglunatide (ABT-523): A soluble Fc fusion protein that combines the heavy chain fragment crystallizable region (Fc) of an immunoglobulin with the extracellular domain of the human interleukin-6 receptor (IL-6R). This fusion protein functions as a decoy receptor, neutralizing IL-6 and its downstream signaling pathways in rheumatoid arthritis.
2. Etanercept (Enbrel): A soluble TNF receptor p75 Fc fusion protein that binds to tumor necrosis factor-alpha (TNF-α) and inhibits its proinflammatory activity, making it a valuable therapeutic option for treating autoimmune diseases like rheumatoid arthritis, ankylosing spondylitis, and psoriasis.
3. Abatacept (Orencia): A fusion protein consisting of the extracellular domain of cytotoxic T-lymphocyte antigen 4 (CTLA-4) linked to the Fc region of an immunoglobulin, which downregulates T-cell activation and proliferation in autoimmune diseases like rheumatoid arthritis.
4. Belimumab (Benlysta): A monoclonal antibody that targets B-lymphocyte stimulator (BLyS) protein, preventing its interaction with the B-cell surface receptor and inhibiting B-cell activation in systemic lupus erythematosus (SLE).
5. Romiplostim (Nplate): A fusion protein consisting of a thrombopoietin receptor agonist peptide linked to an immunoglobulin Fc region, which stimulates platelet production in patients with chronic immune thrombocytopenia (ITP).
6. Darbepoetin alfa (Aranesp): A hyperglycosylated erythropoiesis-stimulating protein that functions as a longer-acting form of recombinant human erythropoietin, used to treat anemia in patients with chronic kidney disease or cancer.
7. Palivizumab (Synagis): A monoclonal antibody directed against the F protein of respiratory syncytial virus (RSV), which prevents RSV infection and is administered prophylactically to high-risk infants during the RSV season.
8. Ranibizumab (Lucentis): A recombinant humanized monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A (VEGF-A), used in the treatment of age-related macular degeneration, diabetic retinopathy, and other ocular disorders.
9. Cetuximab (Erbitux): A chimeric monoclonal antibody that binds to epidermal growth factor receptor (EGFR), used in the treatment of colorectal cancer and head and neck squamous cell carcinoma.
10. Adalimumab (Humira): A fully humanized monoclonal antibody that targets tumor necrosis factor-alpha (TNF-α), used in the treatment of various inflammatory diseases, including rheumatoid arthritis, psoriasis, and Crohn's disease.
11. Bevacizumab (Avastin): A recombinant humanized monoclonal antibody that binds to VEGF-A, used in the treatment of various cancers, including colorectal, lung, breast, and kidney cancer.
12. Trastuzumab (Herceptin): A humanized monoclonal antibody that targets HER2/neu receptor, used in the treatment of breast cancer.
13. Rituximab (Rituxan): A chimeric monoclonal antibody that binds to CD20 antigen on B cells, used in the treatment of non-Hodgkin's lymphoma and rheumatoid arthritis.
14. Palivizumab (Synagis): A humanized monoclonal antibody that binds to the F protein of respiratory syncytial virus, used in the prevention of respiratory syncytial virus infection in high-risk infants.
15. Infliximab (Remicade): A chimeric monoclonal antibody that targets TNF-α, used in the treatment of various inflammatory diseases, including Crohn's disease, ulcerative colitis, rheumatoid arthritis, and ankylosing spondylitis.
16. Natalizumab (Tysabri): A humanized monoclonal antibody that binds to α4β1 integrin, used in the treatment of multiple sclerosis and Crohn's disease.
17. Adalimumab (Humira): A fully human monoclonal antibody that targets TNF-α, used in the treatment of various inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis.
18. Golimumab (Simponi): A fully human monoclonal antibody that targets TNF-α, used in the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.
19. Certolizumab pegol (Cimzia): A PEGylated Fab' fragment of a humanized monoclonal antibody that targets TNF-α, used in the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease.
20. Ustekinumab (Stelara): A fully human monoclonal antibody that targets IL-12 and IL-23, used in the treatment of psoriasis, psoriatic arthritis, and Crohn's disease.
21. Secukinumab (Cosentyx): A fully human monoclonal antibody that targets IL-17A, used in the treatment of psoriasis, psoriatic arthritis, and ankylosing spondylitis.
22. Ixekizumab (Taltz): A fully human monoclonal antibody that targets IL-17A, used in the treatment of psoriasis and psoriatic arthritis.
23. Brodalumab (Siliq): A fully human monoclonal antibody that targets IL-17 receptor A, used in the treatment of psoriasis.
24. Sarilumab (Kevzara): A fully human monoclonal antibody that targets the IL-6 receptor, used in the treatment of rheumatoid arthritis.
25. Tocilizumab (Actemra): A humanized monoclonal antibody that targets the IL-6 receptor, used in the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, giant cell arteritis, and chimeric antigen receptor T-cell-induced cytokine release syndrome.
26. Siltuximab (Sylvant): A chimeric monoclonal antibody that targets IL-6, used in the treatment of multicentric Castleman disease.
27. Satralizumab (Enspryng): A humanized monoclonal antibody that targets IL-6 receptor alpha, used in the treatment of neuromyelitis optica spectrum disorder.
28. Sirukumab (Plivensia): A human monoclonal antibody that targets IL-6, used in the treatment

Autoimmunity is a medical condition in which the body's immune system mistakenly attacks and destroys healthy tissues within the body. In normal function, the immune system recognizes and fights off foreign substances such as bacteria, viruses, and toxins. However, when autoimmunity occurs, the immune system identifies self-molecules or tissues as foreign and produces an immune response against them.

This misguided response can lead to chronic inflammation, tissue damage, and impaired organ function. Autoimmune diseases can affect various parts of the body, including the joints, skin, glands, muscles, and blood vessels. Some common examples of autoimmune diseases are rheumatoid arthritis, lupus, multiple sclerosis, type 1 diabetes, Hashimoto's thyroiditis, and Graves' disease.

The exact cause of autoimmunity is not fully understood, but it is believed to involve a combination of genetic, environmental, and lifestyle factors that trigger an abnormal immune response in susceptible individuals. Treatment for autoimmune diseases typically involves managing symptoms, reducing inflammation, and suppressing the immune system's overactive response using medications such as corticosteroids, immunosuppressants, and biologics.

Molecular sequence data refers to the specific arrangement of molecules, most commonly nucleotides in DNA or RNA, or amino acids in proteins, that make up a biological macromolecule. This data is generated through laboratory techniques such as sequencing, and provides information about the exact order of the constituent molecules. This data is crucial in various fields of biology, including genetics, evolution, and molecular biology, allowing for comparisons between different organisms, identification of genetic variations, and studies of gene function and regulation.

CD274, also known as B7-H1 or PD-L1 (programmed death ligand 1), is a type of protein that functions as an immune checkpoint regulator. It is expressed on the surface of certain cells, including some cancer cells and activated immune cells. CD274 binds to the PD-1 receptor on T cells, which helps to downregulate or turn off their immune response. This can allow cancer cells to evade detection and destruction by the immune system.

CD274 is an important target for immunotherapy in cancer treatment. Drugs called checkpoint inhibitors that block the interaction between CD274 and PD-1 have been developed and approved for use in certain types of cancer, such as melanoma, lung cancer, and kidney cancer. These drugs work by boosting the immune system's ability to recognize and attack cancer cells.

Immunomodulation is the process of modifying or regulating the immune system's response. It can involve either stimulating or suppressing various components of the immune system, such as white blood cells, antibodies, or cytokines. This can be achieved through various means, including medications (such as immunosuppressive drugs used in organ transplantation), vaccines, and other therapies.

The goal of immunomodulation is to restore balance to an overactive or underactive immune system, depending on the specific medical condition being treated. It can help to prevent or treat diseases that result from abnormal immune responses, such as autoimmune disorders, allergies, and infections.

CD1

Histocompatibility antigens, class I are proteins found on the surface of most cells in the body. They play a critical role in the immune system's ability to differentiate between "self" and "non-self." These antigens are composed of three polypeptides - two heavy chains and one light chain - and are encoded by genes in the major histocompatibility complex (MHC) on chromosome 6 in humans.

Class I MHC molecules present peptide fragments from inside the cell to CD8+ T cells, also known as cytotoxic T cells. This presentation allows the immune system to detect and destroy cells that have been infected by viruses or other intracellular pathogens, or that have become cancerous.

There are three main types of class I MHC molecules in humans: HLA-A, HLA-B, and HLA-C. The term "HLA" stands for human leukocyte antigen, which reflects the original identification of these proteins on white blood cells (leukocytes). The genes encoding these molecules are highly polymorphic, meaning there are many different variants in the population, and matching HLA types is essential for successful organ transplantation to minimize the risk of rejection.

Immunological models are simplified representations or simulations of the immune system's structure, function, and interactions with pathogens or other entities. These models can be theoretical (conceptual), mathematical, or computational and are used to understand, explain, and predict immunological phenomena. They help researchers study complex immune processes and responses that cannot be easily observed or manipulated in vivo.

Theoretical immunological models provide conceptual frameworks for understanding immune system behavior, often using diagrams or flowcharts to illustrate interactions between immune components. Mathematical models use mathematical equations to describe immune system dynamics, allowing researchers to simulate and analyze the outcomes of various scenarios. Computational models, also known as in silico models, are created using computer software and can incorporate both theoretical and mathematical concepts to create detailed simulations of immunological processes.

Immunological models are essential tools for advancing our understanding of the immune system and developing new therapies and vaccines. They enable researchers to test hypotheses, explore the implications of different assumptions, and identify areas requiring further investigation.

Coculture techniques refer to a type of experimental setup in which two or more different types of cells or organisms are grown and studied together in a shared culture medium. This method allows researchers to examine the interactions between different cell types or species under controlled conditions, and to study how these interactions may influence various biological processes such as growth, gene expression, metabolism, and signal transduction.

Coculture techniques can be used to investigate a wide range of biological phenomena, including the effects of host-microbe interactions on human health and disease, the impact of different cell types on tissue development and homeostasis, and the role of microbial communities in shaping ecosystems. These techniques can also be used to test the efficacy and safety of new drugs or therapies by examining their effects on cells grown in coculture with other relevant cell types.

There are several different ways to establish cocultures, depending on the specific research question and experimental goals. Some common methods include:

1. Mixed cultures: In this approach, two or more cell types are simply mixed together in a culture dish or flask and allowed to grow and interact freely.
2. Cell-layer cultures: Here, one cell type is grown on a porous membrane or other support structure, while the second cell type is grown on top of it, forming a layered coculture.
3. Conditioned media cultures: In this case, one cell type is grown to confluence and its culture medium is collected and then used to grow a second cell type. This allows the second cell type to be exposed to any factors secreted by the first cell type into the medium.
4. Microfluidic cocultures: These involve growing cells in microfabricated channels or chambers, which allow for precise control over the spatial arrangement and flow of nutrients, waste products, and signaling molecules between different cell types.

Overall, coculture techniques provide a powerful tool for studying complex biological systems and gaining insights into the mechanisms that underlie various physiological and pathological processes.

Antibody specificity refers to the ability of an antibody to bind to a specific epitope or antigenic determinant on an antigen. Each antibody has a unique structure that allows it to recognize and bind to a specific region of an antigen, typically a small portion of the antigen's surface made up of amino acids or sugar residues. This highly specific binding is mediated by the variable regions of the antibody's heavy and light chains, which form a pocket that recognizes and binds to the epitope.

The specificity of an antibody is determined by its unique complementarity-determining regions (CDRs), which are loops of amino acids located in the variable domains of both the heavy and light chains. The CDRs form a binding site that recognizes and interacts with the epitope on the antigen. The precise fit between the antibody's binding site and the epitope is critical for specificity, as even small changes in the structure of either can prevent binding.

Antibody specificity is important in immune responses because it allows the immune system to distinguish between self and non-self antigens. This helps to prevent autoimmune reactions where the immune system attacks the body's own cells and tissues. Antibody specificity also plays a crucial role in diagnostic tests, such as ELISA assays, where antibodies are used to detect the presence of specific antigens in biological samples.

Anti-idiotypic antibodies are a type of immune protein that recognizes and binds to the unique identifying region (idiotype) of another antibody. These antibodies are produced by the immune system as part of a regulatory feedback mechanism, where they can modulate or inhibit the activity of the original antibody. They have been studied for their potential use in immunotherapy and vaccine development.

Homologous transplantation is a type of transplant surgery where organs or tissues are transferred between two genetically non-identical individuals of the same species. The term "homologous" refers to the similarity in structure and function of the donated organ or tissue to the recipient's own organ or tissue.

For example, a heart transplant from one human to another is an example of homologous transplantation because both organs are hearts and perform the same function. Similarly, a liver transplant, kidney transplant, lung transplant, and other types of organ transplants between individuals of the same species are also considered homologous transplantations.

Homologous transplantation is in contrast to heterologous or xenogeneic transplantation, where organs or tissues are transferred from one species to another, such as a pig heart transplanted into a human. Homologous transplantation is more commonly performed than heterologous transplantation due to the increased risk of rejection and other complications associated with xenogeneic transplants.

Spontaneous remission in a medical context refers to the disappearance or significant improvement of symptoms of a disease or condition without any specific treatment being administered. In other words, it's a situation where the disease resolves on its own, without any apparent cause. While spontaneous remission can occur in various conditions, it is relatively rare and not well understood. It's important to note that just because a remission occurs without treatment doesn't mean that medical care should be avoided, as many conditions can worsen or lead to complications if left untreated.

Papillomavirus E7 proteins are small, viral regulatory proteins encoded by the E7 gene in papillomaviruses (HPVs). These proteins play a crucial role in the life cycle of HPVs and are associated with the development of various types of cancer, most notably cervical cancer.

The E7 protein functions as a transcriptional activator and can bind to and degrade the retinoblastoma protein (pRb), which is a tumor suppressor. By binding to and inactivating pRb, E7 promotes the expression of genes required for cell cycle progression, leading to uncontrolled cell growth and proliferation.

E7 proteins are also capable of inducing genetic alterations, such as chromosomal instability and DNA damage, which can contribute to the development of cancer. Additionally, E7 has been shown to inhibit apoptosis (programmed cell death) and promote angiogenesis (the formation of new blood vessels), further contributing to tumor growth and progression.

Overall, Papillomavirus E7 proteins are important oncogenic factors that play a central role in the development of HPV-associated cancers.

An antigen is a substance (usually a protein) that is recognized as foreign by the immune system and stimulates an immune response, leading to the production of antibodies or activation of T-cells. Antigens can be derived from various sources, including bacteria, viruses, fungi, parasites, and tumor cells. They can also come from non-living substances such as pollen, dust mites, or chemicals.

Antigens contain epitopes, which are specific regions on the antigen molecule that are recognized by the immune system. The immune system's response to an antigen depends on several factors, including the type of antigen, its size, and its location in the body.

In general, antigens can be classified into two main categories:

1. T-dependent antigens: These require the help of T-cells to stimulate an immune response. They are typically larger, more complex molecules that contain multiple epitopes capable of binding to both MHC class II molecules on antigen-presenting cells and T-cell receptors on CD4+ T-cells.
2. T-independent antigens: These do not require the help of T-cells to stimulate an immune response. They are usually smaller, simpler molecules that contain repetitive epitopes capable of cross-linking B-cell receptors and activating them directly.

Understanding antigens and their properties is crucial for developing vaccines, diagnostic tests, and immunotherapies.

Molecular targeted therapy is a type of treatment that targets specific molecules involved in the growth, progression, and spread of cancer. These molecules can be proteins, genes, or other molecules that contribute to the development of cancer. By targeting these specific molecules, molecular targeted therapy aims to block the abnormal signals that promote cancer growth and progression, thereby inhibiting or slowing down the growth of cancer cells while minimizing harm to normal cells.

Examples of molecular targeted therapies include monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis inhibitors, and immunotherapies that target specific immune checkpoints. These therapies can be used alone or in combination with other cancer treatments such as chemotherapy, radiation therapy, or surgery. The goal of molecular targeted therapy is to improve the effectiveness of cancer treatment while reducing side effects and improving quality of life for patients.

Interleukin-10 (IL-10) is an anti-inflammatory cytokine that plays a crucial role in the modulation of immune responses. It is produced by various cell types, including T cells, macrophages, and dendritic cells. IL-10 inhibits the production of pro-inflammatory cytokines, such as TNF-α, IL-1, IL-6, IL-8, and IL-12, and downregulates the expression of costimulatory molecules on antigen-presenting cells. This results in the suppression of T cell activation and effector functions, which ultimately helps to limit tissue damage during inflammation and promote tissue repair. Dysregulation of IL-10 has been implicated in various pathological conditions, including chronic infections, autoimmune diseases, and cancer.

The immune system is a complex network of cells, tissues, and organs that work together to defend the body against harmful invaders. It recognizes and responds to threats such as bacteria, viruses, parasites, fungi, and damaged or abnormal cells, including cancer cells. The immune system has two main components: the innate immune system, which provides a general defense against all types of threats, and the adaptive immune system, which mounts specific responses to particular threats.

The innate immune system includes physical barriers like the skin and mucous membranes, chemical barriers such as stomach acid and enzymes in tears and saliva, and cellular defenses like phagocytes (white blood cells that engulf and destroy invaders) and natural killer cells (which recognize and destroy virus-infected or cancerous cells).

The adaptive immune system is more specific and takes longer to develop a response but has the advantage of "remembering" previous encounters with specific threats. This allows it to mount a faster and stronger response upon subsequent exposures, providing immunity to certain diseases. The adaptive immune system includes T cells (which help coordinate the immune response) and B cells (which produce antibodies that neutralize or destroy invaders).

Overall, the immune system is essential for maintaining health and preventing disease. Dysfunction of the immune system can lead to a variety of disorders, including autoimmune diseases, immunodeficiencies, and allergies.

Immunologic memory, also known as adaptive immunity, refers to the ability of the immune system to recognize and mount a more rapid and effective response upon subsequent exposure to a pathogen or antigen that it has encountered before. This is a key feature of the vertebrate immune system and allows for long-term protection against infectious diseases.

Immunologic memory is mediated by specialized cells called memory T cells and B cells, which are produced during the initial response to an infection or immunization. These cells persist in the body after the pathogen has been cleared and can quickly respond to future encounters with the same or similar antigens. This rapid response leads to a more effective and efficient elimination of the pathogen, resulting in fewer symptoms and reduced severity of disease.

Immunologic memory is the basis for vaccines, which work by exposing the immune system to a harmless form of a pathogen or its components, inducing an initial response and generating memory cells that provide long-term protection against future infections.

Lymphoma is a type of cancer that originates from the white blood cells called lymphocytes, which are part of the immune system. These cells are found in various parts of the body such as the lymph nodes, spleen, bone marrow, and other organs. Lymphoma can be classified into two main types: Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).

HL is characterized by the presence of a specific type of abnormal lymphocyte called Reed-Sternberg cells, while NHL includes a diverse group of lymphomas that lack these cells. The symptoms of lymphoma may include swollen lymph nodes, fever, night sweats, weight loss, and fatigue.

The exact cause of lymphoma is not known, but it is believed to result from genetic mutations in the lymphocytes that lead to uncontrolled cell growth and division. Exposure to certain viruses, chemicals, and radiation may increase the risk of developing lymphoma. Treatment options for lymphoma depend on various factors such as the type and stage of the disease, age, and overall health of the patient. Common treatments include chemotherapy, radiation therapy, immunotherapy, and stem cell transplantation.

Immunoconjugates are biomolecules created by the conjugation (coupling) of an antibody or antibody fragment with a cytotoxic agent, such as a drug, radionuclide, or toxin. This coupling is designed to direct the cytotoxic agent specifically to target cells, usually cancer cells, against which the antibody is directed, thereby increasing the effectiveness and reducing the side effects of the therapy.

The antibody part of the immunoconjugate recognizes and binds to specific antigens (proteins or other molecules) on the surface of the target cells, while the cytotoxic agent part enters the cell and disrupts its function, leading to cell death. The linker between the two parts is designed to be stable in circulation but can release the cytotoxic agent once inside the target cell.

Immunoconjugates are a promising area of research in targeted cancer therapy, as they offer the potential for more precise and less toxic treatments compared to traditional chemotherapy. However, their development and use also pose challenges, such as ensuring that the immunoconjugate binds specifically to the target cells and not to normal cells, optimizing the dose and schedule of treatment, and minimizing the risk of resistance to the therapy.

B-lymphocytes, also known as B-cells, are a type of white blood cell that plays a key role in the immune system's response to infection. They are responsible for producing antibodies, which are proteins that help to neutralize or destroy pathogens such as bacteria and viruses.

When a B-lymphocyte encounters a pathogen, it becomes activated and begins to divide and differentiate into plasma cells, which produce and secrete large amounts of antibodies specific to the antigens on the surface of the pathogen. These antibodies bind to the pathogen, marking it for destruction by other immune cells such as neutrophils and macrophages.

B-lymphocytes also have a role in presenting antigens to T-lymphocytes, another type of white blood cell involved in the immune response. This helps to stimulate the activation and proliferation of T-lymphocytes, which can then go on to destroy infected cells or help to coordinate the overall immune response.

Overall, B-lymphocytes are an essential part of the adaptive immune system, providing long-lasting immunity to previously encountered pathogens and helping to protect against future infections.

Lymph nodes are small, bean-shaped organs that are part of the immune system. They are found throughout the body, especially in the neck, armpits, groin, and abdomen. Lymph nodes filter lymph fluid, which carries waste and unwanted substances such as bacteria, viruses, and cancer cells. They contain white blood cells called lymphocytes that help fight infections and diseases by attacking and destroying the harmful substances found in the lymph fluid. When an infection or disease is present, lymph nodes may swell due to the increased number of immune cells and fluid accumulation as they work to fight off the invaders.

Prostatic neoplasms refer to abnormal growths in the prostate gland, which can be benign or malignant. The term "neoplasm" simply means new or abnormal tissue growth. When it comes to the prostate, neoplasms are often referred to as tumors.

Benign prostatic neoplasms, such as prostate adenomas, are non-cancerous overgrowths of prostate tissue. They usually grow slowly and do not spread to other parts of the body. While they can cause uncomfortable symptoms like difficulty urinating, they are generally not life-threatening.

Malignant prostatic neoplasms, on the other hand, are cancerous growths. The most common type of prostate cancer is adenocarcinoma, which arises from the glandular cells in the prostate. Prostate cancer often grows slowly and may not cause any symptoms for many years. However, some types of prostate cancer can be aggressive and spread quickly to other parts of the body, such as the bones or lymph nodes.

It's important to note that while prostate neoplasms can be concerning, early detection and treatment can significantly improve outcomes for many men. Regular check-ups with a healthcare provider are key to monitoring prostate health and catching any potential issues early on.

"Carcinoma, Lewis lung" is a term used to describe a specific type of lung cancer that was first discovered in strain C57BL/6J mice by Dr. Margaret R. Lewis in 1951. It is a spontaneously occurring undifferentiated carcinoma that originates from the lung epithelium and is highly invasive and metastatic, making it a popular model for studying cancer biology and testing potential therapies.

The Lewis lung carcinoma (LLC) cells are typically characterized by their rapid growth rate, ability to form tumors when implanted into syngeneic mice, and high levels of vascular endothelial growth factor (VEGF), which promotes angiogenesis and tumor growth.

It is important to note that while the LLC model has been useful for studying certain aspects of lung cancer, it may not fully recapitulate the complexity and heterogeneity of human lung cancers. Therefore, findings from LLC studies should be validated in more clinically relevant models before being translated into human therapies.

Myeloid cells are a type of immune cell that originate from the bone marrow. They develop from hematopoietic stem cells, which can differentiate into various types of blood cells. Myeloid cells include monocytes, macrophages, granulocytes (such as neutrophils, eosinophils, and basophils), dendritic cells, and mast cells. These cells play important roles in the immune system, such as defending against pathogens, modulating inflammation, and participating in tissue repair and remodeling.

Myeloid cell development is a tightly regulated process that involves several stages of differentiation, including the commitment to the myeloid lineage, proliferation, and maturation into specific subtypes. Dysregulation of myeloid cell development or function can contribute to various diseases, such as infections, cancer, and autoimmune disorders.

Amyloid beta-peptides (Aβ) are small protein fragments that are crucially involved in the pathogenesis of Alzheimer's disease. They are derived from a larger transmembrane protein called the amyloid precursor protein (APP) through a series of proteolytic cleavage events.

The two primary forms of Aβ peptides are Aβ40 and Aβ42, which differ in length by two amino acids. While both forms can be harmful, Aβ42 is more prone to aggregation and is considered to be the more pathogenic form. These peptides have the tendency to misfold and accumulate into oligomers, fibrils, and eventually insoluble plaques that deposit in various areas of the brain, most notably the cerebral cortex and hippocampus.

The accumulation of Aβ peptides is believed to initiate a cascade of events leading to neuroinflammation, oxidative stress, synaptic dysfunction, and neuronal death, which are all hallmarks of Alzheimer's disease. Although the exact role of Aβ in the onset and progression of Alzheimer's is still under investigation, it is widely accepted that they play a central part in the development of this debilitating neurodegenerative disorder.

Tumor-associated carbohydrate antigens (TACAs) are a type of tumor antigen that are expressed on the surface of cancer cells. These antigens are abnormal forms of carbohydrates, also known as glycans, which are attached to proteins and lipids on the cell surface.

TACAs are often overexpressed or expressed in a different form on cancer cells compared to normal cells. This makes them attractive targets for cancer immunotherapy because they can be recognized by the immune system as foreign and elicit an immune response. Some examples of TACAs include gangliosides, fucosylated glycans, and sialylated glycans.

Tumor-associated carbohydrate antigens have been studied as potential targets for cancer vaccines, antibody therapies, and other immunotherapeutic approaches. However, their use as targets for cancer therapy is still in the early stages of research and development.

Intravesical administration refers to the instillation of medication directly into the bladder through a catheter or other medical device. This method is often used to deliver treatments for various bladder conditions, such as interstitial cystitis, bladder cancer, and chronic bladder infections. The medication is held in the bladder for a specified period, usually ranging from a few minutes to several hours, before being urinated out. This allows the medication to come into close contact with the bladder lining, potentially enhancing its effectiveness while minimizing systemic side effects.

Interleukin-15 (IL-15) is a small protein with a molecular weight of approximately 14 to 15 kilodaltons. It belongs to the class of cytokines known as the four-alpha-helix bundle family, which also includes IL-2, IL-4, and IL-7.

IL-15 is primarily produced by monocytes, macrophages, and dendritic cells, but it can also be produced by other cell types such as fibroblasts, epithelial cells, and endothelial cells. It plays a crucial role in the immune system by regulating the activation, proliferation, and survival of various immune cells, including T cells, natural killer (NK) cells, and dendritic cells.

IL-15 binds to its receptor complex, which consists of three components: IL-15Rα, IL-2/IL-15Rβ, and the common γ-chain (γc). The binding of IL-15 to this receptor complex leads to the activation of several signaling pathways, including the JAK-STAT, MAPK, and PI3K pathways.

IL-15 has a wide range of biological activities, including promoting the survival and proliferation of T cells and NK cells, enhancing their cytotoxic activity, and regulating their differentiation and maturation. It also plays a role in the development and maintenance of memory T cells, which are critical for long-term immunity to pathogens.

Dysregulation of IL-15 signaling has been implicated in various diseases, including autoimmune disorders, chronic inflammation, and cancer. Therefore, IL-15 is a potential target for therapeutic intervention in these conditions.

Anti-allergic agents, also known as antihistamines, are a class of medications used to treat allergies. They work by blocking the action of histamine, a substance in the body that is released during an allergic reaction and causes symptoms such as itching, sneezing, runny nose, and watery eyes.

There are two main types of antihistamines: first-generation and second-generation. First-generation antihistamines, such as diphenhydramine (Benadryl) and chlorpheniramine (Chlor-Trimeton), can cause drowsiness and other side effects, such as dry mouth and blurred vision. They are typically used for the treatment of short-term symptoms, such as those caused by seasonal allergies or a mild reaction to an insect bite.

Second-generation antihistamines, such as loratadine (Claritin) and cetirizine (Zyrtec), are less likely to cause drowsiness and other side effects. They are often used for the long-term treatment of chronic allergies, such as those caused by dust mites or pet dander.

In addition to their use in treating allergies, antihistamines may also be used to treat symptoms of motion sickness, insomnia, and anxiety. It is important to follow the instructions on the label when taking antihistamines and to talk to a healthcare provider if you have any questions or concerns about using these medications.

The "Graft vs Tumor Effect" is a term used in the field of transplantation medicine, particularly in allogeneic hematopoietic stem cell transplantation (HSCT). It refers to the anti-tumor activity exhibited by donor immune cells (graft) against residual malignant cells (tumor) in the recipient's body.

After HSCT, the donor's immune system is reconstituted in the recipient's body. If the donor and recipient are not identical, there may be differences in their major and minor histocompatibility antigens, which can lead to a graft-versus-host disease (GVHD) where the donor's immune cells attack the recipient's tissues. However, these same donor immune cells can also recognize and target any residual tumor cells in the recipient's body, leading to a graft vs tumor effect.

This effect can contribute to the elimination of residual malignant cells and reduce the risk of relapse, particularly in hematological malignancies such as leukemia and lymphoma. However, it is important to balance this effect with the risk of GVHD, which can cause significant morbidity and mortality. Therefore, strategies such as donor selection, graft manipulation, and immunosuppressive therapy are used to optimize the graft vs tumor effect while minimizing GVHD.

Adenoviridae is a family of viruses that includes many species that can cause various types of illnesses in humans and animals. These viruses are non-enveloped, meaning they do not have a lipid membrane, and have an icosahedral symmetry with a diameter of approximately 70-90 nanometers.

The genome of Adenoviridae is composed of double-stranded DNA, which contains linear chromosomes ranging from 26 to 45 kilobases in length. The family is divided into five genera: Mastadenovirus, Aviadenovirus, Atadenovirus, Siadenovirus, and Ichtadenovirus.

Human adenoviruses are classified under the genus Mastadenovirus and can cause a wide range of illnesses, including respiratory infections, conjunctivitis, gastroenteritis, and upper respiratory tract infections. Some serotypes have also been associated with more severe diseases such as hemorrhagic cystitis, hepatitis, and meningoencephalitis.

Adenoviruses are highly contagious and can be transmitted through respiratory droplets, fecal-oral route, or by contact with contaminated surfaces. They can also be spread through contaminated water sources. Infections caused by adenoviruses are usually self-limiting, but severe cases may require hospitalization and supportive care.

B-cell lymphoma is a type of cancer that originates from the B-lymphocytes, which are a part of the immune system and play a crucial role in fighting infections. These cells can develop mutations in their DNA, leading to uncontrolled growth and division, resulting in the formation of a tumor.

B-cell lymphomas can be classified into two main categories: Hodgkin's lymphoma and non-Hodgkin's lymphoma. B-cell lymphomas are further divided into subtypes based on their specific characteristics, such as the appearance of the cells under a microscope, the genetic changes present in the cancer cells, and the aggressiveness of the disease.

Some common types of B-cell lymphomas include diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and Burkitt lymphoma. Treatment options for B-cell lymphomas depend on the specific subtype, stage of the disease, and other individual factors. Treatment may include chemotherapy, radiation therapy, immunotherapy, targeted therapy, or stem cell transplantation.

Colonic neoplasms refer to abnormal growths in the large intestine, also known as the colon. These growths can be benign (non-cancerous) or malignant (cancerous). The two most common types of colonic neoplasms are adenomas and carcinomas.

Adenomas are benign tumors that can develop into cancer over time if left untreated. They are often found during routine colonoscopies and can be removed during the procedure.

Carcinomas, on the other hand, are malignant tumors that invade surrounding tissues and can spread to other parts of the body. Colorectal cancer is the third leading cause of cancer-related deaths in the United States, and colonic neoplasms are a significant risk factor for developing this type of cancer.

Regular screenings for colonic neoplasms are recommended for individuals over the age of 50 or those with a family history of colorectal cancer or other risk factors. Early detection and removal of colonic neoplasms can significantly reduce the risk of developing colorectal cancer.

T-cell receptors (TCRs) are proteins found on the surface of T cells, which are a type of white blood cell in the immune system. They play a critical role in adaptive immunity, allowing T cells to recognize and respond to specific targets such as infected or cancerous cells.

A gene is a segment of DNA that contains the instructions for making a particular protein. In the case of TCRs, there are two types of genes involved: TCR alpha (TRAV) and TCR beta (TRB) genes. These genes are located in a region of the human genome called the T-cell receptor locus.

During T-cell development, a process called V(D)J recombination occurs, which randomly assembles different segments of the TRAV and TRB genes to create a unique TCR alpha and TCR beta chain, respectively. This results in a vast diversity of TCRs, allowing the immune system to recognize a wide variety of targets.

The assembled TCR alpha and beta chains then form a heterodimer that is expressed on the surface of the T cell. When a TCR recognizes its specific target, it triggers a series of events that ultimately leads to the destruction of the targeted cell.

Monoclonal murine-derived antibodies are a type of laboratory-produced antibody that is identical in structure, having been derived from a single clone of cells. These antibodies are created using mouse cells and are therefore composed entirely of mouse immune proteins. They are designed to bind specifically to a particular target protein or antigen, making them useful tools for research, diagnostic testing, and therapeutic applications.

Monoclonal antibodies offer several advantages over polyclonal antibodies (which are derived from multiple clones of cells and can recognize multiple epitopes on an antigen). Monoclonal antibodies have a consistent and uniform structure, making them more reliable for research and diagnostic purposes. They also have higher specificity and affinity for their target antigens, allowing for more sensitive detection and measurement.

However, there are some limitations to using monoclonal murine-derived antibodies in therapeutic applications. Because they are composed entirely of mouse proteins, they can elicit an immune response in humans, leading to the production of human anti-mouse antibodies (HAMA) that can neutralize their effectiveness. To overcome this limitation, researchers have developed chimeric and humanized monoclonal antibodies that incorporate human protein sequences, reducing the risk of an immune response.

Autoimmune diseases are a group of disorders in which the immune system, which normally protects the body from foreign invaders like bacteria and viruses, mistakenly attacks the body's own cells and tissues. This results in inflammation and damage to various organs and tissues in the body.

In autoimmune diseases, the body produces autoantibodies that target its own proteins or cell receptors, leading to their destruction or malfunction. The exact cause of autoimmune diseases is not fully understood, but it is believed that a combination of genetic and environmental factors contribute to their development.

There are over 80 different types of autoimmune diseases, including rheumatoid arthritis, lupus, multiple sclerosis, type 1 diabetes, Hashimoto's thyroiditis, Graves' disease, psoriasis, and inflammatory bowel disease. Symptoms can vary widely depending on the specific autoimmune disease and the organs or tissues affected. Treatment typically involves managing symptoms and suppressing the immune system to prevent further damage.

CD19 is a type of protein found on the surface of B cells, which are a type of white blood cell that plays a key role in the body's immune response. CD19 is a marker that helps identify and distinguish B cells from other types of cells in the body. It is also a target for immunotherapy in certain diseases, such as B-cell malignancies.

An antigen is any substance that can stimulate an immune response, particularly the production of antibodies. In the context of CD19, antigens refer to substances that can bind to CD19 and trigger a response from the immune system. This can include proteins, carbohydrates, or other molecules found on the surface of bacteria, viruses, or cancer cells.

Therefore, 'antigens, CD19' refers to any substances that can bind to the CD19 protein on B cells and trigger an immune response. These antigens may be used in the development of immunotherapies for the treatment of B-cell malignancies or other diseases.

Lymphocytes are a type of white blood cell that is an essential part of the immune system. They are responsible for recognizing and responding to potentially harmful substances such as viruses, bacteria, and other foreign invaders. There are two main types of lymphocytes: B-lymphocytes (B-cells) and T-lymphocytes (T-cells).

B-lymphocytes produce antibodies, which are proteins that help to neutralize or destroy foreign substances. When a B-cell encounters a foreign substance, it becomes activated and begins to divide and differentiate into plasma cells, which produce and secrete large amounts of antibodies. These antibodies bind to the foreign substance, marking it for destruction by other immune cells.

T-lymphocytes, on the other hand, are involved in cell-mediated immunity. They directly attack and destroy infected cells or cancerous cells. T-cells can also help to regulate the immune response by producing chemical signals that activate or inhibit other immune cells.

Lymphocytes are produced in the bone marrow and mature in either the bone marrow (B-cells) or the thymus gland (T-cells). They circulate throughout the body in the blood and lymphatic system, where they can be found in high concentrations in lymph nodes, the spleen, and other lymphoid organs.

Abnormalities in the number or function of lymphocytes can lead to a variety of immune-related disorders, including immunodeficiency diseases, autoimmune disorders, and cancer.

Gene transfer techniques, also known as gene therapy, refer to medical procedures where genetic material is introduced into an individual's cells or tissues to treat or prevent diseases. This can be achieved through various methods:

1. **Viral Vectors**: The most common method uses modified viruses, such as adenoviruses, retroviruses, or lentiviruses, to carry the therapeutic gene into the target cells. The virus infects the cell and inserts the new gene into the cell's DNA.

2. **Non-Viral Vectors**: These include methods like electroporation (using electric fields to create pores in the cell membrane), gene guns (shooting gold particles coated with DNA into cells), or liposomes (tiny fatty bubbles that can enclose DNA).

3. **Direct Injection**: In some cases, the therapeutic gene can be directly injected into a specific tissue or organ.

The goal of gene transfer techniques is to supplement or replace a faulty gene with a healthy one, thereby correcting the genetic disorder. However, these techniques are still largely experimental and have their own set of challenges, including potential immune responses, issues with accurate targeting, and risks of mutations or cancer development.

A Radioallergosorbent Test (RAST) is a type of blood test used in the diagnosis of allergies. It measures the presence and levels of specific antibodies, called immunoglobulin E (IgE), produced by the immune system in response to certain allergens. In this test, a small amount of blood is taken from the patient and then mixed with various allergens. If the patient has developed IgE antibodies against any of these allergens, they will bind to them, forming an antigen-antibody complex.

The mixture is then passed over a solid phase, such as a paper or plastic surface, which has been coated with allergen-specific antibodies. These antibodies will capture the antigen-antibody complexes formed in the previous step. A radioactive label is attached to a different type of antibody (called anti-IgE), which then binds to the IgE antibodies captured on the solid phase. The amount of radioactivity detected is proportional to the quantity of IgE antibodies present, providing an indication of the patient's sensitivity to that specific allergen.

While RAST tests have been largely replaced by more modern and sensitive techniques, such as fluorescence enzyme immunoassays (FEIA), they still provide valuable information in diagnosing allergies and guiding treatment plans.

Epitope mapping is a technique used in immunology to identify the specific portion or regions (called epitopes) on an antigen that are recognized and bind to antibodies or T-cell receptors. This process helps to understand the molecular basis of immune responses against various pathogens, allergens, or transplanted tissues.

Epitope mapping can be performed using different methods such as:

1. Peptide scanning: In this method, a series of overlapping peptides spanning the entire length of the antigen are synthesized and tested for their ability to bind to antibodies or T-cell receptors. The peptide that shows binding is considered to contain the epitope.
2. Site-directed mutagenesis: In this approach, specific amino acids within the antigen are altered, and the modified antigens are tested for their ability to bind to antibodies or T-cell receptors. This helps in identifying the critical residues within the epitope.
3. X-ray crystallography and NMR spectroscopy: These techniques provide detailed information about the three-dimensional structure of antigen-antibody complexes, allowing for accurate identification of epitopes at an atomic level.

The results from epitope mapping can be useful in various applications, including vaccine design, diagnostic test development, and understanding the basis of autoimmune diseases.

Immunosuppression is a state in which the immune system's ability to mount an immune response is reduced, compromised or inhibited. This can be caused by certain medications (such as those used to prevent rejection of transplanted organs), diseases (like HIV/AIDS), or genetic disorders. As a result, the body becomes more susceptible to infections and cancer development. It's important to note that immunosuppression should not be confused with immunity, which refers to the body's ability to resist and fight off infections and diseases.

Asthma is a chronic respiratory disease characterized by inflammation and narrowing of the airways, leading to symptoms such as wheezing, coughing, shortness of breath, and chest tightness. The airway obstruction in asthma is usually reversible, either spontaneously or with treatment.

The underlying cause of asthma involves a combination of genetic and environmental factors that result in hypersensitivity of the airways to certain triggers, such as allergens, irritants, viruses, exercise, and emotional stress. When these triggers are encountered, the airways constrict due to smooth muscle spasm, swell due to inflammation, and produce excess mucus, leading to the characteristic symptoms of asthma.

Asthma is typically managed with a combination of medications that include bronchodilators to relax the airway muscles, corticosteroids to reduce inflammation, and leukotriene modifiers or mast cell stabilizers to prevent allergic reactions. Avoiding triggers and monitoring symptoms are also important components of asthma management.

There are several types of asthma, including allergic asthma, non-allergic asthma, exercise-induced asthma, occupational asthma, and nocturnal asthma, each with its own set of triggers and treatment approaches. Proper diagnosis and management of asthma can help prevent exacerbations, improve quality of life, and reduce the risk of long-term complications.

"Intralymphatic injection" is a medical procedure that involves the administration of a substance directly into the lymphatic vessels. The lymphatic system is a part of the immune system and plays a crucial role in fighting infections and diseases. It consists of a network of vessels, nodes, and organs that help to transport fluids, nutrients, and waste products throughout the body.

Intralymphatic injections are typically used for diagnostic or therapeutic purposes. For example, they may be used to administer vaccines, medications, or contrast agents for imaging studies. The procedure is usually performed under the guidance of ultrasound or other imaging techniques to ensure accurate placement of the injection.

It's important to note that intralymphatic injections are different from subcutaneous or intramuscular injections, which involve injecting a substance into the tissue just under the skin or into the muscle, respectively. Intralymphatic injections require specialized training and expertise to perform safely and effectively.

Nasal provocation tests are a type of diagnostic procedure used in allergy testing to determine the specific allergens that cause a person's nasal symptoms. In this test, a small amount of an allergen is introduced into the patient's nostril using a spray or drops. The patient's response is then observed and measured for any signs of an allergic reaction, such as sneezing, runny nose, or congestion.

The test may be performed with a single allergen or with a series of allergens to identify which specific substances the patient is allergic to. The results of the test can help guide treatment decisions and management strategies for allergies, including immunotherapy (allergy shots) and avoidance measures.

It's important to note that nasal provocation tests should only be performed under the supervision of a trained healthcare professional, as there is a small risk of inducing a severe allergic reaction.

Immunoglobulin idiotypes refer to the unique antigenic determinants found on the variable regions of an immunoglobulin (antibody) molecule. These determinants are specific to each individual antibody and can be used to distinguish between different antibodies produced by a single individual or between antibodies produced by different individuals.

The variable region of an antibody is responsible for recognizing and binding to a specific antigen. The amino acid sequence in this region varies between different antibodies, and it is these variations that give rise to the unique idiotypes. Idiotypes can be used as markers to study the immune response, including the clonal selection and affinity maturation of B cells during an immune response.

Immunoglobulin idiotypes are also important in the development of monoclonal antibodies for therapeutic use. By identifying and isolating a specific antibody with the desired idiotype, it is possible to produce large quantities of identical antibodies that can be used to treat various diseases, including cancer and autoimmune disorders.

HLA-A1 antigen is a type of human leukocyte antigen (HLA) class I molecule that plays an important role in the immune system. The HLAs are proteins found on the surface of cells that help the immune system distinguish between the body's own cells and foreign substances, such as viruses and bacteria.

The HLA-A1 antigen is one of several different types of HLA-A molecules, and it is determined by a specific set of genes located on chromosome 6. The HLA-A1 antigen is expressed on the surface of some cells in the human body and can be detected through laboratory testing.

The HLA-A1 antigen is associated with certain diseases or conditions, such as an increased risk of developing certain types of cancer or autoimmune disorders. It is also used as a marker for tissue typing in organ transplantation to help match donors and recipients and reduce the risk of rejection.

It's important to note that the presence or absence of HLA-A1 antigen alone does not determine whether someone will develop a particular disease or experience a successful organ transplant. Other genetic and environmental factors also play a role in these outcomes.

Th2 cells, or T helper 2 cells, are a type of CD4+ T cell that plays a key role in the immune response to parasites and allergens. They produce cytokines such as IL-4, IL-5, IL-13 which promote the activation and proliferation of eosinophils, mast cells, and B cells, leading to the production of antibodies such as IgE. Th2 cells also play a role in the pathogenesis of allergic diseases such as asthma, atopic dermatitis, and allergic rhinitis.

It's important to note that an imbalance in Th1/Th2 response can lead to immune dysregulation and disease states. For example, an overactive Th2 response can lead to allergic reactions while an underactive Th2 response can lead to decreased ability to fight off parasitic infections.

It's also worth noting that there are other subsets of CD4+ T cells such as Th1, Th17, Treg and others, each with their own specific functions and cytokine production profiles.

Vitiligo is a medical condition characterized by the loss of pigmentation in patches of skin, resulting in irregular white depigmented areas. It's caused by the destruction of melanocytes, the cells responsible for producing melanin, which gives our skin its color. The exact cause of vitiligo is not fully understood, but it's thought to be an autoimmune disorder where the immune system mistakenly attacks and destroys melanocytes. It can affect people of any age, gender, or ethnicity, although it may be more noticeable in people with darker skin tones. The progression of vitiligo is unpredictable and can vary from person to person. Treatment options include topical creams, light therapy, oral medications, and surgical procedures, but the effectiveness of these treatments varies depending on the individual case.

Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a laboratory technique used in molecular biology to amplify and detect specific DNA sequences. This technique is particularly useful for the detection and quantification of RNA viruses, as well as for the analysis of gene expression.

The process involves two main steps: reverse transcription and polymerase chain reaction (PCR). In the first step, reverse transcriptase enzyme is used to convert RNA into complementary DNA (cDNA) by reading the template provided by the RNA molecule. This cDNA then serves as a template for the PCR amplification step.

In the second step, the PCR reaction uses two primers that flank the target DNA sequence and a thermostable polymerase enzyme to repeatedly copy the targeted cDNA sequence. The reaction mixture is heated and cooled in cycles, allowing the primers to anneal to the template, and the polymerase to extend the new strand. This results in exponential amplification of the target DNA sequence, making it possible to detect even small amounts of RNA or cDNA.

RT-PCR is a sensitive and specific technique that has many applications in medical research and diagnostics, including the detection of viruses such as HIV, hepatitis C virus, and SARS-CoV-2 (the virus that causes COVID-19). It can also be used to study gene expression, identify genetic mutations, and diagnose genetic disorders.

Inbred NOD (Nonobese Diabetic) mice are a strain of laboratory mice that are genetically predisposed to develop autoimmune diabetes. This strain was originally developed in Japan and has been widely used as an animal model for studying type 1 diabetes and its complications.

NOD mice typically develop diabetes spontaneously at around 12-14 weeks of age, although the onset and severity of the disease can vary between individual mice. The disease is caused by a breakdown in immune tolerance, leading to an autoimmune attack on the insulin-producing beta cells of the pancreas.

Inbred NOD mice are highly valuable for research purposes because they exhibit many of the same genetic and immunological features as human patients with type 1 diabetes. By studying these mice, researchers can gain insights into the underlying mechanisms of the disease and develop new treatments and therapies.

Blocking antibodies are a type of antibody that binds to a specific antigen but does not cause the immune system to directly attack the antigen. Instead, blocking antibodies prevent the antigen from interacting with other molecules or receptors, effectively "blocking" its activity. This can be useful in therapeutic settings, where blocking antibodies can be used to inhibit the activity of harmful proteins or toxins.

For example, some blocking antibodies have been developed to target and block the activity of specific cytokines, which are signaling molecules involved in inflammation and immune responses. By blocking the interaction between the cytokine and its receptor, these antibodies can help to reduce inflammation and alleviate symptoms in certain autoimmune diseases or chronic inflammatory conditions.

It's important to note that while blocking antibodies can be useful for therapeutic purposes, they can also have unintended consequences if they block the activity of essential proteins or molecules. Therefore, careful consideration and testing are required before using blocking antibodies as a treatment.

Autoantigens are substances that are typically found in an individual's own body, but can stimulate an immune response because they are recognized as foreign by the body's own immune system. In autoimmune diseases, the immune system mistakenly attacks and damages healthy tissues and organs because it recognizes some of their components as autoantigens. These autoantigens can be proteins, DNA, or other molecules that are normally present in the body but have become altered or exposed due to various factors such as infection, genetics, or environmental triggers. The immune system then produces antibodies and activates immune cells to attack these autoantigens, leading to tissue damage and inflammation.

The Interleukin-2 Receptor alpha Subunit (IL-2Rα), also known as CD25, is a protein that is expressed on the surface of certain immune cells, such as activated T-cells and B-cells. It is a subunit of the interleukin-2 receptor, which plays a crucial role in the activation and regulation of the immune response. The IL-2Rα binds to interleukin-2 (IL-2) with high affinity, forming a complex that initiates intracellular signaling pathways involved in T-cell proliferation, differentiation, and survival. IL-2Rα is also a target for immunosuppressive therapies used to prevent rejection of transplanted organs and to treat autoimmune diseases.

A cell line is a culture of cells that are grown in a laboratory for use in research. These cells are usually taken from a single cell or group of cells, and they are able to divide and grow continuously in the lab. Cell lines can come from many different sources, including animals, plants, and humans. They are often used in scientific research to study cellular processes, disease mechanisms, and to test new drugs or treatments. Some common types of human cell lines include HeLa cells (which come from a cancer patient named Henrietta Lacks), HEK293 cells (which come from embryonic kidney cells), and HUVEC cells (which come from umbilical vein endothelial cells). It is important to note that cell lines are not the same as primary cells, which are cells that are taken directly from a living organism and have not been grown in the lab.

Interleukin-4 (IL-4) is a type of cytokine, which is a cell signaling molecule that mediates communication between cells in the immune system. Specifically, IL-4 is produced by activated T cells and mast cells, among other cells, and plays an important role in the differentiation and activation of immune cells called Th2 cells.

Th2 cells are involved in the immune response to parasites, as well as in allergic reactions. IL-4 also promotes the growth and survival of B cells, which produce antibodies, and helps to regulate the production of certain types of antibodies. In addition, IL-4 has anti-inflammatory effects and can help to downregulate the immune response in some contexts.

Defects in IL-4 signaling have been implicated in a number of diseases, including asthma, allergies, and certain types of cancer.

Anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis is a type of autoimmune encephalitis, which is a inflammation of the brain. It occurs when the body's immune system produces antibodies against NMDA receptors, which are proteins found on the surface of certain brain cells (neurons). These antibodies can bind to and disrupt the function of the NMDA receptors, leading to a range of neurological symptoms.

The symptoms of anti-NMDA receptor encephalitis typically develop over several weeks or months and can include:

* Behavioral changes, such as anxiety, agitation, or paranoia
* Memory loss
* Seizures
* Movement disorders, such as involuntary jerking or twitching of muscles
* Speech difficulties
* Loss of consciousness
* Autonomic instability (problems regulating heart rate, blood pressure, breathing and temperature)

The diagnosis is confirmed by detecting the anti-NMDA receptor antibodies in the cerebrospinal fluid (CSF) or serum. Treatment typically involves a combination of immunotherapy (such as corticosteroids, intravenous immunoglobulin, and plasma exchange) and tumor removal if a tumor is present.

It's important to note that this disorder can affect both children and adults, and it can be associated with ovarian teratoma in women of childbearing age.

4-1BB ligand, also known as CD137L or TNFSF9, is a type II transmembrane protein that belongs to the tumor necrosis factor (TNF) superfamily. It is a ligand for the 4-1BB receptor (CD137), which is a costimulatory molecule expressed on activated T cells.

The interaction between 4-1BB and its ligand provides a critical costimulatory signal that enhances T cell activation, proliferation, and survival. This signaling pathway plays an important role in the regulation of immune responses and has been implicated in various physiological and pathological processes, including autoimmunity, infectious diseases, and cancer.

In the context of cancer immunotherapy, agonistic antibodies targeting 4-1BB have shown promise in preclinical and clinical studies as a means to enhance anti-tumor immune responses. The binding of these antibodies to 4-1BB leads to its clustering and activation, which in turn promotes the expansion and survival of tumor-specific T cells, thereby enhancing their ability to eliminate cancer cells.

A clone is a group of cells that are genetically identical to each other because they are derived from a common ancestor cell through processes such as mitosis or asexual reproduction. Therefore, the term "clone cells" refers to a population of cells that are genetic copies of a single parent cell.

In the context of laboratory research, cells can be cloned by isolating a single cell and allowing it to divide in culture, creating a population of genetically identical cells. This is useful for studying the behavior and characteristics of individual cell types, as well as for generating large quantities of cells for use in experiments.

It's important to note that while clone cells are genetically identical, they may still exhibit differences in their phenotype (physical traits) due to epigenetic factors or environmental influences.

Immunoglobulin fragments refer to the smaller protein units that are formed by the digestion or break-down of an intact immunoglobulin, also known as an antibody. Immunoglobulins are large Y-shaped proteins produced by the immune system to identify and neutralize foreign substances such as pathogens or toxins. They consist of two heavy chains and two light chains, held together by disulfide bonds.

The digestion or break-down of an immunoglobulin can occur through enzymatic cleavage, which results in the formation of distinct fragments. The most common immunoglobulin fragments are:

1. Fab (Fragment, antigen binding) fragments: These are formed by the digestion of an intact immunoglobulin using the enzyme papain. Each Fab fragment contains a single antigen-binding site, consisting of a portion of one heavy chain and one light chain. The Fab fragments retain their ability to bind to specific antigens.
2. Fc (Fragment, crystallizable) fragments: These are formed by the digestion of an intact immunoglobulin using the enzyme pepsin or through the natural breakdown process in the body. The Fc fragment contains the constant region of both heavy chains and is responsible for effector functions such as complement activation, binding to Fc receptors on immune cells, and antibody-dependent cellular cytotoxicity (ADCC).

These immunoglobulin fragments play crucial roles in various immune responses and diagnostic applications. For example, Fab fragments can be used in immunoassays for the detection of specific antigens, while Fc fragments can mediate effector functions that help eliminate pathogens or damaged cells from the body.

The "Graft versus Leukemia (GvL) Effect" is a term used in the field of hematopoietic stem cell transplantation to describe a desirable outcome where the donor's immune cells (graft) recognize and attack the recipient's leukemia cells (host). This effect occurs when the donor's T-lymphocytes, natural killer cells, and other immune cells become activated against the recipient's malignant cells.

The GvL effect is often observed in patients who have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT), where the donor and recipient are not genetically identical. The genetic disparity between the donor and recipient creates an environment that allows for the recognition of host leukemia cells as foreign, triggering an immune response against them.

While the GvL effect can be beneficial in eliminating residual leukemia cells, it can also lead to complications such as graft-versus-host disease (GvHD), where the donor's immune cells attack the recipient's healthy tissues. Balancing the GvL effect and minimizing GvHD remains a significant challenge in allo-HSCT.

Intravenous Immunoglobulins (IVIG) are a preparation of antibodies, specifically immunoglobulins, that are derived from the plasma of healthy donors. They are administered intravenously to provide passive immunity and help boost the immune system's response in individuals with weakened or compromised immune systems. IVIG can be used for various medical conditions such as primary immunodeficiency disorders, secondary immunodeficiencies, autoimmune diseases, and some infectious diseases. The administration of IVIG can help prevent infections, reduce the severity and frequency of infections, and manage the symptoms of certain autoimmune disorders. It is important to note that while IVIG provides temporary immunity, it does not replace a person's own immune system.

Cyclophosphamide is an alkylating agent, which is a type of chemotherapy medication. It works by interfering with the DNA of cancer cells, preventing them from dividing and growing. This helps to stop the spread of cancer in the body. Cyclophosphamide is used to treat various types of cancer, including lymphoma, leukemia, multiple myeloma, and breast cancer. It can be given orally as a tablet or intravenously as an injection.

Cyclophosphamide can also have immunosuppressive effects, which means it can suppress the activity of the immune system. This makes it useful in treating certain autoimmune diseases, such as rheumatoid arthritis and lupus. However, this immunosuppression can also increase the risk of infections and other side effects.

Like all chemotherapy medications, cyclophosphamide can cause a range of side effects, including nausea, vomiting, hair loss, fatigue, and increased susceptibility to infections. It is important for patients receiving cyclophosphamide to be closely monitored by their healthcare team to manage these side effects and ensure the medication is working effectively.

"Mycobacterium bovis" is a species of slow-growing, aerobic, gram-positive bacteria in the family Mycobacteriaceae. It is the causative agent of tuberculosis in cattle and other animals, and can also cause tuberculosis in humans, particularly in those who come into contact with infected animals or consume unpasteurized dairy products from infected cows. The bacteria are resistant to many common disinfectants and survive for long periods in a dormant state, making them difficult to eradicate from the environment. "Mycobacterium bovis" is closely related to "Mycobacterium tuberculosis," the bacterium that causes tuberculosis in humans, and both species share many genetic and biochemical characteristics.

CD40 ligand (CD40L or CD154) is a type II transmembrane protein and a member of the tumor necrosis factor (TNF) superfamily. It is primarily expressed on activated CD4+ T cells, but can also be found on other immune cells such as activated B cells, macrophages, and dendritic cells.

CD40 ligand binds to its receptor, CD40, which is mainly expressed on the surface of antigen-presenting cells (APCs) such as B cells, dendritic cells, and macrophages. The interaction between CD40L and CD40 plays a crucial role in the activation and regulation of the immune response.

CD40L-CD40 signaling is essential for T cell-dependent B cell activation, antibody production, and class switching. It also contributes to the activation and maturation of dendritic cells, promoting their ability to stimulate T cell responses. Dysregulation of CD40L-CD40 signaling has been implicated in various autoimmune diseases, transplant rejection, and cancer.

Multiple myeloma is a type of cancer that forms in a type of white blood cell called a plasma cell. Plasma cells help your body fight infection by producing antibodies. In multiple myeloma, cancerous plasma cells accumulate in the bone marrow and crowd out healthy blood cells. Rather than producing useful antibodies, the cancer cells produce abnormal proteins that can cause complications such as kidney damage, bone pain and fractures.

Multiple myeloma is a type of cancer called a plasma cell neoplasm. Plasma cell neoplasms are diseases in which there is an overproduction of a single clone of plasma cells. In multiple myeloma, this results in the crowding out of normal plasma cells, red and white blood cells and platelets, leading to many of the complications associated with the disease.

The abnormal proteins produced by the cancer cells can also cause damage to organs and tissues in the body. These abnormal proteins can be detected in the blood or urine and are often used to monitor the progression of multiple myeloma.

Multiple myeloma is a relatively uncommon cancer, but it is the second most common blood cancer after non-Hodgkin lymphoma. It typically occurs in people over the age of 65, and men are more likely to develop multiple myeloma than women. While there is no cure for multiple myeloma, treatments such as chemotherapy, radiation therapy, and stem cell transplantation can help manage the disease and its symptoms, and improve quality of life.

Perforin is a protein that plays a crucial role in the immune system's response to virally infected or cancerous cells. It is primarily produced and released by cytotoxic T-cells and natural killer (NK) cells, two types of white blood cells involved in defending the body against infection and disease.

Perforin functions by creating pores or holes in the membrane of target cells, leading to their lysis or destruction. This process allows for the release of cellular contents and the exposure of intracellular antigens, which can then be processed and presented to other immune cells, thereby enhancing the immune response against the pathogen or abnormal cells.

In summary, perforin is a vital component of the immune system's cytotoxic activity, contributing to the elimination of infected or malignant cells and maintaining overall health and homeostasis in the body.

A "knockout" mouse is a genetically engineered mouse in which one or more genes have been deleted or "knocked out" using molecular biology techniques. This allows researchers to study the function of specific genes and their role in various biological processes, as well as potential associations with human diseases. The mice are generated by introducing targeted DNA modifications into embryonic stem cells, which are then used to create a live animal. Knockout mice have been widely used in biomedical research to investigate gene function, disease mechanisms, and potential therapeutic targets.

Urinary Bladder Neoplasms are abnormal growths or tumors in the urinary bladder, which can be benign (non-cancerous) or malignant (cancerous). Malignant neoplasms can be further classified into various types of bladder cancer, such as urothelial carcinoma, squamous cell carcinoma, and adenocarcinoma. These malignant tumors often invade surrounding tissues and organs, potentially spreading to other parts of the body (metastasis), which can lead to serious health consequences if not detected and treated promptly and effectively.

Cell separation is a process used to separate and isolate specific cell types from a heterogeneous mixture of cells. This can be accomplished through various physical or biological methods, depending on the characteristics of the cells of interest. Some common techniques for cell separation include:

1. Density gradient centrifugation: In this method, a sample containing a mixture of cells is layered onto a density gradient medium and then centrifuged. The cells are separated based on their size, density, and sedimentation rate, with denser cells settling closer to the bottom of the tube and less dense cells remaining near the top.

2. Magnetic-activated cell sorting (MACS): This technique uses magnetic beads coated with antibodies that bind to specific cell surface markers. The labeled cells are then passed through a column placed in a magnetic field, which retains the magnetically labeled cells while allowing unlabeled cells to flow through.

3. Fluorescence-activated cell sorting (FACS): In this method, cells are stained with fluorochrome-conjugated antibodies that recognize specific cell surface or intracellular markers. The stained cells are then passed through a laser beam, which excites the fluorophores and allows for the detection and sorting of individual cells based on their fluorescence profile.

4. Filtration: This simple method relies on the physical size differences between cells to separate them. Cells can be passed through filters with pore sizes that allow smaller cells to pass through while retaining larger cells.

5. Enzymatic digestion: In some cases, cells can be separated by enzymatically dissociating tissues into single-cell suspensions and then using various separation techniques to isolate specific cell types.

These methods are widely used in research and clinical settings for applications such as isolating immune cells, stem cells, or tumor cells from biological samples.

GPI-linked proteins are a type of cell surface protein that are attached to the plasma membrane via a glycosylphosphatidylinositol (GPI) anchor. The GPI anchor is a complex glycolipid molecule that acts as a molecular tether, connecting the protein to the outer leaflet of the lipid bilayer of the cell membrane.

The GPI anchor is synthesized in the endoplasmic reticulum (ER) and added to proteins in the ER or Golgi apparatus during protein trafficking. The addition of the GPI anchor to a protein occurs in a post-translational modification process called GPI anchoring, which involves the transfer of the GPI moiety from a lipid carrier to the carboxyl terminus of the protein.

GPI-linked proteins are found on the surface of many different types of cells, including red blood cells, immune cells, and nerve cells. They play important roles in various cellular processes, such as cell signaling, cell adhesion, and enzyme function. Some GPI-linked proteins also serve as receptors for bacterial toxins and viruses, making them potential targets for therapeutic intervention.

Surface antigens are molecules found on the surface of cells that can be recognized by the immune system as being foreign or different from the host's own cells. Antigens are typically proteins or polysaccharides that are capable of stimulating an immune response, leading to the production of antibodies and activation of immune cells such as T-cells.

Surface antigens are important in the context of infectious diseases because they allow the immune system to identify and target infected cells for destruction. For example, viruses and bacteria often display surface antigens that are distinct from those found on host cells, allowing the immune system to recognize and attack them. In some cases, these surface antigens can also be used as targets for vaccines or other immunotherapies.

In addition to their role in infectious diseases, surface antigens are also important in the context of cancer. Tumor cells often display abnormal surface antigens that differ from those found on normal cells, allowing the immune system to potentially recognize and attack them. However, tumors can also develop mechanisms to evade the immune system, making it difficult to mount an effective response.

Overall, understanding the properties and behavior of surface antigens is crucial for developing effective immunotherapies and vaccines against infectious diseases and cancer.

Transfer factors are natural immune system components that are passed from one individual to another, usually through blood products. They are small proteins called cytokines that are secreted by certain white blood cells (T-lymphocytes or T-cells) and function to regulate the immune system's response to foreign substances.

Transfer factors can be extracted from human blood and given to individuals with weakened immune systems, such as those undergoing chemotherapy or suffering from immune deficiency disorders, to help enhance their immune response. They have also been used in the treatment of chronic fatigue syndrome, allergies, and certain viral infections.

It's important to note that while transfer factors have shown promise in some studies, more research is needed to fully understand their effectiveness and safety.

Hypersensitivity, Immediate: Also known as Type I hypersensitivity, it is an exaggerated and abnormal immune response that occurs within minutes to a few hours after exposure to a second dose of an allergen (a substance that triggers an allergic reaction). This type of hypersensitivity is mediated by immunoglobulin E (IgE) antibodies, which are produced by the immune system in response to the first exposure to the allergen. Upon subsequent exposures, these IgE antibodies bind to mast cells and basophils, leading to their degranulation and the release of mediators such as histamine, leukotrienes, and prostaglandins. These mediators cause a variety of symptoms, including itching, swelling, redness, and pain at the site of exposure, as well as systemic symptoms such as difficulty breathing, wheezing, and hypotension (low blood pressure). Examples of immediate hypersensitivity reactions include allergic asthma, hay fever, anaphylaxis, and some forms of food allergy.

Ovarian neoplasms refer to abnormal growths or tumors in the ovary, which can be benign (non-cancerous) or malignant (cancerous). These growths can originate from various cell types within the ovary, including epithelial cells, germ cells, and stromal cells. Ovarian neoplasms are often classified based on their cell type of origin, histological features, and potential for invasive or metastatic behavior.

Epithelial ovarian neoplasms are the most common type and can be further categorized into several subtypes, such as serous, mucinous, endometrioid, clear cell, and Brenner tumors. Some of these epithelial tumors have a higher risk of becoming malignant and spreading to other parts of the body.

Germ cell ovarian neoplasms arise from the cells that give rise to eggs (oocytes) and can include teratomas, dysgerminomas, yolk sac tumors, and embryonal carcinomas. Stromal ovarian neoplasms develop from the connective tissue cells supporting the ovary and can include granulosa cell tumors, thecomas, and fibromas.

It is essential to diagnose and treat ovarian neoplasms promptly, as some malignant forms can be aggressive and potentially life-threatening if not managed appropriately. Regular gynecological exams, imaging studies, and tumor marker tests are often used for early detection and monitoring of ovarian neoplasms. Treatment options may include surgery, chemotherapy, or radiation therapy, depending on the type, stage, and patient's overall health condition.

Transfection is a term used in molecular biology that refers to the process of deliberately introducing foreign genetic material (DNA, RNA or artificial gene constructs) into cells. This is typically done using chemical or physical methods, such as lipofection or electroporation. Transfection is widely used in research and medical settings for various purposes, including studying gene function, producing proteins, developing gene therapies, and creating genetically modified organisms. It's important to note that transfection is different from transduction, which is the process of introducing genetic material into cells using viruses as vectors.

Leukemia is a type of cancer that originates from the bone marrow - the soft, inner part of certain bones where new blood cells are made. It is characterized by an abnormal production of white blood cells, known as leukocytes or blasts. These abnormal cells accumulate in the bone marrow and interfere with the production of normal blood cells, leading to a decrease in red blood cells (anemia), platelets (thrombocytopenia), and healthy white blood cells (leukopenia).

There are several types of leukemia, classified based on the specific type of white blood cell affected and the speed at which the disease progresses:

1. Acute Leukemias - These types of leukemia progress rapidly, with symptoms developing over a few weeks or months. They involve the rapid growth and accumulation of immature, nonfunctional white blood cells (blasts) in the bone marrow and peripheral blood. The two main categories are:
- Acute Lymphoblastic Leukemia (ALL) - Originates from lymphoid progenitor cells, primarily affecting children but can also occur in adults.
- Acute Myeloid Leukemia (AML) - Develops from myeloid progenitor cells and is more common in older adults.

2. Chronic Leukemias - These types of leukemia progress slowly, with symptoms developing over a period of months to years. They involve the production of relatively mature, but still abnormal, white blood cells that can accumulate in large numbers in the bone marrow and peripheral blood. The two main categories are:
- Chronic Lymphocytic Leukemia (CLL) - Affects B-lymphocytes and is more common in older adults.
- Chronic Myeloid Leukemia (CML) - Originates from myeloid progenitor cells, characterized by the presence of a specific genetic abnormality called the Philadelphia chromosome. It can occur at any age but is more common in middle-aged and older adults.

Treatment options for leukemia depend on the type, stage, and individual patient factors. Treatments may include chemotherapy, targeted therapy, immunotherapy, stem cell transplantation, or a combination of these approaches.

Minor histocompatibility antigens (miHA) are proteins that exist in cells which can stimulate an immune response, particularly in the context of transplantation. Unlike major histocompatibility complex (MHC) antigens, which are highly polymorphic and well-known to trigger strong immune responses, miHA are generally less variable and may not be as immediately apparent to the immune system.

Minor histocompatibility antigens can arise from differences in genetic sequences that code for proteins outside of the MHC region. These differences can result in the production of altered or unique peptides that can be presented on the surface of cells via MHC molecules, where they may be recognized as foreign by the immune system.

In the context of transplantation, the recipient's immune system may recognize and attack donor tissues expressing these miHA, leading to graft rejection or graft-versus-host disease (GVHD). This is particularly relevant in hematopoietic stem cell transplantation (HSCT), where the transferred stem cells can differentiate into various cell types, including immune cells that may recognize and attack the recipient's tissues.

Understanding miHA and their role in transplant rejection has led to the development of strategies to minimize graft rejection and GVHD, such as T-cell depletion or targeted therapies against specific miHA.

A glioma is a type of tumor that originates from the glial cells in the brain. Glial cells are non-neuronal cells that provide support and protection for nerve cells (neurons) within the central nervous system, including providing nutrients, maintaining homeostasis, and insulating neurons.

Gliomas can be classified into several types based on the specific type of glial cell from which they originate. The most common types include:

1. Astrocytoma: Arises from astrocytes, a type of star-shaped glial cells that provide structural support to neurons.
2. Oligodendroglioma: Develops from oligodendrocytes, which produce the myelin sheath that insulates nerve fibers.
3. Ependymoma: Originate from ependymal cells, which line the ventricles (fluid-filled spaces) in the brain and spinal cord.
4. Glioblastoma multiforme (GBM): A highly aggressive and malignant type of astrocytoma that tends to spread quickly within the brain.

Gliomas can be further classified based on their grade, which indicates how aggressive and fast-growing they are. Lower-grade gliomas tend to grow more slowly and may be less aggressive, while higher-grade gliomas are more likely to be aggressive and rapidly growing.

Symptoms of gliomas depend on the location and size of the tumor but can include headaches, seizures, cognitive changes, and neurological deficits such as weakness or paralysis in certain parts of the body. Treatment options for gliomas may include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

Delayed hypersensitivity, also known as type IV hypersensitivity, is a type of immune response that takes place several hours to days after exposure to an antigen. It is characterized by the activation of T cells (a type of white blood cell) and the release of various chemical mediators, leading to inflammation and tissue damage. This reaction is typically associated with chronic inflammatory diseases, such as contact dermatitis, granulomatous disorders (e.g. tuberculosis), and certain autoimmune diseases.

The reaction process involves the following steps:

1. Sensitization: The first time an individual is exposed to an antigen, T cells are activated and become sensitized to it. This process can take several days.
2. Memory: Some of the activated T cells differentiate into memory T cells, which remain in the body and are ready to respond quickly if the same antigen is encountered again.
3. Effector phase: Upon subsequent exposure to the antigen, the memory T cells become activated and release cytokines, which recruit other immune cells (e.g. macrophages) to the site of inflammation. These cells cause tissue damage through various mechanisms, such as phagocytosis, degranulation, and the release of reactive oxygen species.
4. Chronic inflammation: The ongoing immune response can lead to chronic inflammation, which may result in tissue destruction and fibrosis (scarring).

Examples of conditions associated with delayed hypersensitivity include:

* Contact dermatitis (e.g. poison ivy, nickel allergy)
* Tuberculosis
* Leprosy
* Sarcoidosis
* Rheumatoid arthritis
* Type 1 diabetes mellitus
* Multiple sclerosis
* Inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis)

Spontaneous neoplasm regression is a rare and somewhat controversial phenomenon in which a tumor or malignancy appears to decrease in size or disappear without any treatment or with treatment that is typically not expected to produce such an effect. This can occur through various mechanisms, including immune-mediated processes, apoptosis (programmed cell death), differentiation of cancer cells into normal cells, and angiogenesis inhibition (preventing the growth of new blood vessels that feed the tumor).

Spontaneous regression of neoplasms is not well understood and is considered unpredictable. It has been reported in various types of cancers, including neuroblastoma, melanoma, renal cell carcinoma, and others. However, it should be noted that spontaneous regression does not imply a cure, as the tumor may still recur or metastasize later on.

In summary, spontaneous neoplasm regression refers to the partial or complete disappearance of a malignancy without any specific treatment or with treatment that is not typically associated with such an effect.

CD28 is a co-stimulatory molecule that plays an important role in the activation and regulation of T cells, which are key players in the immune response. It is a type of protein found on the surface of T cells and interacts with other proteins called B7-1 (also known as CD80) and B7-2 (also known as CD86) that are expressed on the surface of antigen-presenting cells (APCs).

When a T cell encounters an APC that is presenting an antigen, the T cell receptor (TCR) on the surface of the T cell recognizes and binds to the antigen. However, this interaction alone is not enough to fully activate the T cell. The engagement of CD28 with B7-1 or B7-2 provides a critical co-stimulatory signal that promotes T cell activation, proliferation, and survival.

CD28 is also an important target for immune checkpoint inhibitors, which are drugs used to treat cancer by blocking the inhibitory signals that prevent T cells from attacking tumor cells. By blocking CD28, these drugs can enhance the anti-tumor response of T cells and improve cancer outcomes.

Single-chain antibodies (scFvs) are small, artificial protein molecules that contain the antigen-binding sites of immunoglobulins. They are formed by linking the variable regions of the heavy and light chains of an antibody via a flexible peptide linker, creating a single polypeptide chain. This design allows scFvs to maintain the specificity of traditional antibodies while being significantly smaller in size, more stable, and easier to produce. They have various applications in research, diagnostics, and therapeutics, including targeted drug delivery, tumor imaging, and the development of novel therapies for cancer and other diseases.

Artificial cells are synthetic constructs that mimic certain functions or structures of natural living cells. They can be created using a variety of materials and methods, including lipid vesicles, polymers, and biomaterials. Artificial cells may be designed to perform specific tasks, such as delivering drugs, sensing environmental changes, or producing chemicals.

It's important to note that artificial cells are not living organisms and do not possess all the functions of natural cells. They also differ from cellular machinery or organelles that can be isolated from natural cells and used for specific purposes. Artificial cells are a topic of ongoing research in fields such as biomedicine, bioengineering, and nanotechnology.

IgG receptors, also known as Fcγ receptors (Fc gamma receptors), are specialized protein molecules found on the surface of various immune cells, such as neutrophils, monocytes, macrophages, and some lymphocytes. These receptors recognize and bind to the Fc region of IgG antibodies, one of the five classes of immunoglobulins in the human body.

IgG receptors play a crucial role in immune responses by mediating different effector functions, including:

1. Antibody-dependent cellular cytotoxicity (ADCC): IgG receptors on natural killer (NK) cells and other immune cells bind to IgG antibodies coated on the surface of virus-infected or cancer cells, leading to their destruction.
2. Phagocytosis: When IgG antibodies tag pathogens or foreign particles, phagocytes like neutrophils and macrophages recognize and bind to these immune complexes via IgG receptors, facilitating the engulfment and removal of the targeted particles.
3. Antigen presentation: IgG receptors on antigen-presenting cells (APCs) can internalize immune complexes, process the antigens, and present them to T cells, thereby initiating adaptive immune responses.
4. Inflammatory response regulation: IgG receptors can modulate inflammation by activating or inhibiting downstream signaling pathways in immune cells, depending on the specific type of Fcγ receptor and its activation state.

There are several types of IgG receptors (FcγRI, FcγRII, FcγRIII, and FcγRIV) with varying affinities for different subclasses of IgG antibodies (IgG1, IgG2, IgG3, and IgG4). The distinct functions and expression patterns of these receptors contribute to the complexity and fine-tuning of immune responses in the human body.

Messenger RNA (mRNA) is a type of RNA (ribonucleic acid) that carries genetic information copied from DNA in the form of a series of three-base code "words," each of which specifies a particular amino acid. This information is used by the cell's machinery to construct proteins, a process known as translation. After being transcribed from DNA, mRNA travels out of the nucleus to the ribosomes in the cytoplasm where protein synthesis occurs. Once the protein has been synthesized, the mRNA may be degraded and recycled. Post-transcriptional modifications can also occur to mRNA, such as alternative splicing and addition of a 5' cap and a poly(A) tail, which can affect its stability, localization, and translation efficiency.

Immunohistochemistry (IHC) is a technique used in pathology and laboratory medicine to identify specific proteins or antigens in tissue sections. It combines the principles of immunology and histology to detect the presence and location of these target molecules within cells and tissues. This technique utilizes antibodies that are specific to the protein or antigen of interest, which are then tagged with a detection system such as a chromogen or fluorophore. The stained tissue sections can be examined under a microscope, allowing for the visualization and analysis of the distribution and expression patterns of the target molecule in the context of the tissue architecture. Immunohistochemistry is widely used in diagnostic pathology to help identify various diseases, including cancer, infectious diseases, and immune-mediated disorders.

Methylcholanthrene is a polycyclic aromatic hydrocarbon that is used in research to induce skin tumors in mice. It is a potent carcinogen and mutagen, and exposure to it can increase the risk of cancer in humans. It is not typically found in medical treatments or therapies.

Nasal obstruction is a medical condition that refers to any blockage or restriction in the normal flow of air through the nasal passages. This can be caused by various factors such as inflammation, swelling, or physical abnormalities in the nasal cavity. Common causes of nasal obstruction include allergies, sinusitis, deviated septum, enlarged turbinates, and nasal polyps. Symptoms may include difficulty breathing through the nose, nasal congestion, and nasal discharge. Treatment options depend on the underlying cause and may include medications, surgery, or lifestyle changes.

T-lymphocytes, also known as T-cells, are a type of white blood cell that plays a key role in the immune response. They help to protect the body from infection and disease by identifying and attacking foreign substances such as viruses and bacteria.

Helper-inducer T-lymphocytes, also known as CD4+ T-cells or Th0 cells, are a specific subset of T-lymphocytes that help to coordinate the immune response. They do this by activating other immune cells, such as B-lymphocytes (which produce antibodies) and cytotoxic T-lymphocytes (which directly attack infected cells). Helper-inducer T-lymphocytes also release cytokines, which are signaling molecules that help to regulate the immune response.

Helper-inducer T-lymphocytes can differentiate into different subsets of T-cells, depending on the type of cytokines they are exposed to. For example, they can differentiate into Th1 cells, which produce cytokines that help to activate cytotoxic T-lymphocytes and macrophages; or Th2 cells, which produce cytokines that help to activate B-lymphocytes and eosinophils.

It is important to note that helper-inducer T-lymphocytes play a crucial role in the immune response, and dysfunction of these cells can lead to immunodeficiency or autoimmune disorders.

Glioblastoma, also known as Glioblastoma multiforme (GBM), is a highly aggressive and malignant type of brain tumor that arises from the glial cells in the brain. These tumors are characterized by their rapid growth, invasion into surrounding brain tissue, and resistance to treatment.

Glioblastomas are composed of various cell types, including astrocytes and other glial cells, which make them highly heterogeneous and difficult to treat. They typically have a poor prognosis, with a median survival rate of 14-15 months from the time of diagnosis, even with aggressive treatment.

Symptoms of glioblastoma can vary depending on the location and size of the tumor but may include headaches, seizures, nausea, vomiting, memory loss, difficulty speaking or understanding speech, changes in personality or behavior, and weakness or paralysis on one side of the body.

Standard treatment for glioblastoma typically involves surgical resection of the tumor, followed by radiation therapy and chemotherapy with temozolomide. However, despite these treatments, glioblastomas often recur, leading to a poor overall prognosis.

Pore-forming cytotoxic proteins are a group of toxins that can create pores or holes in the membranes of cells, leading to cell damage or death. These toxins are produced by various organisms, including bacteria, fungi, and plants, as a defense mechanism or to help establish an infection.

The pore-forming cytotoxic proteins can be divided into two main categories:

1. Membrane attack complex/perforin (MACPF) domain-containing proteins: These are found in many organisms, including humans. They form pores by oligomerizing, or clustering together, in the target cell membrane. An example of this type of toxin is the perforin protein, which is released by cytotoxic T cells and natural killer cells to destroy virus-infected or cancerous cells.
2. Cholesterol-dependent cytolysins (CDCs): These are mainly produced by gram-positive bacteria. They bind to cholesterol in the target cell membrane, forming a prepore structure that then undergoes conformational changes to create a pore. An example of a CDC is alpha-hemolysin from Staphylococcus aureus, which can lyse red blood cells and damage various other cell types.

These pore-forming cytotoxic proteins play a significant role in host-pathogen interactions and have implications for the development of novel therapeutic strategies.

Arthropods are a phylum of animals that includes insects, spiders, crustaceans, and other creatures with jointed appendages. Arthropod proteins, therefore, refer to the proteins that are found in these organisms. These proteins play various roles in the structure, function, and regulation of arthropod cells, tissues, and organs.

Arthropod proteins can be classified into several categories based on their functions, such as structural proteins, enzymes, signaling proteins, and defense proteins. Structural proteins provide support and protection to the arthropod exoskeleton, which is composed mainly of chitin and proteins. Enzymes are proteins that catalyze chemical reactions in arthropod metabolism, while signaling proteins regulate various physiological processes, including growth, development, and reproduction. Defense proteins protect arthropods from pathogens, parasites, and environmental stressors.

Arthropod proteins have attracted significant interest in biomedical research due to their potential applications in drug discovery, vaccine development, and diagnostic tools. For example, some arthropod proteins have been identified as promising targets for the development of new insecticides and antiparasitic drugs. Additionally, arthropod-derived proteins have been used in the production of recombinant vaccines against infectious diseases such as Lyme disease and malaria.

Understanding the structure and function of arthropod proteins is essential for advancing our knowledge of arthropod biology, evolution, and ecology. It also has important implications for human health, agriculture, and environmental conservation.

Forkhead transcription factors (FOX) are a family of proteins that play crucial roles in the regulation of gene expression through the process of binding to specific DNA sequences, thereby controlling various biological processes such as cell growth, differentiation, and apoptosis. These proteins are characterized by a conserved DNA-binding domain, known as the forkhead box or FOX domain, which adopts a winged helix structure that recognizes and binds to the consensus sequence 5'-(G/A)(T/C)AA(C/A)A-3'.

The FOX family is further divided into subfamilies based on the structure of their DNA-binding domains, with each subfamily having distinct functions. For example, FOXP proteins are involved in brain development and function, while FOXO proteins play a key role in regulating cellular responses to stress and metabolism. Dysregulation of forkhead transcription factors has been implicated in various diseases, including cancer, diabetes, and neurodegenerative disorders.

Muromonab-CD3 is a type of immunosuppressant medication that is used in the treatment of acute organ rejection in patients who have received organ transplants. It is a monoclonal antibody that specifically targets and binds to the CD3 receptor found on the surface of T-lymphocytes, which are a type of white blood cell that plays a central role in the immune response.

By binding to the CD3 receptor, Muromonab-CD3 inhibits the activation and proliferation of T-lymphocytes, thereby suppressing the immune system's ability to recognize and attack the transplanted organ. This helps to prevent or reverse the process of acute organ rejection.

Muromonab-CD3 is administered intravenously and is typically given as a series of doses over several days. It may be used in combination with other immunosuppressive drugs to achieve optimal results. As with any medication, Muromonab-CD3 can have side effects, including fever, chills, nausea, and headache. More serious side effects, such as anaphylaxis or severe infections, may also occur, and patients should be closely monitored during treatment.

Humoral immunity is a type of immune response in which the body produces proteins called antibodies that circulate in bodily fluids such as blood and help to protect against infection. This form of immunity involves the interaction between antigens (foreign substances that trigger an immune response) and soluble factors, including antibodies, complement proteins, and cytokines.

When a pathogen enters the body, it is recognized as foreign by the immune system, which triggers the production of specific antibodies to bind to and neutralize or destroy the pathogen. These antibodies are produced by B cells, a type of white blood cell that is part of the adaptive immune system.

Humoral immunity provides protection against extracellular pathogens, such as bacteria and viruses, that exist outside of host cells. It is an important component of the body's defense mechanisms and plays a critical role in preventing and fighting off infections.

Adenocarcinoma is a type of cancer that arises from glandular epithelial cells. These cells line the inside of many internal organs, including the breasts, prostate, colon, and lungs. Adenocarcinomas can occur in any of these organs, as well as in other locations where glands are present.

The term "adenocarcinoma" is used to describe a cancer that has features of glandular tissue, such as mucus-secreting cells or cells that produce hormones. These cancers often form glandular structures within the tumor mass and may produce mucus or other substances.

Adenocarcinomas are typically slow-growing and tend to spread (metastasize) to other parts of the body through the lymphatic system or bloodstream. They can be treated with surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of these treatments. The prognosis for adenocarcinoma depends on several factors, including the location and stage of the cancer, as well as the patient's overall health and age.

Carcinoembryonic antigen (CEA) is a protein that is normally produced in small amounts during fetal development. In adults, low levels of CEA can be found in the blood, but elevated levels are typically associated with various types of cancer, particularly colon, rectal, and breast cancer.

Measurement of CEA levels in the blood is sometimes used as a tumor marker to monitor response to treatment, detect recurrence, or screen for secondary cancers in patients with a history of certain types of cancer. However, it's important to note that CEA is not a specific or sensitive indicator of cancer and can be elevated in various benign conditions such as inflammation, smoking, and some gastrointestinal diseases. Therefore, the test should be interpreted in conjunction with other clinical and diagnostic findings.

Tyrosinase, also known as monophenol monooxygenase, is an enzyme (EC 1.14.18.1) that catalyzes the ortho-hydroxylation of monophenols (like tyrosine) to o-diphenols (like L-DOPA) and the oxidation of o-diphenols to o-quinones. This enzyme plays a crucial role in melanin synthesis, which is responsible for the color of skin, hair, and eyes in humans and animals. Tyrosinase is found in various organisms, including plants, fungi, and animals. In humans, tyrosinase is primarily located in melanocytes, the cells that produce melanin. The enzyme's activity is regulated by several factors, such as pH, temperature, and metal ions like copper, which are essential for its catalytic function.

Cross-priming is a process in the immune system where antigens from one cell are presented to and recognized by T cells of another cell, leading to an immune response. This mechanism allows for the activation of cytotoxic CD8+ T cells against viruses or cancer cells that may not be directly accessible to the immune system.

In a typical scenario, a professional antigen-presenting cell (APC) such as a dendritic cell captures and processes antigens from an infected or damaged cell. The APC then migrates to the draining lymph node where it presents the antigens on its major histocompatibility complex class I (MHC-I) molecules to CD8+ T cells. This presentation of antigens from one cell to the T cells of another is referred to as cross-priming.

Cross-priming plays a crucial role in the initiation of immune responses against viruses, bacteria, and cancer cells, and has implications for vaccine design and immunotherapy strategies.

'C3H' is the name of an inbred strain of laboratory mice that was developed at the Jackson Laboratory in Bar Harbor, Maine. The mice are characterized by their uniform genetic background and have been widely used in biomedical research for many decades.

The C3H strain is particularly notable for its susceptibility to certain types of cancer, including mammary tumors and lymphomas. It also has a high incidence of age-related macular degeneration and other eye diseases. The strain is often used in studies of immunology, genetics, and carcinogenesis.

Like all inbred strains, the C3H mice are the result of many generations of brother-sister matings, which leads to a high degree of genetic uniformity within the strain. This makes them useful for studying the effects of specific genes or environmental factors on disease susceptibility and other traits. However, it also means that they may not always be representative of the genetic diversity found in outbred populations, including humans.

Lentinan is a polysaccharide derived from the shiitake mushroom (Lentinula edodes) that has been studied for its potential immune-enhancing and anti-cancer effects. It is a beta-glucan with a complex structure, including both β-(1,3)-D-glucan and β-(1,6)-D-glucan branches.

In the medical context, lentinan is considered an immunomodulator, as it can stimulate various immune cells like macrophages, neutrophils, and natural killer (NK) cells. These immune cells play crucial roles in recognizing and eliminating foreign substances, including cancer cells and pathogens.

Lentinan has been investigated for its potential therapeutic benefits in treating several types of cancer, such as gastric, colorectal, and breast cancers. However, most of the research is still preclinical or based on small-scale clinical trials, so more extensive studies are needed to confirm its efficacy and safety before it can be widely adopted in medical practice.

It's important to note that lentinan supplements should not replace conventional cancer treatments but may potentially be used as an adjunct therapy under the guidance of a healthcare professional.

Survival analysis is a branch of statistics that deals with the analysis of time to event data. It is used to estimate the time it takes for a certain event of interest to occur, such as death, disease recurrence, or treatment failure. The event of interest is called the "failure" event, and survival analysis estimates the probability of not experiencing the failure event until a certain point in time, also known as the "survival" probability.

Survival analysis can provide important information about the effectiveness of treatments, the prognosis of patients, and the identification of risk factors associated with the event of interest. It can handle censored data, which is common in medical research where some participants may drop out or be lost to follow-up before the event of interest occurs.

Survival analysis typically involves estimating the survival function, which describes the probability of surviving beyond a certain time point, as well as hazard functions, which describe the instantaneous rate of failure at a given time point. Other important concepts in survival analysis include median survival times, restricted mean survival times, and various statistical tests to compare survival curves between groups.

... , Alzheimer's disease clinical research#Active immunotherapy, Mantle cell lymphoma § Immunotherapy, Yang, ... The categories of active immunotherapy divide into: Non-specific active immunotherapy: generating a general immune system ... Active immunotherapies fall under the category of activation immunotherapies, which is a subset of immunotherapies that ... Active immunotherapy is a type of immunotherapy that aims to stimulate the host's immune system or a specific immune response ...
Immunomodulators are the active agents of immunotherapy. They are a diverse array of recombinant, synthetic, and natural ... while immunotherapies that reduce or suppress are classified as suppression immunotherapies. Immunotherapy is under preliminary ... Immunotherapy may produce long-term benefits. Immunotherapy is partly effective in some people and ineffective in others, but ... BCG immunotherapy induces both local and systemic immune responses. The mechanisms by which BCG immunotherapy mediates tumor ...
Immunotherapies can be categorized as active or passive based on their ability to engage the host immune system against cancer ... What is Cancer Immunotherapy Association for Immunotherapy of Cancer Society for Immunotherapy of Cancer "And Then There Were ... Active immunotherapy specifically targets tumor cells via the immune system. Examples include therapeutic cancer vaccines (also ... Active cytotoxic T-cells are required for the immune system to attack melanoma cells. Normally inhibited active melanoma- ...
Immunotherapy. This stimulates the host immune system to recognize and attack Aβ, or provide antibodies that either prevent ... In order to initiate partial inhibition of β- and γ-secretase, a compound is needed that can block the large active site of ... Prevention of oligomerization of Aβ has been exemplified by active or passive Aβ immunization. In this process antibodies to Aβ ... However literature reviews have raised questions as to immunotherapy's overall efficacy. One such study assessing ten anti-Ab42 ...
"An immune-active tumor microenvironment favors clinical response to ipilimumab". Cancer Immunology, Immunotherapy. 61 (7): 1019 ... "Neutrophils produce biologically active macrophage inflammatory protein-3alpha (MIP-3alpha)/CCL20 and MIP-3beta/CCL19". ...
Immunotherapy Radioactive contamination India portal Medicine portal Please see Selected bibliography section "Professor Dr. ... cell targets and active principles. Narosa Publishing House. p. 155.{{cite book}}: CS1 maint: multiple names: authors list ( ... 163-. ISBN 978-1-329-93291-3. Shakti N. Upadhyay (1999). Immunopharmacology: Strategies for Immunotherapy. CRC Press. pp. 10-. ... cell targets and active principles. Narosa Publishing House. p. 155.{{cite book}}: CS1 maint: multiple names: authors list ( ...
Immunotherapy is another potential approach. Monoclonal antibodies against Junin virus have been tested in animal models. An ... active case finding and follow-up of contacts. Very few treatment methods are available. The current lack of a licensed vaccine ... "Rational design of universal immunotherapy for TfR1-tropic arenaviruses". Nature Communications. 11 (1): 67. Bibcode:2020NatCo ... immunotherapeutic agent active against all tested mammarenaviruses that use the transferrin receptor 1 as their receptor was ...
DNDN is also using ACI technology Active cellular immunotherapy "This is a therapeutic platform using the patient's own cells ... "Cancer Treatment, Active Cellular Immunotherapy". Dendreon.com. "ACI Product Candidate - Ovarian, Colon Cancer Treatment". ... Lapuleucel-T is an investigational active immunotherapy product consisting of autologous peripheral blood mononuclear cells, ... "Clinical experience with CD64-directed immunotherapy. An overview". Cancer Immunology, Immunotherapy. 45 (3-4): 210-215. doi: ...
Highly Active Relapsing Remitting, sometimes called Rapidly Worsening relapsing remitting, is a clinical form considered ... Baecher-Allan, C.; Kaskow, B. J.; Weiner, H. L. (Feb 2018). "Multiple Sclerosis: Mechanisms and Immunotherapy". Neuron. 97 (4 ... Díaz C, Zarco LA, Rivera DM, Highly active multiple sclerosis: An update, Mult Scler Relat Disord. 2019 May;30:215-224. doi: ... Given the side effects of all MS medications, this is currently an active field of research. Main:Multiple sclerosis biomarkers ...
Hollinshead, A (1991). "Active specific immunotherapy and immunochemotherapy in the treatment of lung and colon cancer". ... because of her 280 published articles on active immunotherapy, and developing, managing, and testing the epitome activity for ... "Adjuvant specific active lung cancer immunotherapy trials. Tumor-associated antigens" (PDF). Cancer. 60 (6): 1249-62. doi: ... In 2013 she was recognized by GWAA (George Washington Alumni Association) for being the "Mother of Immunotherapy". 2014 She was ...
The goal of immunotherapy is to enhance aspects of the immune system. Both active and passive vaccinations have been proposed ... Brody DL, Holtzman DM (2008). "Active and passive immunotherapy for neurodegenerative disorders". Annual Review of Neuroscience ... immunotherapy approaches". Journal of Neurochemistry. 120 (Suppl 1): 186-93. doi:10.1111/j.1471-4159.2011.07458.x. PMID ...
Kinsey, BM; Kosten, TR; Orson, FM (2010). "Active immunotherapy for the Treatment of Cocaine Dependence". Drugs of the Future. ...
The best treatment approach is to improve the immune status in immunodeficient individuals using highly active antiretroviral ... Currently, research is being done in molecular-based immunotherapy. For example, synthetic isoflavone derivates have been shown ... For HIV-infected persons, highly active antiretroviral therapy (HAART) is the mainstay of preventing and managing ... Use of partially active antiparasitic drugs (eg, nitazoxanide or paromomycin combined with azithromycin) should be considered ...
January 30, 1999). "Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial". Lancet. ... Hanna MG Jr; Hoover HC Jr; Vermorken JB; Harris JE; Pinedo HM (Mar 21, 2001). "Adjuvant active specific immunotherapy of stage ... Hanna MG Jr; Hoover HC Jr; Pinedo HM; Finer M (July 6, 2006). "Active specific immunotherapy with autologous tumor cell ... Mar 1, 1993). "Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III ...
... "have had the good fortune to develop an active immunity against the toxin." He hypothesized that by injecting people with hay ... Immunotherapy is not recommended as a stand-alone treatment for asthma. Side effects during sublingual immunotherapy treatment ... Sublingual immunotherapy appears to be better tolerated than subcutaneous immunotherapy and causes fewer side effects. The ... allergen immunotherapy compared to other forms of allergen immunotherapy administration due to the variability of immunotherapy ...
He remains active as a senior editor for the journal. In 2007, he was recruited to Genentech as the VP of Research Oncology to ... There, the company is developing understanding of immunology and along that, immunotherapy. Mellman is a member of the United ...
It is named for the pioneer of cancer immunotherapy, William B. Coley. Lloyd J. Old Award The Lloyd J. Old Award in Cancer ... Immunology recognizes an active scientist whose outstanding and innovative research in cancer immunology has had a far-reaching ... It also funds clinical trials testing promising immunotherapies in a variety of cancer types and convenes scientific ... an American orthopedic surgeon and a pioneer of cancer immunotherapy. Grounded in Dr. Coley's pioneering work, the Cancer ...
Palena is active in the area of tumor immunology and cancer immunotherapy. Palena's current research is focused on the ... Palena researches tumor immunology and cancer immunotherapy. Palena received a B.S. and Ph.D. degree in biochemistry from the ... and a target for T-cell-mediated immunotherapy. Her studies have shown that brachyury is overexpressed in various human ...
"Alphabetical Index of Active Members" (PDF). Amacad.org. Archived from the original (PDF) on 2016-05-27. Retrieved 2016-07-02. ... These discoveries have potential applications in targeted immunotherapy and disease treatment. Kiessling has received a number ... She has made contributions to the synthesis and study of many biologically active molecules, including glycosyl donors, ... Strong, Laura; Kiessling, Laura (1999). "A General Synthetic Route to Defined, Biologically Active Multivalent Arrays". Journal ...
Ninety percent of horses with active ulceration treated with ta schizophyllan-containing polysaccharide blend showed complete ... Okamura, K (1989). "Adjuvant immunotherapy: two randomized controlled studies of patients with cervical cancer". Biomed ... Slovis, N (2017). "Polysaccharide Treatment Reduces Gastric Ulceration in Active Horses". Journal of Equine Veterinary Science ...
It is most active during the neonatal and pre-adolescent periods. The thymus is located between the inferior neck and the ... TLOs may also promote an anti-tumor response when patients are treated with immunotherapy. TLOs have been referred to in many ... TLOs that contain an active germinal center tend to have a better prognosis than those with TLOs without a germinal center. The ... TLOs often have an active germinal center, surrounded by a network of follicular dendritic cells (FDCs). TLOs are thought to ...
She is also an active participant in increasing diversity in STEM, either by visiting middle and high schools or through panels ... Her lab leverages computational models to interrogate angiogenesis, metabolism, and immunotherapy. Finley's lab has built ...
There is active research on trying oral immunotherapy (OIT) to desensitize people to egg allergens. A Cochrane Review concluded ... Romantsik, O; Tosca, MA; Zappettini, S; Calevo, MG (20 April 2018). "Oral and sublingual immunotherapy for egg allergy". The ... "Comprehensive Review of Current Knowledge on Egg Oral Immunotherapy". J Investig Allergol Clin Immunol. 25 (5): 316-28, quiz 2 ...
... (Bexmarilimab) is a new cancer immunotherapy drug under development in Finland by Faron Pharmaceuticals. The drug is ... an anti-Clever-1 antibody which can convert immune suppressive type-2 tumour-associated macrophages (TAMs) to immune active ... All articles with unsourced statements, Articles with unsourced statements from February 2023, Immunotherapy, Experimental ...
"Active Pharmaceutical Ingredient (API)". Biocon. 3 July 2020. Retrieved 26 December 2022. "Review for "Pharmacokinetic and ... Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy and nephrology products. Some of ... The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, ... have entered into a long-term supply agreement for the commercial manufacturing of the active pharmaceutical ingredient, ...
He remained active in two family businesses, Chiltern International and Downtown Music Publishing. In late 2015, Myers was ... fighting cancer with aggressive new treatments, including the latest immunotherapy medicines. He died in London on 8 April 2017 ...
None are pharmacologically active. The drug is excreted mainly as the original substance, of which 38% are found in the feces ... Participants must have also experienced an inadequate response to or intolerance to Immunotherapy or TNF inhibitors. ... In April 2023, upadacitinib was approved in the EU for the treatment of moderately to severely active Crohn's disease in adults ... In April 2023, upadacitinib was approved in the EU for the treatment of moderately to severely active Crohn's disease in adults ...
The newer agent lurbinectedin is active in relapsed SCLC and was approved for medical use in the United States in June 2020. In ... "Focus on immunotherapy and patient perspective highlight the IASLC 2019 Small Cell Lung Cancer Meeting". The International ... According to a European study published in BMJ Open, "Despite recent advances adding immunotherapy to chemotherapy in the ... 2018, the FDA approved two immunotherapies for small cell lung cancer: 1. Nivolumab (Opdivo), and 2. Atezolizumab (Tecentriq) ...
Kennedy was active in the search for an HIV vaccine for almost as long as the disease has existed. Kennedy has stated, "I first ... Immunotherapy. Kennedy received his MS and PhD from the University of Hawaii in Honolulu after attending graduate school there ...
"Clinical effects of adjuvant active specific immunotherapy differ between patients with microsatellite-stable and ... Immunotherapy. 56 (1): 88-94. doi:10.1007/s00262-006-0166-2. PMID 16622680. S2CID 6401524. Fishman M, Hunter TB, Soliman H, ... Journal of Immunotherapy. 31 (1): 72-80. doi:10.1097/cji.0b013e31815ba792. PMID 18157014. S2CID 42910390. Berger M, Horst JL, ... "Identification of different tumor escape mechanisms in several metastases from a melanoma patient undergoing immunotherapy". ...
Active immunotherapy, Alzheimers disease clinical research#Active immunotherapy, Mantle cell lymphoma § Immunotherapy, Yang, ... The categories of active immunotherapy divide into: Non-specific active immunotherapy: generating a general immune system ... Active immunotherapies fall under the category of activation immunotherapies, which is a subset of immunotherapies that ... Active immunotherapy is a type of immunotherapy that aims to stimulate the hosts immune system or a specific immune response ...
Neuropathology after active Abeta42 immunotherapy: implications for Alzheimers disease pathogenesis. Acta Neuropathol. 2010 ...
Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies. Clin. Transl. ... Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies ... EUROPEAN INNOVATION PARTNERSHIP; GRASS-POLLEN ALLERGY; SUBLINGUAL IMMUNOTHERAPY; INTERNATIONAL CONSENSUS; RUSH IMMUNOTHERAPY; ... This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand ...
One way in which biologists and medics use immunotherapy is by injecting antigen-incubated Dendritic Cells (DCs) into mice to ... immunotherapy has become an important alternative to fight cancer. ... when the immunotherapy is active. The condition of stability of such point is given by Equation (25). This gives us a range of ... For this work 64 immunotherapies were proposed, where each immunotherapy is a combination injected into the mouse and the time ...
BCG is also contraindicated in active tuberculosis infections; however, a recent study found there was no difference in ... Overview of BCG Immunotherapy Overview of BCG Immunotherapy. Bacillus Calmette-Guérin (BCG), a live attenuated strain of ... Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer Overview of BCG Immunotherapy. Updated: Dec 13, 2022 ... encoded search term (Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer) and Bacillus Calmette-Guérin Immunotherapy for ...
Active HPK1 phosphorylates a protein in the TCR that flags it for destruction. It also reduces the TCR signaling that is so ... An attractive cancer immunotherapy approach is the prodrug. For example, a systemically administered prodrug could remain ... CancersCytokinesDrug discoveryDrug research and developmentImmune cellsImmune componentImmune signallingImmunologyImmunotherapy ... Instead, we will focus on cancer immunotherapy. Moreover, we will give ourselves time to explore overlooked byways, rather like ...
Autologous Cellular Immunotherapy Treatment of Metastatic Prostate Cancer (CAG-00422N). ... If your session expires, you will lose all items in your basket and any active searches. If you would like to extend your ... MEDCAC Meeting for On Label and Off-Label Use of Autologous Cellular Immunotherapy Treatment of Metastatic Prostate Cancer ... Autologous Cellular Immunotherapy Treatment of Metastatic Prostate Cancer. CAG-00422N. You are here ...
Mature B cells in tumors of responders suggest active role in tumor immune response ... "Based on these results, it may now be possible for us to identify more types of sarcomas for which we can use immunotherapy ... "These results suggest there may be new ways of predicting responses to immunotherapy by including B cells as a novel biomarker ... B-cell enrichment predictive of immunotherapy response in melanoma, sarcoma and kidney cancer. Multiple studies point to ...
The highest titers were measured while the patient had active infection and was critically ill. The ELISA optical density ratio ... Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia Yaseen M. Arabi. , Ali H. Hajeer, ... Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia. ...
Cellular immunotherapy is under investigation for the treatment of metastatic melanoma, colon cancer, breast cancer and ... Quick View - Cellular Immunotherapy For Metastatic Melanoma, Breast Cancer And Pancreatic Cancer LOA Data ... Cellular Immunotherapy For Metastatic Melanoma, Breast Cancer And Pancreatic Cancer in Pancreatic CancerDrug Details: ... Access a live Likelihood of Approval and Phase Transition Success Rate Model - Cellular Immunotherapy For Metastatic Melanoma, ...
Active immunotherapy has been successful against infectious agents that cause self-limiting diseases. Effective immunotherapy ... Active immunotherapy against cancer is less effective, mainly because cancer cells have developed strategies to escape the ... Passive immunotherapy. Passive immunotherapy involves the direct administration of antibodies to a patient to provide immunity ... Mechanisms that impede effective immunotherapy. There are a number of impediments to the effective immunotherapy of cancer that ...
Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. Ronald Levy, Kristen N. Ganjoo, John P. ... Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. Journal of Clinical Oncology. 2014 Jun 10;32 ... Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. In: Journal of Clinical Oncology. 2014 ; Vol ... Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. / Levy, Ronald; Ganjoo, Kristen N.; Leonard ...
Cancer Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E) ... Cancer Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E) ... Cancer Immunotherapy - Global Key Competitors Percentage Market Share in 2022 (E). *Competitive Market Presence - Strong/Active ... Cancer Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E) ...
Texture of meat alternatives vastly improved by platform creating alternative active proteins. ... Home News and Trends Can this Positive Phase III Immunotherapy End Spinal Fractures due to Osteoporosis? ... UCB in Brussels is developing immunotherapies for a range of chronic diseases, which has now gotten good phase III results for ... Can this Positive Phase III Immunotherapy End Spinal Fractures due to Osteoporosis?. ...
A majority (53.3%) had active IA at their most recent follow-up. IA was less likely to improve in those with longer duration of ...
Kleiman MAR Costs and Benefits of Immunotherapies or Depot Medications for the Treatment of Drug Abuse Committee on ... Immunotherapies and Sustained-Release Formulations for Treating Drug Addiction National Academy of Sciences 2003 ... suggests that the excess of costs over benefits for a month of active heavy cigarette smoking is on the order of $500; the ... Committee on Immunotherapies and Sustained-Release Formulations for Treating Drug Addiction National Academy of Sciences. 2003 ...
Kleiman MAR Costs and Benefits of Immunotherapies or Depot Medications for the Treatment of Drug Abuse Committee on ... Immunotherapies and Sustained-Release Formulations for Treating Drug Addiction National Academy of Sciences 2003 ... suggests that the excess of costs over benefits for a month of active heavy cigarette smoking is on the order of $500; the ... Committee on Immunotherapies and Sustained-Release Formulations for Treating Drug Addiction National Academy of Sciences. 2003 ...
The NKG2D pathway is integral to immune surveillance and an active area of immunotherapy research. ... Immunotherapy represents a paradigm shift in cancer treatment; instead of targeting tumor cells, the goal of immunotherapy is ... Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol (2007) 7:329-39. doi:10.1038/nri2073 ... Immunotherapy with liposome-bound TRAIL overcomes partial protection to soluble TRAIL-induced apoptosis offered by down- ...
immunotherapy. *targeted therapies. *active surveillance. *supportive care, such as massage therapy or psychotherapy for ...
Patients with advanced lung cancer are already benefiting from immunotherapy. New clinical data also show benefits in earlier ... The most common grade 3-4 events in the active treatment group were hepatitis (4%), rash (1.4%), and pneumonitis (0.8%). ... Immunotherapy has already had a huge impact on treatment of patients with later stages of non-small cell lung cancer (NSCLC): ... "This is an important advance in understanding the role of immunotherapy in earlier stage lung cancer" and "potentially a step ...
If you are thinking of buying anything from Amazon, buy it through Amazon Smile, select Cancer Active as your charity and you ... CLL Leukaemia and immunotherapy. Two separate studies using CAR-T immunotherapy announced results almost simultaneously in ... Stanley Riddell talking of this living immunotherapy cautioned that much like current chemotherapy, it is not going to be a ...
If you are thinking of buying anything from Amazon, buy it through Amazon Smile, select Cancer Active as your charity and you ... PD-1 inhibitor drugs such as Keytruda and Opdivo seem to increase inflammation in the immunotherapy patient resulting in ... A small study (1) of 20 Austrians who had had a checkpoint inhibitor, PD-1 immunotherapy treatment for melanoma (for example, ...
Overall, it looked as if the patient had died during an active phase of plaque removal, Nicoll said. ... Sorrento: Immunotherapy Update Hot Off Lectern of AD/PD Conference. Go to another part. Series - International Conference on ... This first installment of our hot-off-the-podium dispatches summarizes the status of AD immunotherapy research. The setback in ... Finally, Nicoll addressed the current worry that Aβ immunotherapy may remove parenchymal Aβ but cause trouble at the brains ...
FDA Approves Novel Car T-Immunotherapy for the Treatment of Multiple Myeloma , Page Components ... We have 22 currently active grants focused on multiple myeloma supporting world-class researchers studying a range of novel ... Our initial investment in CAR T in the 1990s, when CAR T, and indeed immunotherapy to treat cancer was in its infancy, has ... FDA Approves Novel Car T-Immunotherapy for the Treatment of Multiple Myeloma By Lee Greenberger, PhD, Chief Scientific Officer ...
Moreover, some immunotherapies that reduce or suppress th... ... Immunotherapy, also called biologic therapy, is a cancer ... Unlike generic drugs that have active pharmaceutical substance, biosimilars are almost identical to their creator biologic ... Moreover, some immunotherapies that reduce or suppress the immune response are known as suppression immunotherapies. Cell-based ... As immunotherapy is used as a first line of treatment in the management of cancer the corresponding market is expected to ...
COVID-19 and Immunotherapy. The use of immunotherapy for the treatment of cancer is now considered mainstream. The number of ... For patients with active COVID-19 requiring active therapy for a cancer diagnosis, agents that can exacerbate the pulmonary ... There are active efforts by both the National Cancer Institute (NCI) and international groups to examine the impact of surgery ... For lung cancer patients with known SARS-CoV-2 or active COVID-19, consideration of delay in radiotherapy for a few weeks until ...
Yang, L., DuTemple, B., Gorczynski, R. M., Levy, G. & Zhang, L. Evidence for epitope spreading and active suppression in skin ... Vanderlugt, C., Miller, S. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2, 85 ... Epitope spreading in immune-mediated diseases: implications for immunotherapy. *Carol L. Vanderlugt1 & ...
1: IL-21 and rIFNα immunotherapies are biologically active in SIV-infected, ART-treated RMs.. ... IL-21 and rIFNα immunotherapies are biologically active in SIV-infected, ART-treated RMs. Sixteen RMs were intravenously (i.v ... 1i), indicating that the designed immunotherapy impacted NK cell imprinting while CD8+ T-cell responses remained tepid. ... It has been previously demonstrated that NK cell functionality is responsive to immunotherapies with IL-21 and interferon alpha ...
There are active research protocols ongoing at Northside Hospital involving the use of immunotherapy to treat certain cancers. ... Cell-Based Immunotherapies (including CAR T-Cell Therapy) Cell-based immunotherapies, including CAR T-cell therapy, refer to a ... Types of Cancer Immunotherapies. Several different types of cancer immunotherapy are being utilized both commercially and in ... Our Immunotherapy Program physicians are experts in administering CAR T-cell therapy and other immunotherapy cancer treatments ...
  • Vaccine therapies are a type of specific active immunotherapy. (wikipedia.org)
  • Therefore, they can be used for therapies such as antibody-directed enzyme pro drug therapy and radio immunotherapy. (pharmiweb.com)
  • A number of nasal steroids and newer antihistamines provide significant relief for most people with this disorder, but when these medical therapies fail, immunotherapy is a second-line option. (aafp.org)
  • The study highlights the need for more research into combination therapies like this one, because many people with cancer do not respond to immunotherapy or experience a reoccurrence of their tumors after treatment. (trustedhealthproducts.com)
  • Combining immunotherapy with chemotherapy for the treatment of certain patients with advanced cervical cancer provides a treatment option for these women in an area of high unmet need. (msd-australia.com.au)
  • Active surveillance is typically used for small tumors, often in older adults and people with poorer overall health, who may not be able to tolerate other types of treatment well. (healthline.com)
  • While the active agent (IC87361) radiosensitizes in both hypoxia and normoxia, the prodrug (SN38023) has radiosensitizing effects only in hypoxic tumors. (utsouthwestern.edu)
  • The recent FDA approvals of the programmed cell death protein 1 (PD-1)-targeted checkpoint inhibitors pembrolizumab and nivolumab mark the latest successes in the rapidly expanding field of cancer immunotherapies. (frontiersin.org)
  • Julie R. Gralow, MD, ASCO chief medical officer and executive vice president, said that "immune checkpoint inhibitors have certainly changed the treatment landscape for many types of cancers" and the current study "is the first time we've seen an immunotherapy that's effective in treating early stage NSCLC. (medscape.com)
  • For all patients with advanced cancer, immunotherapy using PD-1 inhibitors has really changed the face of cancer treatment. (trustedhealthproducts.com)
  • Tumor samples were collected from patients at baseline and during treatment through the APOLLO platform , and detailed immune profiling was completed in part by the immunotherapy platform , both part of the Moon Shots Program. (mdanderson.org)
  • In the MyVax group (n = 195), anti-Id IRs were observed in 41% of patients, with a median PFS of 40 months, significantly exceeding the median PFS observed in patients without such Id-induced IRs and in those receiving control immunotherapy. (johnshopkins.edu)
  • Immunotherapy has already had a huge impact on treatment of patients with later stages of non-small cell lung cancer (NSCLC): new clinical data are now showing benefits in patients with earlier stage disease. (medscape.com)
  • This is an important advance in understanding the role of immunotherapy in earlier stage lung cancer" and "potentially a step forward for many patients. (medscape.com)
  • A small study (1) of 20 Austrians who had had a checkpoint inhibitor, PD-1 immunotherapy treatment for melanoma (for example, Pembrolizumab or Nivolumab) showed that all patients developed more inflammation and more atherosclerosis, increasing the risk of cardiovascular problems, according to a study published in the American Heart Association journal Circulation. (canceractive.com)
  • Our initial investment in CAR T in the 1990's, when CAR T, and indeed immunotherapy to treat cancer was in its infancy, has turned into a game-changing therapeutic giving new hope to patients with limited treatment options and often very poor prognoses. (lls.org)
  • Furthermore, the sale of biosimilars among patients and hospitals is expected to increase significantly during the forecast period thereby supporting growth of the global immunotherapy drugs market. (pharmiweb.com)
  • The first two patients who received CAR-T therapy were still in remission a decade later, showing that the engineered cancer-fighting T cells can remain active in the body over the long term. (poz.com)
  • Durham and colleagues performed a follow-up study to evaluate the long-term efficacy of immunotherapy in patients who were previously shown to respond to this treatment. (aafp.org)
  • During the three years of the study, scores for total hay fever symptoms, rescue medications and the visual-analog scale remained low and were similar in the patients who continued monthly immunotherapy and those who received placebo extracts. (aafp.org)
  • In addition, the scores were similar to those recorded during the first three years of the initial study when all patients were receiving active immunotherapy. (aafp.org)
  • However, the degree of reaction was markedly lower compared with the control patients who had never received immunotherapy. (aafp.org)
  • A late-phase skin response (six to 24 hours) was essentially absent in both groups of immunotherapy patients. (aafp.org)
  • We have found that the reason patients with metastatic melanoma do not initially respond to immunotherapy with an anti-PD-1 is that their immune system was not ready," says Dr. Antoni Ribas, the study's lead author, a professor of medicine at the David Geffen School of Medicine at UCLA and director of the UCLA Jonsson Comprehensive Cancer Center Tumor Immunology Program . (trustedhealthproducts.com)
  • We are really starting to understand the science of how immunotherapies work in patients. (trustedhealthproducts.com)
  • You will explore the mechanisms and clinical use of allergen immunotherapy, enabling you to identify appropriate patients and initiate treatment/refer accordingly. (imperial.ac.uk)
  • This life-course perspective should be considered in allergen immunotherapy. (uni-koeln.de)
  • It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing. (uni-koeln.de)
  • Cellular immunotherapy is under investigation for the treatment of metastatic melanoma, colon cancer, breast cancer and pancreatic cancer. (globaldata.com)
  • A UCLA -led study recently found that a treatment that uses a bacteria-like agent in combination with an immunotherapy drug could help some people with advanced melanoma. (trustedhealthproducts.com)
  • Active immunotherapies induce an immune response through direct immune system stimulation, while immunotherapies that administer antibodies directly to the system are classified as passive immunotherapies. (wikipedia.org)
  • Increasing use of these antibodies in the drug development processes is expected to drive the global immunotherapy drugs market growth during the forecast period. (pharmiweb.com)
  • Administration of exogenous antibodies constitutes passive humoral immunotherapy. (msdmanuals.com)
  • Active immunotherapy is also used for treatment of neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, prion disease, and multiple sclerosis. (wikipedia.org)
  • Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis. (alzforum.org)
  • Lausanne, Switzerland, June 27, 2023 - AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its wholly-owned anti-amyloid beta (Abeta) active immunotherapy (vaccine)-candidate, ACI-24.060, for treatment of Alzheimer's disease. (cohesionbureau.com)
  • Theme co-leader, Jinming Gao, Ph.D., has collaborated with Zhijian "James" Chen, Ph.D., to develop nanoparticle vaccines to activate the STING pathway to boost antitumour immunity and the response to cancer immunotherapy. (utsouthwestern.edu)
  • The categories of active immunotherapy divide into: Non-specific active immunotherapy: generating a general immune system response using cytokines and other cell signaling molecules. (wikipedia.org)
  • Active immunotherapies fall under the category of activation immunotherapies, which is a subset of immunotherapies that activate the immune system as opposed immunotherapies that suppress the immune system. (wikipedia.org)
  • Two separate studies using CAR-T immunotherapy announced results almost simultaneously in February 2016. (canceractive.com)
  • Moreover, with increasing need for mAbs, the global immunotherapy drugs market is expected to witness significant growth during forecast period 2016-2024. (pharmiweb.com)
  • The research - published in the journal Cancer Discovery - showed that using the immunotherapy drug pembrolizumab and the experimental agent SD-101 altered the microenvironment around the tumor in a way that enabled the immune system to more effectively attack the cancer. (trustedhealthproducts.com)
  • 8 KEYTRUDA contains the active ingredient pembrolizumab. (msd-australia.com.au)
  • Antigen-specific active immunotherapy for ovarian cancer. (nih.gov)
  • Specific active immunotherapy: the generation of cell-mediated and antibody immune responses focused on specific antigens expressed by the cancer cells, typically using a vaccine platform. (wikipedia.org)
  • We performed a multicenter, randomized trial comparing a specific vaccine (MyVax), comprising Id chemically coupled to keyhole limpet hemocyanin (KLH) plus granulocyte macrophage colony-stimulating factor (GM-CSF) to a control immunotherapy with KLH plus GM-CSF. (johnshopkins.edu)
  • Despite its proven efficacy, the main concern to date is whether the benefit of immunotherapy persists after it is discontinued. (aafp.org)
  • There are active research protocols ongoing at Northside Hospital involving the use of immunotherapy to treat certain cancers. (northside.com)
  • Moreover, some immunotherapies that reduce or suppress the immune response are known as suppression immunotherapies. (pharmiweb.com)
  • Active immunotherapy is a type of immunotherapy that aims to stimulate the host's immune system or a specific immune response to a disease or pathogen and is most commonly used in cancer treatments. (wikipedia.org)
  • One way in which biologists and medics use immunotherapy is by injecting antigen-incubated Dendritic Cells (DCs) into mice to stimulate an immune response. (mdpi.com)
  • Immunotherapy , also known as biological therapy, is a type of cancer treatment that refers to ways we stimulate the immune system to identify and better fight cancer. (northside.com)
  • Active immunotherapies can elicit generic and specific immune responses depending on the goal of the treatment. (wikipedia.org)
  • Kleiman MAR. "Costs and Benefits of Immunotherapies or Depot Medications for the Treatment of Drug Abuse" Committee on Immunotherapies and Sustained-Release Formulations for Treating Drug Addiction National Academy of Sciences . (erowid.org)
  • Immunotherapy, also called biologic therapy, is a cancer treatment that enhances the body's natural defenses to fight off cancer cells. (pharmiweb.com)
  • This is owing to increasing use of immunotherapy as a first line of treatment in cancer. (pharmiweb.com)
  • As immunotherapy is used as a first line of treatment in the management of cancer the corresponding market is expected to expand significantly. (pharmiweb.com)
  • Northside Hospital Cancer Institute's Immunotherapy Program is part of our nationally recognized treatment center for blood and marrow transplants. (northside.com)
  • Cell-based immunotherapies, including CAR T-cell therapy, refer to a treatment option where immune cells are taken directly from a patient and genetically modified to be more effective tumor-fighting immune cells. (northside.com)
  • How Is Immunotherapy Different From Conventional Cancer Treatment? (northside.com)
  • Furthermore, antiangiogenic agents, which have a budding role in the treatment of mesothelioma, may eventually be used by clinicians in combination with immunotherapy, she said. (medscape.com)
  • Dr Tsao served as discussant during a session that featured two new studies, one of immunotherapy in the setting of relapsed disease, and the other of an antiangiogenic agent as part of initial treatment. (medscape.com)
  • More data are needed to determine the utility of combination immunotherapy vs nivolumab alone, said Dr Scherpereel. (medscape.com)
  • It has been previously demonstrated that NK cell functionality is responsive to immunotherapies with IL-21 and interferon alpha (IFNα). (nature.com)
  • Tumor antigens have been a main target in specific active immunotherapy by way of vaccination. (wikipedia.org)
  • They include passive vaccination-Elan is completing a phase 1 trial of a humanized monoclonal antibody to Aβ and is preparing a phase 2 at several sites in the U.S.-and preclinical work on active immunogens made by conjugating small Aβ fragments to an external carrier. (alzforum.org)
  • it may be active and specific, as a result of naturally acquired (apparent or inapparent) infection or intentional vaccination (artificial active i. (theodora.com)
  • Yang-Xin Fu, M.D., Ph.D., is leading a multipronged investigation to understand the mechanisms underlying ionizing radiation-induced resistance and to test newly developed personalized immunotherapies to overcome this resistance. (utsouthwestern.edu)
  • Purpose: Idiotypes (Ids), the unique portions of tumor immunoglobulins, can serve as targets for passive and active immunotherapies for lymphoma. (johnshopkins.edu)
  • A number of immunologic interventions, both passive and active, can be directed against tumor cells. (msdmanuals.com)
  • Passive cellular immunotherapy references A number of immunologic interventions, both passive and active, can be directed against tumor cells. (msdmanuals.com)
  • Those achieving sustained partial or complete remission (n = 287 [44%]) were randomly assigned at a ratio of 2:1 to receive one injection per month for 7 months of MyVax or control immunotherapy. (johnshopkins.edu)
  • Both achieved full remission-Olson was cancer-free within weeks-and their cancer did not return, leading senior study author Carl June, MD, director of the Center for Cellular Immunotherapies and the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania, to say they were cured. (poz.com)
  • The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Sante). (uni-koeln.de)
  • Active immunotherapy has been successful against infectious agents that cause self-limiting diseases. (oncolink.org)
  • Effective immunotherapy for chronic diseases and cancer, however, will require the optimization of many aspects of the immune system. (oncolink.org)
  • Increasing incidences of cancer and autoimmune diseases coupled with increasing demand for immunotherapy drugs is likely to support the market growth. (pharmiweb.com)
  • The purpose of this study is to determine whether a 12-week, home-based, virtually supervised exercise intervention is feasible and improves various health outcomes among individuals with advanced lung cancer receiving immunotherapy. (dana-farber.org)
  • Aug. 30, 2023 The use of active mechanical circulatory support is growing rapidly around the world. (sciencedaily.com)
  • How did immunotherapy compare to other treatments you may have received, if any? (cancerresearch.org)
  • The global market for Cancer Immunotherapy estimated at US$117.5 Billion in the year 2022, is projected to reach a revised size of US$378.5 Billion by 2030, growing at a CAGR of 15.7% over the analysis period 2022-2030. (researchandmarkets.com)
  • The Cancer Immunotherapy market in the U.S. is estimated at US$32 Billion in the year 2022. (researchandmarkets.com)
  • The Global Market for Cancer Immunotherapy was estimated to be valued at $117.5 Billion in 2022. (researchandmarkets.com)
  • Specific active immunotherapy administers a specific antigen as the therapy. (wikipedia.org)
  • Northside Hospital Cancer Institute is among select centers in the country offering chimeric antigen receptor (CAR) T-cell therapy, one of the most promising cell-based cancer immunotherapies available. (northside.com)
  • In passive cellular immunotherapy, specific effector cells are directly infused and are not induced within the patient. (msdmanuals.com)
  • In passive cellular immunotherapy, specific effector cells. (msdmanuals.com)
  • The authors also raise the question as to whether immunotherapy should be used earlier in the course of allergic rhinitis. (aafp.org)
  • Immunotherapy of allergic disease. (cdc.gov)
  • If you're at a high risk of recurrence, your doctor may recommend targeted therapy or immunotherapy after surgery. (healthline.com)
  • Other researchers at the AACR event indicated that they are exploring alternative approaches to cancer immunotherapy. (genengnews.com)
  • In the first study, known as MAPS-2, French researchers concluded that immunotherapy with checkpoint blockade may slow the growth of mesothelioma after relapse. (medscape.com)
  • PD-1 inhibitor drugs such as Keytruda and Opdivo seem to increase inflammation in the immunotherapy patient resulting in greater levels of cardiovascular disease later in life. (canceractive.com)
  • Given previous findings on a role of IL-21 and IFNα in regulating NK cell function, and that NKG2a low CD16 + NK cells are generated while expressing high levels of IL-21R in nonpathogenic SIV infection, we sought to determine whether immunotherapy with IL-21 and IFNα rescues AGM-like profiles of NK cell maturation and activity in SIV-infected rhesus macaques (RMs). (nature.com)
  • Dale Schenk of Elan led off an immunotherapy symposium by noting second-generation approaches his company is currently exploring. (alzforum.org)
  • The highest titers were measured while the patient had active infection and was critically ill. (cdc.gov)
  • Our recently published market research report on the Global Cancer Immunotherapy Market provides a comprehensive analysis and insights expected to be pivotal for business leaders and strategists. (researchandmarkets.com)
  • This first installment of our hot-off-the-podium dispatches summarizes the status of AD immunotherapy research. (alzforum.org)
  • Several different types of cancer immunotherapy are being utilized both commercially and in research studies. (northside.com)
  • Dive into the research topics where Linda Karlsson is active. (lu.se)
  • Join us and the world's leading scientists in the pursuit of life saving immunotherapies that will forever change how we treat cancer, from the inside out. (cancerresearch.org)